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1. Introduction and outline 
 
Deoxyribonucleic acid (DNA) as a genetic information carrier plays an essential role in the 
development and functioning of every living organism. The information stored in the 
DNA sequences is transcribed into an intermediary molecule called messenger 
ribonucleic acid (mRNA).[1] The mRNA guides the biosynthesis of proteins, which in turn 
interact with other biomolecules such as DNA scaffolds and assist in various cellular 
events such as replication, repair, regulation of gene expression as well as in the 
structuring of DNA itself.[2]  In most cases, metal ions play an important role in providing 
a basic biologically active structure and cellular functions to most of the enzymes.[3] 
Understanding the significance of protein-DNA interactions and its correlation to genetic 
disorders has played a crucial role in the development of novel therapeutics in past few 
decades. Mimicking the active site of protein domains and studying their interactions 
with their consensus DNA sequences might assist in probing the binding pocket and 
furthermore, corroborates the understanding of their structural aspects, binding mode 
and binding parameters. Additionally, since metal ions are not only essential for the 
biological activity of most of the proteins but also have electrostatic affinity for the 
polyanionic nucleic acid targets (DNA/RNA) in the cell,  incorporation of metal binding 
sites in such peptide sequences might render it with unique biochemical properties. In 
this line of thought, the following two projects were pursued during the course of this 
doctoral thesis. 
Metal ions interact with DNA in numerous ways forming both covalent and non-covalent 
linkages. The cis-(NH3)2Pt-dGpG site is an example of a covalent modification of DNA by 
cisplatin,[4] a widely used chemotherapeutic agent. Herein, the cis-diammineplatinum 
centre coordinates with two adjacent guanine residues at the N7 position forming an 
intrastrand crosslinked DNA. The resulting kinked DNA duplex is stabilized by the binding 
of a class of proteins called the high mobility group proteins, which inhibit the binding of 
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cellular repair proteins and lead to cell death. In the first project, platinum 
complex/peptide chimeras mimicking the integration host factor (IHF) were synthesized 
and tested for their DNA binding abilities. IHF is a DNA architectural protein which 
sequence specifically binds to DNA and induces a bend > 160˚ in dsDNA through minor 
grove intercalation (Figure 1.1 A).[5]  The motivation behind the synthesis of such 
chimerical peptides is to enhance site specific targeting of cisplatin by means of peptide-
DNA recognition. Additionally, since IHF induces a drastic bend in the DNA double helix, 
tethering a platinum chelating unit to the IHF mimicking peptide might have a synergistic 
effect of the two on their DNA binding and bending abilities. 
The design of the chimerical peptide is based on a model peptide proposed by 
E. K. Liebler that mimics IHF.[6] The IHF mimicking peptide contains a small lysine 
dendrimer, a cyclic peptide core and a glycine oligomer (Figure 1.1 B). The lysine 
dendrimer resembles the positively charged globular body of IHF whereas the cyclic 
peptide resembles the recognition unit that interacts with the minor groove of DNA. The 
glycine oligomer not only contains the platinum chelating unit but also tethers to the 
dendrimer with the cyclic recognition unit. The DNA binding of the platinum containing 
IHF mimicking peptides in comparison with the anticancer drug cisplatin was tested by 







Figure 1.1: (A) IHF cocrystallized with its consensus DNA binding site. The image has been reproduced using 
PyMOL (PDB entry: 1IHF).
[5]
  (B) The IHF mimicking  model peptide consisting of a minor grove binding 
cyclic unit, a positively charged lysine dendrimer and a glycine linker including the platinum chelating unit.  
  A   B 
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In a second project, a semi-synthetic method was utilized for the preparation of a zinc 
finger domain consisting of a tandem repeat of three zinc fingers. The Zif268, a Cys2His2 
type of zinc finger domain is one of the most abundant selective DNA binding proteins in 
the human organism and plays an important role in the regulation of transcriptional 
processes (Figure 1.2 A).[7, 8] Single fingers fold into a characteristic ββα structure which is 
induced by the coordination of a zinc ion.[9] The α-helix formed thereby serves as a 
recognition unit and binds to three consecutive base pairs in the DNA sequence. It is 
known that in nature for having better selectivity for target DNA sequences a tandem 
repeat of at least two zinc fingers is necessary while in most domains three or more zinc 




Figure 1.2: (A) Zif268 containing a tandem repeat of three zinc fingers wrapped around its consensus DNA 
binding site. (B) The Zf3 domain modified to contain a triazacyclononane ligand as an additional Zn
2+
 
coordination site. (pdb code: 1AAY).
[9]
 Image genetrated by PyMOL. 
 
Following a semi-synthetic strategy, proposed by F. Fehr,[10] the modified Zif268 domain 
containing a tandem repeat of three zinc fingers (Zf13) was constructed. The approach 
utilizes expressed protein ligation in which the zinc fingers 1 and 2 (Zf12) need to be 
expressed in E. coli whereas the zinc finger 3 (zf3) can be synthesized using conventional 
solid phase peptide synthesis (SPPS). A 1,2,3-triazole based histidine mimic reported by 
A. Nadler,[11] containing an additional zinc binding site, was incorporated into the 
  A   B 
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synthetic domain (Zf3) using SPPS (Figure 1.2 B). The two peptide fragments Zf12 and Zf3 
were then linked together by applying native chemical ligation leading to the formation 
of the modified Zf13 sequence. The introduction of the artificial amino acid within the 
Zf13 domain positions will place the metal centre in close proximity to DNA and might 
assist in sequence specific cleavage of DNA by hydrolyzing the phosphodiester bond. The 
modified zinc finger constructs were characterized using mass spectroscopy and their 
secondary structures were elucidated by utilizing CD spectroscopy. The preliminary 
experiments to test DNA binding and cleavage ability of the modified zinc finger were 
performed using CD spectroscopy and gel electrophoresis.   
The ultimate goal of the work done in this PhD thesis is to mimic protein domains that 
have specific recognition and interaction with their corresponding DNA binding sites. The 
design and synthesis of metal containing peptides mimicking such appended protein 
domains offer a possibility to exploit their recognition properties to direct the peptide 
towards a particular DNA sequence and additionally, to modulate their biochemical 
reactivity with the target DNA. The novel library of peptides with enhanced cell 
penetrating, target directing and recognition properties generated henceforth has the 
potential to be developed as sequence specific therapeutic targets, artificial model 












2. Cisplatin – as a chemotherapeutic agent  
 
Metals play an important role in the regulation of numerous biochemical transformations 
in all living cells and as a consequence an excess or deficit of metal ions is associated with 
pathological disorders.[3] Since almost 5000 years, medicinal inorganic chemistry has 
been applied for the treatment of various ailments such as diabetes, cancer, rheumatoid 
arthritis and cardiovascular diseases.[12] The unique properties of metal complexes such 
as Lewis acidity, electrophilicity, redox activity, variable coordination modes  and more 
importantly their ability to interact with the electron rich biomolecules such as DNA, RNA 
and proteins have made them interesting targets for the development of novel 
metallopharmaceuticals.[13, 14] In recent years, the importance of inorganic complexes in 
medicine as both therapeutic and diagnostic agents has enormously increased.[15]  
 
2.1. Platinum based chemotherapeutics 
Platinum based metal coordination complexes have found clinical value through their 
therapeutic efficacy against cancer.[16-19] The first and one of the most famous examples 
of a platinum containing chemotherapeutic agent cisplatin,[20]  serendipitously 
discovered by Rosenberg in 1965[21] was a stepping stone in the field of medicinal 
inorganic chemistry. Since the discovery of the biological activity of the drug,[22] 
significant interest has been aroused amongst researchers to understand its mode of 
action against cancer. While several analogues of cisplatin have been synthesized for 
evaluating their anti-cancer potential, only a few of them have been registered as 
marketed chemotherapeutics [23, 24, 30] (Figure 2.1) and till date cisplatin is the most 
effective drug for the treatment of ovarian, testicular, head, neck and bladder 
cancer.[25-28] Currently, apart from cisplatin only two drugs, carboplatin and oxaliplatin,  
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have received approval from the FDA and are in clinical use worldwide for the treatment 
of ovarian and colorectal cancer, respectively.[29, 30] 
 
 
Figure 2.1: Chemical structures of platinum based drugs clinically approved for chemotherapy in at least 
one nation, of which only cisplatin, carboplatin and oxaliplatin have been approved worldwide.
[30] 
 
However, the usage of these commonly prescribed drugs owing to their poor solubility, 
poor oral bioavailability and lack of selectivity is associated with severe dose limiting side 
effects which include nephrotoxicity, neurotoxicity, ototoxicity and emetogenesis.[20] In 
addition to these issues, another major drawback compromising their therapeutic utility 
is the presence of intrinsic resistance or onset of resistance followed by 
chemotherapy.[28] The key to expanding the scope of platinum based chemotherapy lies 
in development of novel therapeutic targets that are able to minimize the toxic side 
effects and are more efficient in combating drug resistance.      






2.2. How does cisplatin function as an anticancer agent? 
A thorough understanding of the mode of action of platinum based drugs against cancer 
is very important in order to develop novel anticancer drugs with improved properties as 
well as to enhance the chemotherapeutic efficacy of the existing class of drugs. This 
section sequentially sheds light on the string of complex cellular events that are 
responsible for the anticancer activity of cisplatin which include its cellular uptake and 
transport to the nuclear DNA, covalent modification of DNA in the chromatin, interaction 
of various cellular proteins with platinum-DNA adduct and inhibition of cellular repair 
machinery ultimately  triggering cell death. 
 
2.2.1. Entry and activation of cisplatin in the cells 
Cisplatin is usually administered as an intravenous injection into the blood stream. In 
order to ensure a successful chemotherapy, the drug must be efficiently imported from 
the extracellular medium into the cell followed by formation of active species readily 
available for reaction with various cellular components. The cellular uptake of cisplatin 
occurs either by passive diffusion or by an active transport mechanism.[31, 32] Passive 
diffusion is an energy independent process and results from a concentration gradient of 
the drug molecules across the cell membrane. On the contrary, in an active transport 
mechanism a particular carrier molecule is responsible for the transport of a specific kind 
of cargo into the cells (Figure 2.2). The plasma membrane copper transporters, involved 
in the influx (Ctr1) and efflux (ATP7A and ATP7B) of copper have also shown to directly 
influence the accumulation and removal of platinum based metal complexes from the 
cell.[33-35]  
In the blood stream, where the chloride concentration is much higher (~100 mM) 
compared to the intracellular environment cisplatin exists in the relatively stable neutral 
form. The lower chloride concentration (~3-20 mM) inside the cells leads to replacement 
of either one or both the chloride ions with water molecules.[36] The resulting mono-aqua 
species [Pt(NH3)2Cl(OH2)]
+ and di-aqua species [Pt(NH3)2(OH2)2]
2+ are the active form of 
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the drug which can potentially react with various cellular constituents including cellular 
phospholipids, DNA, RNA, proteins, thiol containing molecules and cytoskeletal 
microfilaments.[37-39]. 
 
        
 
Figure 2.2: Schematic representation of the mechanism of cisplatin influx and efflux across the cell 





There is also evidence supporting the formation of the hydroxo species, [Pt(NH3)2Cl(OH)] 
and [Pt(NH3)2(OH)2]
+,[40, 41] resulting from the loss of protons from the aqua complexes. 
However, the hydroxo species are rather inert towards substitution whereas the cationic 
mono-aqua species [Pt(NH3)2Cl(OH2)]
+ are readily available for reaction with the 
polyanionic DNA by means of electrostatic interactions. Side reaction of these species 
with cellular thiols is known to reduce the formation of cisplatin adducts with DNA and is 
considered to be one of the reasons for resistance development reducing the potency of 
the drug.  
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2.2.2. Covalent modification of DNA by cisplatin 
The cytotoxic effect of cisplatin predominantly arises from the binding of the mono-aqua 
complex [Pt(NH3)2Cl(OH2)]
+ with the N7 atoms of the purine bases resulting in the 
formation of covalent adducts with nuclear DNA.[42-47] At first, the mono-functional 
adduct is formed by replacement of the water ligand with a guanine residue followed by 
aquation of the second chloride ion. Subsequent ring closure by nucleophilic attack of 
another neighboring N7 atom of a guanine or an adenine base pair leads to the 
formation of the bi-functional adduct with the same strand (intrastrand adduct) or 
opposite strands (interstrand adduct) of the DNA duplex. The various modes of cisplatin 
binding to DNA have been identified and structurally well characterized by performing 
enzymatic digestion of cisplatin modified DNA followed by chromatographic purification 
and NMR analysis of individual components.[48]  These studies reveal that the major 
components of adducts include 60-65% 1,2-d(GpG),  20-25%  1,2-d(GpA), 5-10% 
1,3-d(GpXpG) (X is an additional base pair between two guanines) intrastrand crosslinks 
and a small amount of interstrand d(GpG) crosslinks (Figure 2.3). 
 
              
 
Figure 2.3: Representation of various kinds of adducts formed by binding of cisplatin to DNA. 
(a) Intrastrand 1,2-d(GpG) adduct; (b) intrastrand 1,2-d(GpA) adduct; (c) intrastrand 1,3-d(GpXpG) adduct 




(a) (b) (c) (d) 
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2.2.3. DNA distortion by cisplatin  
X-ray crystallography and NMR studies have provided further insight into the structure of 
cisplatin-DNA adducts (Figure 2.4).[49-52] The major adduct cis-[1,2-{Pt(NH3)2}
2+d(GpG)] 
(Figure 2.4 a), formed by crosslinking between adjacent guanine residues on same strand 
of DNA distorts the duplex by inducing a bend of around 34˚ towards the major groove as 
well as by local unwinding of about 13˚ near the platination site.[53] The intrastrand 
adduct cis-[1,3-{Pt(NH3)2}
2+d(GpTpG)] contains an additional nucleotide in between the 
crosslinked guanine residues (Figure 2.4 b). The 1,3-intrastand adduct despite of 
exhibiting a more pronounced distortion in the proximity of the platination site has a 
much lower impact on the global structure of DNA compared to the 1,2-intrastrand 
crosslink.  Contrary to the effect of intrastrand crosslinking, the interstrand crosslinking 
between guanine residues on opposite strands of the duplex induces a bend towards the 
minor groove of DNA (Figure 2.4 c).[51] The formation of 1,2-intrastrand crosslinks is 
considered to be crucial for the chemotherapeutic efficacy of the cisplatin as 
experiments indicate that the therapeutically inactive trans isomer of cisplatin, 
transplatin, is  unable to form them.[54, 55] 
   
                
 
Figure 2.4: Structures of cisplatin-DNA adducts formed by covalent crosslinking between cisplatin and DNA. 
(a) cis-[1,2-{Pt(NH3)2}
2+




d(GpTpG)], pdb code: 1DA4;
[50]
 
and (c) interstrand d(GpG) adduct, pdb code: 1A2E.
[51]
 Images generated by PyMOL. 
(a) (b) (c) 
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2.3. Proteins that recognize cisplatin-DNA adducts 
The distorted DNA resulting from covalent crosslinking with cisplatin is recognized by 
mainly two classes of proteins. The first class consists of repair proteins which upon 
binding trigger a cellular mechanism to repair the damaged DNA. Resistance 
development in platinum based chemotherapy has been found to be more explicit in 
cells with increased repair of the damaged DNA.[56-58] This indicates a direct correlation 
between cellular repair and the mode of action of platinum containing 
chemotherapeutics. The second class consists of architectural proteins belonging to the 
family of high mobility group (HMG) proteins which bind to the kinked structure of DNA 
and further stabilize the bend. This inhibits the repair process of the damaged DNA and 
thus, interferes with various cellular responses including DNA replication and 
transcription.[59] A thorough understanding of the binding interactions of these proteins 
with cisplatin-DNA lesions is essential to study their influence on the cytotoxicity and 
molecular mechanism of the drug.    
 
2.3.1. Repair proteins 
Various repair proteins recognize a different kind of DNA damage, for instance, that 
resulting from UV radiation, chemical agents or cisplatin-DNA lesions. Upon recognition, 
they prompt a damage repair pathway. The major pathways for repairing cisplatin 
induced DNA damage include nucleotide excision repair (NER)[59] or the mismatch repair 
pathway (MMR)[60]. In the NER pathway an assembly of repair proteins such as TFIIH, 
XPA, RPA function together to specifically recognize and repair the intrastrand 
crosslinked DNA.[61] Cell lines with deficient NER were found to exhibit greater sensitivity 
towards cisplatin.[62, 63] In the MMR pathway in human cell lines, the MMR protein 
hMutSα and its subunit hMSH2 bind to cisplatin-DNA lesions with rather high specificity 
considering it as a mismatch.[64-66] The mismatch repair in the unplatinated nascent 
strand is not possible as long as the cisplatin-DNA lesion is still present in the template 
strand.[64] Several futile attempts of MMR could ultimately trigger a signal for apoptosis 
and result in cell death.     
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2.3.2. High mobility group (HMG) proteins 
The high mobility group (HMG) domains are non-histone proteins involved in the 
structuring of DNA or proteins present in the nucleus or chromatin of the cells in order to 
form higher order protein-DNA and protein-protein complexes.[61, 67-69] Depending on the 
specificity of the HMG proteins to recognize a target DNA sequence, they are sub-divided 
into two categories. The first consists of proteins such as HMG1, HMG2, the 
mitochondrial transcription factor (mtTFA) and the upper binding factor (UBF) that lack 
sequence specificity and are often referred to as structure specific HMG domains. The 
second category consists of sequence specific DNA binding proteins such as the sex 
determining factor (SRY) and the lymphoid enhancer factor (LEF-1). Upon binding, all 
HMG domain proteins predominantly act either by bending DNA or by stabilizing the pre-
bent DNA, thereby facilitating its efficient recognition and interaction with other proteins 
required for performing essential nuclear processes. Structural analysis of complexes 
between HMG domains and their corresponding cognate DNA sequences reveal a sharply 
bent duplex with amino acid side chains of the protein inserted between the base 
pairs.[70, 71]   
 
  







Figure 2.5: X-ray crystal structure of a complex between the rat HMG1 domain A and a 16-mer DNA 
sequence containing a 1, 2-d(GpG) adduct with cisplatin, pdb code: 1CKT.
[74]
 Images generated by PyMOL. 
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The HMG1 proteins consisting of two DNA binding domains, A and B, were found to 
recognize the bent DNA containing cisplatin induced 1,2-d(GpG) and 1,2-d(ApG) 
intrastrand crosslinks more specifically compared to DNA modified by pharmacologically 
inactive platinum analogues.[72, 73] The HMG1 domain protein obtained from rat was co-
crystallized with a 16 base pair DNA sequence with a single intrastrand 1,2-d(GpG) 
crosslink formed by cisplatin (Figure 2.5) and their interactions were studied in detail.[74] 
The L-shaped protein consisting of three α-helices binds to the minor groove of DNA 
while introducing a bend of 61˚ towards the major groove. Additionally, the binding 
results in flattening of the major groove and broadening of the minor groove. The 
hydrophobic side chain of the Phe37 residue intercalates into the minor groove resulting 
in destacking of guanines at the 1,2-d(GpG) site. The mutation of this phenylalanine 
residue with an alanine drastically reduced the binding affinity of the protein domain for 
cisplatin damaged DNA.[75, 76]  
 
2.3.3. Induction of apoptosis by binding of HMG domains  
One of the plausible mechanisms mediating cytotoxicity of cisplatin-DNA adducts is by 
formation of a complex with HMG box proteins which triggers a signal for apoptosis.[77] 
 
 
Figure 2.6: A schematic representation of the repair shield model in which binding of the architectural 
proteins to 1,2-intrastrand d(GpG) cisplatin-DNA adduct  inhibits the repair process by blocking the binding 




Several studies clearly indicate that the binding of architectural proteins such as HMG1, 
mTFA, tsHMG or SRY to the damaged 1,2-d(GpG) site shields its recognition from the 
cellular repair machinery, particularly blocking the nucleotide excision repair pathway 
and ultimately triggers cell death (Figure 2.6).[59, 78, 79] Consistent with this model, termed 
as the repair shield model, cell extracts with deficient HMG1 and HMG2 expression 
exhibited an enhanced repair of cisplatin damaged DNA.[80] Additionally, steroid induced 
overexpression of HMG1 in breast cancer cells sensitizes them towards cisplatin 
treatment.[81] Apart from this model, the “transcription factor hijacking” model also 
justifies the role of HMG domain proteins in cancer treatment.[61] Transcription factors 
such as hUBF bind to cisplatin damaged DNA with a high affinity and as a result, there is a 
competition between the promoter sequence and the cisplatin-DNA lesions.[82] In this 
way cisplatin treatment inhibits the transcription process and endangers the cell 
survival.[83] The crucial role of DNA architectural proteins such as HMG domains in cancer 
treatment make them an interesting pharmacological target. 
 
2.3.4. Various other DNA binding and bending proteins   
Eukaryotic histones are another important class of the chromatin architectural proteins 
that allow condensation of genomic DNA by functioning as spools to wrap the 
enormously long DNA around them.[84] Additionally, they assist in structural 
pre-organization of DNA to enable the binding of various proteins necessary for 
processes such as replication, transcription and recombination. Similar to the HMG1/2 
proteins the linker histone H1 has a propensity to bind to bent and cruciform DNA as well 
as to cisplatin modified DNA.[85] In fact, the linker histones have 20 times greater binding 
affinity towards such distorted DNA sequences as well as occur in 10 fold higher nuclear 
concentration. The stronger binding affinity of linker histones to the cisplatin modified 
DNA hints towards its importance in mediating the toxicity of the drug by affecting DNA 
transcription and repair. 
The integration host factor (IHF) and HU proteins, prokaryotic analogues of histones, 
termed as “histone-like”, share a functional similarity to the eukaryotic HMG1 domains 
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such that in some situations they have been found to be functionally interchangeable.[86] 
Irrespective of their origin both the prokaryotic as well as eukaryotic architectural 
proteins, upon binding to the DNA minor groove result in bending and unwinding of the 
DNA.  However, a distinguishing feature of IHF is its ability to bind to DNA in a sequence 
specific manner and induce a drastic U-turn in duplex, thus, taking the DNA bending 
phenomenon to a new extreme. The structural features of IHF responsible for its DNA 
interaction, DNA binding and bending abilities are described elaborately in the next 
chapter.  The design of a model peptide mimicking such protein domains that not only 
stabilize the cisplatin induced DNA distortion but also assist in further bending the 
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3. Synthesis and DNA interaction studies of the 
platinum complex/peptide chimera mimicking 
Integration Host Factor  
 
Development of novel chemotherapeutic agents with enhanced pharmacological 
properties is of utmost importance. As discussed in the earlier chapter 2, a thorough 
optimization of the drug design is necessary at various levels including enhancement of 
cellular as well as nuclear accumulation, efficient DNA targeting, minimizing resistance 
development and dose limiting toxic side effects. Taking all these requirements into 
consideration several attempts are being made to develop novel therapeutic candidates. 
Varying the coordination sphere of the Pt metal centre modulates its interaction with 
DNA as well as other cellular targets and hence, determines the overall cellular response 
of the drug.[87] Attachment of metal complexes with suitable carrier molecules possessing 
cell penetrating, target directing and recognition properties seems to be a promising 
approach.[88]  
 
3.1. A brief overview of chimeric platinum drugs   
The first and foremost challenge posed on the drug is to be able to cross the biological 
barrier i.e. cell membranes. Hyperpermeability[89] and enhanced cellular retention of 
macromolecules in tumour cells can be exploited to target the tumour tissue either by 
attachment or by encapsulation of the drug with a carrier nanostructure. In contrast to 
small molecules, which rapidly enter the cells by passive diffusion the cellular uptake of 
macromolecules occurs by a kinetically slow process of endocytosis.[90] Supramolecular 
assemblies such as liposomes, miscelles, polymerosomes, polymer conjugates and 
nanoparticles have found utility in biomedical field as nanovehicles for delivering 
therapeutic agents.[91, 92] Remarkably, highly branched dendrimeric peptides due to their 
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well defined architectures, mono-dispersity, abundant terminal groups and multivalent 
surface, are attractive candidates to develop delivery nanoplatforms.[93, 94] Another 
exploitable aspect allowing specific targeting of cancerous cells and facilitating the 
passage of the active drug through the cell membrane is over expression of membrane 
bound receptors in certain kinds of tumours. Effective receptor mediated cellular 
internalization of platinum based drugs has been achieved by tethering the platinum 
moiety to a suitable carrier ligand having a high affinity for the receptor such as the 
antibody against it.[95, 96]  
Nuclear DNA is known to be one of the major targets of anti-cancer drugs. Therefore, 
apart from effective cellular internationalization of the chemotherapeutic, enhancing its 
nuclear localization and interaction with DNA also plays a crucial role in determining its 
clinical success. Attachment of the Pt complex to a carrier molecule which is known to be 
efficient in delivering cargo to the cellular nucleus for e.g., the nuclear localization 
peptide (NLS)[97, 98] has shown enhanced nuclear accumulation of the chimeric drug.[99] 
Numerous DNA targeting agents have been prepared by conjugation of the Pt complex 
with various DNA ligands including intercalators,  groove binders, peptides, polyamides, 
PNA, DNA and amino acid residues.[88] In a previous attempt in the Diederichsen 
group,[100] Pt complexes tethered to positively charged peptides demonstrated enhanced 
interaction with nucleic acid sequences by means of rather non-specific electrostatic 
attraction. Despite being able to efficiently target DNA most of chimeric drugs had little 
or no cytotoxic effect. However, the approach offers tremendous versatility in choosing 
the design of the carrier ligand and the field is yet to be explored to its complete 
potential. With optimization of the design it provides a scope to develop a whole new 
library of target oriented compounds applicable as potential chemotherapeutic agents.  
Peptide based ligands possess several advantages as drug candidates due to their high 
bioavailability, reduced toxicity and moreover, due to their specific interactions with 
DNA.[101-104] In this work, a model peptide mimicking the integration host factor (IHF) has 
been chosen as the platinum complex carrier to target DNA by exploiting its interaction 
with the minor groove as well as its ability to introduce an overwhelming bend in the 
duplex. The Pt complex/peptide chimera is expected to exhibit a synergistic effect of 
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both the platinum chelating unit as well as the body of the IHF mimicking peptide with 
respect to their DNA bending and binding properties.    
 
3.2. Integration Host Factor (IHF) 
As discussed in the earlier chapter 2, the condensation of enormously long genome as 
well as formation of higher order nucleoprotein complexes is essential to regulate 
various cellular activities. Analogous to the eukaryotic histones, in prokaryotic organisms 
this task is achieved by two of the most abundant DNA binding proteins, namely, 
integration host factor (IHF) and histone-like (HU) proteins.[105-107] Together they fall 
under the category of type II DNA binding proteins (DNAB II) and share a peculiar 
sequence homology, particularly in the DNA binding domain. Despite these similarities 
IHF binds to the cognate sequence with a high degree of specificity whereas the HU 
proteins are rather non-specific DNA binders.[108]  On the other hand, the evolutionarily 
unrelated eukaryotic HMG-box domains regardless of having fewer structural aspects in 
common with the HU and IHF proteins have been found to be functionally equivalent to 
them under certain conditions.[86] 
 
3.2.1. The consensus sequence of IHF 
 Apart from regulation of cellular processes, one of the best identified roles of IHF is for 
site-specific recombination in bacteriophage lambda.[109] IHF specifically binds to one of 
the three different core recognition sequences, H’, H1 and H2 sites within the attP phage 
attachment region and assists in integration of phage DNA into the genome of the host 
chromosome.[110] Out of these three, the H’ site is one of the strongest and most well 
characterized binding site. The binding affinity of IHF towards this site lies in the order of 
1 nM and that towards any random sequence has been found to be 103-104 times 
lower.[111, 112] Though the binding of IHF protects more than 25 bp only as few as 9 bp 
located at the 3’ downstream end remain conserved in the binding sites of IHF.[113] The 
degenerate core consensus sequence for specific recognition of IHF consists of a  
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5’-WATCARNNNNTTR-3’ element in which W stands for A or T, R stands for A or G and N 
strands any nucleotide. A relatively non-conserved part of the binding site consists of an 
A/T rich tract extending over 4-5 bp positioned around 8-9 bp upstream of the conserved 
domain.[114] The presence of this A/T rich track results in the formation of a narrow minor 
groove occupied by a well ordered string of water molecules, allowing only water 
mediated hydrogen bonding with the conserved nucleobases. The interaction of IHF with 
such an element hints towards recognition of sequence dependent structure of the 
cognate DNA instead of base pair recognition by IHF. The following section highlights the 
unique structural features of IHF that not just assist in specifically recognizing the 
consensus sequence and but also lead to drastic conformational changes in the DNA 
upon binding. 
 
3.2.2. Structural aspects of IHF facilitating DNA interaction  
The functional utility of IHF arises from its ability to induce a sharp bend of >160˚ in the 
cognate sequence by binding to the minor groove of DNA. An interesting feature of IHF 
domains is that it employs an indirect readout mechanism for binding and wrapping 
around DNA. In case of indirect readout the basis of protein-DNA recognition relies on a 
shape readout wherein the structural aspects of DNA dominate over actual hydrogen 
bonding interactions between the two. Detailed X-ray crystallographic analyses of the 
IHF-DNA co-crystal with a 35-mer DNA fragment including the H’-site of bacteriophage λ 
was performed in order to understand the structure, DNA binding and bending 
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Figure 3.1 : (A)  Co-crystal structure of IHF bound to a 35 bp ds DNA fragment consisting of the H’-site of 
phage λ, wherein, the α-subunit is shown in red and β-unit is shown in blue. The image has been 
reproduced using PyMOL (PDB entry: 1IHF).
[5]
  (B) An illustration of the sequence of amino acids and 
oligonucleotide involved in the structure wherein the arrows point towards the interaction sites between 
them. The core consensus sequence and the A/T-rich 5’ element are marked in bold.   
 
The general structure of IHF is heterodimeric formed by two intertwining subunits, an 
α-subunit and a β-subunit, having 30% sequence similarity.[5,115] Each subunit  
approximately is 10 kDa in size, consisting of 3 α helices and 5 β sheets structures. In the 
IHF-DNA complex,[5] the two long flexible ribbon like arms each made up of two 
anti-parallel β-sheets extend from the globular body of the protein embracing the DNA 
minor groove. A proline residue present at the tip of each arm (Pro65 of the α-subunit 
and Pro64 of the β-subunit) intercalates between the DNA base pairs, thereby disrupting 
the stacking interactions and broadening of the minor groove. The binding of the protein 
to the widened DNA drives drastic conformational changes leading to the formation of 
two sharp kinks separated by a sequence of 9 bp within the duplex. The repulsive forces 
in the bent polyanionic DNA back bone are compensated by its interaction with an 
overall positively charged surface of the protein due the presence of the basic amino 
acids in the large α-helical part [116] (Figure 3.2) as well as with the N-termini of the 
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Figure 3.2: Representation of amino acid residues on the surface of IHF protein wherein the acidic amino 
acids are depicted in red, basic amino acids in blue and neutral in yellow.
[116]
 (A) a helix wheel diagram 





In total, there are as few as 4 bp in the minor groove of the DNA sequence involved in 
hydrogen bonding interactions with IHF. These include interactions between the side 
chains of two arginine residues (Arg60 and Arg63) within the minor groove interacting arm 
of the α-subunit of IHF and the conserved DNA base pairs, each having similar hydrogen 
bond acceptors. On the contrary, analogous arginine residues of the β-subunit have no 
direct contact with the DNA bases but with the phosphate backbone through bridging 
water molecules.  These observations hint towards a higher contribution of the α-subunit 
towards sequence specific recognition of IHF in comparison to the β-subunit.    
 
3.3. Design of the model peptide mimicking IHF 
Our motivation to design the IHF mimicking peptides is to establish elements necessary 
for enhanced DNA interaction of the platinum metal complexes. The IHF mimicking 
model peptide reported earlier in the Diederichsen group, [6, 116, 119] is based on the 
deeper penetrating β-arm of the α-subunit owning to its greater role in specific 
recognition of the IHF consensus sequence. The model is designed taking into account 
  A B 
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various interactions from individual sub-domains for optimum interaction with DNA and 
hence can be divided into three parts (Figure 3.3). Firstly, it consists of a cyclic peptide 
resembling the minor groove binding arm of the α-subunit and containing amino acid 
residues surrounding the intercalating proline. Secondly, it consists of a positively 
charged lysine dendrimer that mimics the globular α-helical body of IHF for facilitating 
electrostatic interactions with the negatively charged DNA. Thirdly, it consists of a glycine 
linker that tethers the cyclic peptide with the dendrimer peptide and additionally, 
contains the platinum chelating unit. The suitable length of the glycine linker was 
determined by Macro Model calculations, by estimating the distance between the minor 
groove binding domain of the α-subunit and the compact body of IHF. The Cα atoms of 
Leu54 and Arg60 were found to be 17.7 Å apart and therefore, a flexible hepta glycine 
linker spanning a range of 22.2 Å was chosen. A norvaline derivative containing a 
dimethylethylenediamine as a side chain functionality was employed as an artificial 
amino acid to replace one of the glycine residues within the linker region for platinum 
coordination.    
          
                
Figure 3.3: The model of the IHF mimicking Pt complex/peptide chimera for enhanced DNA targeting. The 
minor groove binding cyclic peptide and the intercalating Pro residue are depicted in red, the positively 
lysine dendrimer in orange, the glycine linker in gray and the Pt metal centre in blue. 
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 The sequence of the cyclic peptide, in addition to an appended domain of the minor 
groove binding loop containing 10 amino acid residues (GRNPKTGEDI), was extended by 
two more amino acids, a D-proline and a diaminopropionic acid residue.  The D-proline 
offers conformational rigidity assisting in induction of a β-turn in the loop like 
structure [120] and furthermore, in the cyclization of the linear peptide. The 
diaminopropionic acid residue carries two amine functionalities, one of which is utilized 
for the cyclization reaction and the second one is available for subsequent connection of 
the cyclized peptide with the glycine linker. 
Some of the previous designs of the cyclic peptide in the Diederichsen group, included 
cysteine or histidine residues for providing a stable conformation as well as assisting in 
structural pre-organization either by formation of disulfide bridges or by complexation 
with metal ions, respectively.[121] Additionally, the intercalating proline residue was 
exchanged with analogous species to study the influence of different size of the side 
chain functionality, ring conformation and aromaticity on DNA interaction of the IHF 
mimicking peptides.[122] A more recent approach involved synthesis of an IHF mimic 
containing two cyclic recognition units extending from the central compact body, 
resembling the native heterodimeric IHF protein, in order to enhance the DNA binding 
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3.4. Synthesis of the IHF mimicking peptides 
The main motivation behind the synthesis of the IHF mimicking Pt complex/peptide 
chimeras is to enhance sequence specific DNA targeting as well as to observe a combined 
effect of the Pt complex and the IHF mimic with respect to DNA bending properties. We 
have synthesized an artificial amino acid building block for tethering with the platinum 
chelating unit and incorporated it into the peptide domain. Our approach for the 
synthesis of the IHF mimicking peptides involves both solid phase and solution phase 
peptide chemistry based on the Fmoc coupling protocol. The various peptide mimics 
IHF-1/2/3/4, P1 and P2 synthesized henceforth in this study were applied for DNA 
interaction experiments (Figure 3.4). The IHF-2, IHF-3 and IHF-4 are the platinated IHF 
mimicking peptides prepared by placing the platinum chelating unit at different positions 
within the glycine linker. Additionally, the unplatinated mimic IHF-1, the platinated lysine 
dendrimer P1 and the cyclic peptide P2 were prepared for control experiments.  
 
                
 
Figure 3.4: Representation of the various IHF mimicking peptides synthesized for the current study. The 
IHF-2/3/4 are the platinated mimics, IHF-1 is unplatinated mimic, P1 is the platinated lysine dendrimer and 
P2 is the cyclic peptide. 
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3.4.1. Synthesis of the artificial amino acid building blocks  
A norvaline based modified amino acid residue was synthesized to suit the Fmoc based 
SPPS protocol for incorporation into the chimeric peptide sequences. A 
dimethylethylenediamine was introduced into the side chain of the amino acid as a 
platinum chelating unit. The allyloxycarbonyl (Alloc) protection of N,N’-
dimethylethylenediamine 1 yielded N-allyloxycarbonyl-N,N’-dimethylethylenediamine 2. 
Following a literature known procedure,[124] the commercially available N-Boc glutamic 
acid benzyl ester 3 was first reduced to the corresponding alcohol 4 by using sodium 
borohyride and subsequently, brominated under Appel reaction conditions to yield 5. 
The attachment of the platinum chelating ligand to the amino acid is achieved by 
nucleophilic substitution of the bromine residue in compound 5 with 2. The Boc and 
benzyl group of the resulting amino acid 6 were removed and the free N-terminus was 
further protected with the Fmoc group yielding the amino acid 7, to be introduced into 
the Fmoc SPPS cycle.   
 
 
Scheme 3.1: Synthesis of the norvaline based artificial amino acid 7 for platinum coordination. 
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Scheme 3.2: Synthesis of Boc-Lys(Me)2-OH 9 to be incorporated into the lysine dendrimer.
[125] 
 
The synthesis of the lysine dendrimer was accomplished by introduction of 
Boc-Lys(Me)2-OH 8 as a terminal residue in Fmoc SPPS cycle. The synthesis of the 
N-bismethyl lysine was achieved by reductive amination of Boc-(Lys)-OH applying a 




Scheme 3.3: Synthesis of Fmoc-Dap(Alloc)-OH 12 to be incorporated into the cyclic peptide.
[126] 
 
A terminal diaminopropionic acid residue was introduced as Fmoc-Dap(Alloc)-OH 12 into 
the sequence of the cyclic peptide domain by Fmoc SPPS strategy. The tandem removal 
of the Fmoc and the Alloc (compatible with Fmoc protocol) group facilitated cyclization 
and coupling with the glycine linker, respectively. The synthesis of Fmoc-Dap(Alloc)-OH 
12 was accomplished in two steps,[126] by Hoffmann rearrangement of the commercially 
available Fmoc-Asn-OH 10 with iodobenzenediacetate (PIDA) yielding Fmoc-Dap-OH 11    
followed by Alloc protection of the newly generated free amine in the side chain of 11. 
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3.4.2. Synthesis of the cyclic minor groove recognition units 
The sequence of the linear precursor of the cyclic peptide in total contained 12 amino 
acid residues including those from Gly62 to Ileu71 mimicking the minor groove binding arm 
of the IHF α-subunit, a D-proline and a diaminopropionic acid. The synthesis was 
accomplished by Fmoc SPPS protocol starting from a 2-chlorotrityl (2-ClTrt) resin 
preloaded with isoleucine. Standard coupling conditions using HBTU/HOBt as activators 
and DIPEA as base were applied. The deprotection of the Fmoc group was achieved in 
20% piperidine. The cleavage of the peptide from the resin under mild conditions utilizing 
30% HFIP in DCM yielded the protected peptide 13.[127] Subsequently, cyclization of the 
linear peptide was performed with DIC/HOAt and NMM in DCM/DMF (9/1, v/v) yielding 
14. Alloc deprotection of the diaminopropionic acid employing Pd(PPh3)4 and Me2NH.BH3 
rendered peptide 15 with all the other amino acid side chain protecting groups still 
intact.[128, 129] This allows minimal side reactions during the connection of the free amine 
of the cyclic peptide with the carboxylic acid of the glycine linker. Furthermore, complete 
cleavage of the side chain protecting groups is achieved by treatment of 15 in 95% TFA in 
water yielding the cyclic peptide P2, used later in control experiments. 
 
 
Scheme 3.4: Synthesis of the cyclic peptides 15 and P2 for connection with the glycine linker and for 
control experiments, respectively. 
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3.4.3. Synthesis of the dendrimeric units 
The synthesis of the three generation lysine dendrimer along with the glycine linker was 
performed on a NovaSyn®TGT resin preloaded with a glycine residue. The lysine 
dendrimer, positively charged under physiological conditions, provides electrostatic 
interaction with the DNA backbone. While the glycine linker places the cyclic recognition 
unit and the dendrimer at appropriate distance to each other as well as holds the 
platinum chelating unit. All amino acids within the glycine linker both including and 
excluding the platinum chelating unit were coupled by standard Fmoc protocol using 
HOBt/HBTU/DIPEA for coupling and 20% piperidine in NMP for deprotection.  The first 
and the second generation dendrimer were prepared by coupling of Fmoc-Lys(Fmoc)-OH 
onto the glycine linker sequence whereas the third generation dendrimer was obtained 
by coupling of Boc-Lys(Me)2-OH. The use of N-bismethyl lysine for the synthesis of the 
third generation dendrimer offered better solubility to the dendrimeric peptides in 
organic solvents, necessary for solution phase conjugation with the cyclic peptide 15. 
Cleavage of the peptide from the resin applying mild conditions of 30% HFIP in DCM 
yielded the side chain protected peptide dendrimers, 16 without the Pt chelating and 
17a-c containing the platinum chelating unit. The dendrimer 16 was further employed for 
the synthesis of the unplatinated mimic IHF-1 whereas 17a-c were utilized for the 
synthesis of the platinated mimics IHF-2/3/4. 
   
 
Scheme 3.4: Synthesis of the dendrimeric peptides 16 and 17a-c excluding and containing the Pt chelating 
unit, respectively.    
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The N-termini of lysine dendrimer as well as the N-bismethylated residue are protonated 
at pH 7 and have the ability to neutralize the negative charge on the DNA phosphate 
backbone. The platinated lysine dendrimer P1 lacking the minor groove binding cyclic 
recognition unit was synthesized for control experiments in order to test the effect of 
solely electrostatic interactions upon the binding of Pt complex to DNA. The synthesis 
was done in three simple steps starting from deprotection of the Alloc group of the Pt 
chelating unit in 17c with Pd catalyst in the presence of a scavenger Me2NH.BH3 yielding 
peptide 18. Subsequent, platination reaction was performed under exclusion of light 
yielding 19, which was further treated with 95% TFA in water to remove all the amino 
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3.4.4. Synthesis of the unplatinated IHF mimic 
In the absence of the platinum metal centre, the IHF mimicking peptides lack the ability 
to covalently modify DNA. Hence, an unplatinated IHF mimic IHF-1 was prepared for 
control experiments to monitor the DNA interaction of the peptide backbone by 
non-covalent interactions which include electrostatic interactions of the dendrimeric 
peptide and minor groove binding of the cyclic peptide. The cyclic peptide 15 was 
connected to the dendrimeric peptide 16 utilizing activators DIC/HOAt and NMM as base 
in DMF. Subsequently, treatment of the resulting conjugated peptide 20 with 95% TFA 
removed the amino acid side chain protecting groups yielded IHF-1.  
  
                                    
 
Scheme 3.5: Synthesis of the unplatinated IHF mimicking peptide IHF-1. 
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3.4.5 Synthesis of the Pt complex/peptide chimeras 
The IHF mimicking platinum complex/peptide chimera IHF-2, IHF-3 and IHF-4 were 
prepared by placing the platinum chelating unit in proximity to the dendrimeric peptide, 
in between the dendrimer and the cyclic peptide, and towards the cyclic peptide. The 
synthesis of the chimeric peptides was accomplished by a following series of solution 
phase peptide modifications. The dendrimeric peptides 17a-c were connected with the 
cyclic peptide 15 utilizing coupling agents DIC/HOAT and NMM in DMF. The resulting 
conjugated peptides 21a-c upon treatment with palladium catalyst undergo deprotection 
of the Alloc group, orthogonal to Fmoc chemistry, yielding peptides 22a-c. Subsequently, 
platination reaction with K2PtCl4 in DMF/H2O was performed under exclusion of light. 
Deprotection of the side chain protection groups of the resulting platinated peptides 













Scheme 3.6: Synthetic route for the platinated IHF mimicking peptides IHF-2/3/4 with yields varying in the 
range of 45-55%. 
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3.5. DNA binding studies of the IHF mimicking peptides 
The DNA interaction of the IHF mimicking peptides was studied by means of various 
biochemical assays: 1) Agarose gel electrophoresis to study their influence on binding 
and unwinding of supercoiled plasmid DNA. 2) Native and non-denaturing 
polyacrylamide gel electrophoresis to test their binding with IHF consensus DNA 
sequence either including or excluding adjacent guanine residues, the preferred site for 
platination. The former assists in monitoring binding events resulting from both covalent 
and non-covalent interactions whereas the latter assists in exclusively monitoring 
covalent linkages. 3) Thermal melting analysis to test their influence on the stability of 
the DNA duplex containing the GG site. The interactions of the platinated IHF mimics, 
IHF-2/3/4, were compared with the control peptides IHF-1, P1 and P2. 
 
3.5.1. Agarose gel electrophoresis with plasmid DNA 
Native agarose gel electrophoresis was utilized to investigate changes induced in the 
circular plasmid DNA upon interaction with various synthetic peptides (Figure 3.5). 
Platinum based compounds are known to induce local structural perturbation in DNA and 
result in unwinding of the double helix by means of covalent modification.[130] The 
agarose gel migration pattern of plasmid DNA is affected by such DNA conformational 
changes.  Typically, the unwinding of DNA resulting from platination is evident from the 
emergence of a slower migrating band.[131] The interaction of the IHF mimicking peptides 
with the DNA is governed by various forces acting simultaneously. Firstly, via electrostatic 
attraction between the lysine dendrimer, positively charged under physiological 
conditions, and negatively charged phosphates group of the DNA backbone. Secondly, by 
minor groove binding of the cyclic peptide that can interrupt structural organization of 
DNA and induce bending. Thirdly, the IHF mimics containing a platinum chelating unit can 
further enhance the DNA distortion due to their ability to covalently crosslink DNA.  The 
interactions of the negatively supercoiled pUC18 plasmid DNA were studied with various 
IHF mimicking peptides including the unplatinated mimic IHF-1, the platinated mimics 
IHF-2/3/4, the platinated peptide dendrimer P1 and the unplatinated cyclic peptide P2.  
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Due to a more condensed structure the supercoiled plasmid DNA has comparatively a 
faster gel migration than the relaxed form. Monitoring the difference in the migration 
properties of plasmid DNA upon interaction with the IHF mimicking peptides can provide 
information on their DNA binding and unwinding abilities. Prior to electrophoresis the 
peptides were incubated with the plasmid DNA for 2 h at 37 ˚C in 10 mM phosphate 
buffer, pH = 5.8 wherein the ratio of the nucleotide concentration (CDNA) to that of the 
peptide concentration (Cpeptide) (rf = Cpeptide/CDNA) was varied in a range of 0-0.15.  
The platinum containing IHF mimicking peptides IHF-2/3/4 induce a gel shift in the 
migration of the plasmid DNA within 2 h reaction time at an rf value of 0.05 whereas for 
the unplatinated mimic IHF-1 the effect is observed starting at a later rf value of 0.1. 
Therefore, the platinated IHF mimics IHF-2/3/4 have a greater unwinding effect 
compared to the unplatinated mimic IHF-1. The reason behind the enhanced unwinding 
of the platinated mimics IHF-2/3/4 could be attributed to the presence of the platinum 
metal centre as an additional functional unit forming covalent linkages with DNA, 
whereas IHF-1 can interact with DNA only through electrostatic interactions. The 
positively charged platinated peptide P1 which lacks the cyclic unit seems to cause 
perturbation in DNA conformation starting at an rf value of 0.075. On the other hand, the 
minor groove intercalating cyclic peptide P2 alone is not sufficient to induce a change in 
the migration pattern of the plasmid DNA. One of the plausible reasons could be, the 
cyclic peptide in the absence of the positively charged lysine dendrimer is insufficient to 
have electrostatic attraction with negatively charged DNA phosphate backbone. The 
effect is more prominent when comparing the cyclic peptide P2 with the unplatinated 
IHF mimicking peptide IHF-1. Moreover, the platinated lysine dendrimer P1 lacking the 
cyclic peptide domain is not as efficient as the platinated IHF mimics IHF-2/3/4 with 
respect to their DNA binding and unwinding properties. Hence, electrostatic interactions 
of the dendrimeric peptide with the plasmid DNA exclusively are also not sufficient 
enough to assist in maximizing distortion of its structure.  
Therefore, the IHF mimicking peptides IHF-2/3/4 formed by the connection of the cyclic 
minor groove recognition unit with the positively charged dendrimeric unit was 
conformed to be better in terms of their ability to induce gel shifts in the plasmid DNA 
migration pattern. Additionally, the presence of the platinum chelating unit in the IHF 
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mimics leads to enhanced binding and unwinding of the DNA by means of covalent 











Figure 3.5: Agarose gel electrophoresis to study the interaction of the IHF mimicking peptides IHF-1/2/3/4, 
the platinated lysine dendrimer P1 and the cyclic peptide P2 with the negatively supercoiled pUC18 
plasmid DNA (incubation time at 37 ˚C for 2 h, with rf varying from 0 to 0.15, 10 mM Na2HPO4/NaH2PO4, pH 
5.8, [pUC18] = 0.2 mM nucleobases, 1% agarose). 
  
3.5.2. Oligonucleotide binding studies 
Polyacrylamide gel electrophoresis was performed under native and denaturing 
conditions to study the binding interactions of the platinum complex/peptide chimeras 
with IHF consensus sequence contained within 34-mer DNA duplexes. The oligomers 
containing (3’ATTTTTTCGTAACGGATAGTTAAACAACGTTGCT5’) or excluding the 
(3’ATTTTTTCGTAACGAATAGTTAAACAACGTTGCT5’) the GG site, a preferred platination 
site. Each of the two oligonucleotides, consisting of a fluorescent 6-carboxyfluorescein 
rf      0     0.005   0.01  0.025  0.05 0.075  0.1   0.125  0.15     0 
IHF-1 IHF-2 
IHF-3  IHF-4 
       P1 P2 
rf      0     0.005   0.01  0.025  0.05 0.075  0.1   0.125  0.15     0 
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label at the 5’ end for visualization under a fluorescence imager, were annealed with 
their corresponding complimentary DNA to form duplexes D1 and D2, respectively. Prior 
to electrophoresis the peptides were incubated with DNA for 17 h at 37 ˚C in 10 mM 
Na2HPO4/NaH2PO4, 100 mM NaClO4, pH = 5.8. Molecules larger in size tend to migrate 
slowly in the gel compared to smaller molecules. Therefore, monitoring the changes in 
the migration pattern of DNA upon interaction with the peptides can provide information 
on the DNA binding properties of the peptide.[132-134] Visualization of a slower migrating 
DNA band in comparison to the band corresponding to the unbound DNA band clearly 
indicates the binding of the peptides to the DNA. While denaturing gels exclusively allow 
visualization of covalent peptide-DNA linkages, native gels provide additional information 
on the electrostatic interactions. 
Both native and denaturing gels indicate a greater binding affinity of the platinated 
peptides towards duplex D1 containing a GG site (Figure 3.6a and 3.6b) in comparison to 
duplex D2 without a GG site (Figure 3.6c and 3.6d). Additionally, the inability of the 
unplatinated peptide IHF-1 (lane 2) to bind to either of the two duplexes emphasizes the 
importance of the platinum unit for optimal interaction with DNA.  
A detailed study to test the DNA interaction of various IHF mimicking peptides with 
duplex D1 containing the platination site was performed in absence (lane 1-6) and in 
presence (lane 7-11) of cisplatin (Figure 3.6a and 3.6b, respectively). All peptides 
containing a platinum chelating unit led to retardation in the migration properties of the 
DNA duplex (lane 3-6 and lane 7-11). While excluding cisplatin in the DNA binding studies 
(lane 3-6), the mono-peptide DNA conjugate corresponds to the first highest intensity 
band with a slower migration than the unbound DNA. On the contrary, the other less 
intense bands accompanied with larger gel shifts indicate formation of multiple higher 
order peptide-DNA adducts. In the denaturing gel (Figure 3.6a), formation of the peptide-
DNA adduct with IHF-2/3/4 (lane 3-5, 40%) was more efficient than the platinated 
dendrimeric peptide P1 (lane 6, 20%). Additionally, the peptide P1 led to nearly complete 
disappearance of the unbound DNA band due to formation of several higher order 
adducts which were below detection limit. Interestingly, even with five times excess of 
cisplatin covalent binding of duplex D1 to IHF-2/3/4 (lane 7-10, 15%) and dendrimeric 
peptide P1 (lane 11, 10%) was observed. 
 





   








Figure 3.6: Gel electrophoresis to study the interaction of the IHF mimicking peptides with the 34 mer DNA 
duplex D1 consisting of a GG site and duplex D2 excluding the GG site. The samples were incubated for 
17 h at 37 ˚C in 10 mM Na2HPO4/NaH2PO4, 100 mM NaClO4, pH 5.8. (a) (b) Lane 1-11 contain 0.5 µM DNA 
duplex D1. Lane 2-6 contain 10 µM of IHF-1, IHF-2, IHF-3, IHF-4, dendrimeric peptide P1 respectively and 
lane 7-11 contain 50 µM cisplatin in addition to IHF-1, IHF-2, IHF-3, IHF-4 and peptide P1 respectively. (c) 
(d)  Lane 1-6 contain 0.5 µM DNA duplex D2. Lane 2-7 contain 10 µM of IHF-1, IHF-2, IHF-3, IHF-4, 
dendrimeric peptide P1 and the cyclic peptide P2 respectively. (a) (c) Performed under denaturing 
conditions (20% PAA, 7 M urea, 1x TBE). (b) (d) Performed under native conditions (20% PAA, 1x TBE).  
 
In the native gel (Figure 4b), both in absence and presence of cisplatin the peptide-DNA 
adduct formation with duplex D1 was much better with IHF-2/3/4 (lane 3-5, 50% and 
lane 7-11, 31%) compared to that in denaturing gel. These results indicate that the IHF 
mimicking platinum complex/peptide chimeras compete for the same site as cisplatin for 
covalent modification of DNA and at the same time they are also able to non-covalently 
interact with the cisplatin modified DNA. In conclusion, the overall design of the IHF 
mimicking peptides is once again verified to be optimal for maximizing DNA binding 
efficiency of the chimeric peptides.        
(b) 
     1         2           3         4         5          6          7         8          9        10       11 
 Control  IHF-1  IHF-2  IHF-3  IHF-4    P1    IHF-1   IHF-2   IHF-3   IHF-4   P1 +  Cisplatin 
  1           2           3           4          5           6         7           
Control  IHF-1   IHF-2   IHF-3  IHF-4      P1      P2     
(c) 
(d) 
   1         2            3          4          5           6          7           
Control   IHF-1   IHF-2   IHF-3  IHF-4    P1       P2     
+  Cisplatin 
  1          2          3          4          5         6         7           8          9        10       11 
(a) 
     Control   IHF-1   IHF-2   IHF-3   IHF-4    P1      IHF-1   IHF-2   IHF-3   IHF-4    P1
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3.5.2.1. Analysis of sequence specificity of IHF  
In order to test the sequence specificity of the platinated IHF mimicking peptides their 
binding interactions were tested with various DNA duplexes containing a GG site. The 
duplexes D1 and D3-D11 were employed in this study (Table 3.1). The duplexes D1 and 
D3-D10 contain a GG site at distinct positions within the IHF consensus sequence while 
the conserved bases remain intact whereas the duplex D11 is a GG site containing 
random DNA sequence. The peptides were incubated with each DNA duplex for 17 h at 
37 ˚C in 10 mM Na2HPO4/NaH2PO4, pH = 5.8 prior to electrophoresis under native and 
denaturing conditions. All three platinated mimics IHF-2/3/4 seem to have identical 
interaction with every DNA duplex indicating a lack of sequence specificity of the IHF 











Figure 3.7: Gel electrophoresis assay to study the interaction of the IHF mimicking peptides with the 
34 mer DNA duplex consisting of a GG site. The duplexes D1 and D3-D10 consist of the IHF consensus 
sequence whereas the duplex D11 is a random sequence. The samples were incubated for 17 h at 37 ˚C in 
10 mM Na2HPO4/NaH2PO4, 100 mM NaClO4, pH 5.8. Lane 1-11 contain 0.5 µM DNA duplex with 10 µM of 
IHF-4. (a) Performed under native conditions (20% PAA, 1xTBE). (b) Performed under denaturing conditions 
(20% PAA, 7 M urea, 1x TBE).  
 
Control                      D3          D4          D5          D6          D1         D7         D8          D9       D10       D11 
Control                      D3          D4        D5          D6          D1         D7         D8          D9       D10       D11 
    1                                2           3            4            5            6            7             8            9          10          11 
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Table 3.1: Various GG site containing DNA sequences utilized in binding experiments for determining 
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3.5.3. Thermal melting analysis  
Temperature dependent UV spectroscopy was utilized in order to obtain further insight 
into the interactions of IHF mimicking with the 34-mer duplex D1, consisting of the IHF 
consensus sequence and including a GG site within (Figure 3.8). The platinated IHF 
mimicking peptides can influence the thermal stability of the duplex in the following two 
ways: 1) Firstly, they can enhance the duplex stability by binding of peptides utilizing 
minor groove recognition of the cyclic domain and electrostatic interactions of the 
positively charged dendrimeric domain. 2) Secondly, the covalent modification of DNA 
with the platinum chelating unit can either destabilize the duplex when intrastrand 
crosslinks are formed or stabilize the duplex when d(GpG) interstrand crosslinks are 
formed. The melting profile is therefore visualized as a net result of the two 
counteracting effects.[135, 136]  The peptides were pre-incubated with the DNA duplex D1 
in 10 mM phosphate buffer, pH = 5.8 for 17 h at 37 ˚C. Thermal denaturation process was 
measured by heating the sample from 20-95 ˚C whereas the renaturation process was 
measured by cooling from 95-10 ˚C. The thermal melting temperatures (Tm) were 
determined for both heating and cooling cycle by calculating the maxima of the first 
derivative of the corresponding curve (Table 3.2). 
Thermal denaturation and renaturation cycle for duplex D1 (1 µM, 10 mM 
Na2HPO4/NaH2PO4, pH = 5.8) have the same melting temperature when measured alone 
as well as upon incubation with the unplatinated IHF mimics peptides, IHF-1 
(Figure 3.8 A) and cyclic peptide P2 (Figure 3.8 B). The unplatinated IHF mimic IHF-1, on 
the one hand induced a drastic increase in duplex D1 melting temperature (ΔTm ≥ 12 ˚C), 
the cyclic peptide P2 on the other hand induced a mild stabilization effect (ΔTm ~ 1 ˚C). 
This result points towards the ability of the unplatinated IHF mimic IHF-1 to interact with 
the duplex with the help of electrostatic interactions with negatively charged phosphate 
groups on the DNA backbone and hence, enhancing the duplex stability. On the contrary, 
the cyclic peptide P2 lacking the positively charged dendrimeric unit can only interact 
minimally with the DNA duplex. Moreover, the attachment of the dendrimeric unit is 
necessary to bring the cyclic peptide in close proximity to the DNA for facilitating its 
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minor groove recognition. However, the melting profile of the platinated IHF mimics 
IHF-2/3/4 and the dendrimeric peptide P1 were not found to be reversible for the 
heating and the cooling cycle. 
                              
                   








Figure 3.8: The thermal denaturation and renaturation profiles of duplex D1 studied after pre-incubation 
(A) with the unplatinated IHF mimicking peptide IHF-1 and (B) with the cyclic peptide P2 as well as DNA 
alone for 17 h at 37 ˚C (1 µM of DNA with 5 µM of peptides) in 10 mM Na2HPO4/NaH2PO4, pH = 5.8.  
In the heating cycle, all three of the platinated IHF mimics IHF-2/3/4 (ΔTm ~ 6-8 ˚C) as 
well as the platinated dendrimeric peptide P1 (ΔTm ~ 4 ˚C) demonstrate a net increase in 
the duplex stability (Figure 3.9 A and Figure 3.9 B, respectively). However, the increase is 
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duplex DNA undergoes complete denaturation at elevated temperatures, the resulting 
single stranded DNA can readily react with the platinum complex/peptide chimera, 
thereby, facilitating covalent modification of DNA with the platinated peptides. As a 
result of this, the subsequent renaturation of the duplex gets disrupted and is 












Figure 3.9: The thermal denaturation and renaturation profiles of duplex D1 studied after pre-incubation 
(A) with the platinated IHF mimicking peptide IHF-2/3/4 and (B) with the lysine dendrimer P1 as well as 
DNA alone for 17 h at 37 ˚C (1 µM of DNA with 5 µM of peptides) in 10 mM Na2HPO4/NaH2PO4, pH = 5.8. 










Denaturation (20-95) ˚C 
  
Renaturation (95-10) ˚C 
   
Peptide[a] Tm (˚C) ΔTm
b
 (˚C)  Tm (˚C) ΔTm
c
 ˚C 
Control 53.6±0.5 -  52.7±0.1 - 
IHF-1 65.6±0.1 +12  66.0±0.1 +13.3 
IHF-2 61.5±1.5 +7.9  50.2±0.9 -2.5 
IHF-3 62.1±0.9 +8.5  50.0±0.1 -2.7 
IHF-4 59.6±0.6 +6.0  50.6±0.6 -2.1 
P1 57.9±0.3 +4.3  51.1±0.7 -1.6 
P2 54.1±0.1 +0.5  53.9±0.1 +1.2 
 
 
Table 3.2: Summary of melting temperatures (Tm) and changes in melting temperatures (ΔTm) of a GG site 
containing duplex for two subsequent cycle, heating from 20-95 ˚C (denaturation) and cooling from 95-10 
˚C (renaturation). [a] The peptides were pre-incubated with the duplex D1 for 17 h at 37 ˚C in 10 mM 
phosphate buffer, pH = 5.8 wherein the concentration of the DNA was 1 µM and the concentration of the 
peptide was 5 µM. [b] [c] ΔTm
 
represents Tm (in the presence of peptide) - Tm (control DNA) for the heating 




















4. The Zif268 zinc finger domain – as a model 
nuclease 
 
The design of bio-inspired metalloenzymes is an attractive approach to mimic the target 
specificity and activity of naturally occurring enzymes. Metal ions not only play a 
structural role by stabilizing the protein folds but also play a functional role by assisting in 
biochemical transformations. Moreover, metal complexes have tremendous potential to 
interact with nucleic acid sequences by means of electrostatic interactions between the 
cationic metal centre and the negatively charged DNA. The main targets of metal 
complexes within a DNA sequence include oxygen atoms of the phosphate groups, 
various atoms of the nucleobases as well as hydroxyl groups of the sugar unit. The 
previous section elaborated the ability of the platinum complex to covalently modify 
DNA by binding to guanine residues that results in a cytotoxic effect. Apart from this, it is 
also well known that certain metal complexes assist in hydrolytic cleavage of the 
phosphodiester bonds in DNA. The combination of such metal complexes possessing 
DNA cleaving ability with a biomolecular scaffold possessing DNA recognizing properties 
has the potential to develop novel sequence selective model nucleases. This section 
sheds light on the design of artificial zinc finger nucleases targeted towards the 
consensus DNA sequence of the native zinc finger domain.  
   
4.1. Zinc finger domains  
The zinc finger domain is one of the most widely occurring DNA binding motifs 
performing diverse functions in eukaryotic cells including regulation of gene expression 
and apoptosis, protein assembly, RNA packaging, lipid binding, etc. In nature the zinc 
finger domains usually occur as a tandem repeat of three or more single zinc fingers, 




structural role by inducing and stabilizing protein folds around itself. Based on the 
coordination sphere around the metal centre, the zinc fingers can be classified into 
different types such as Cys2His2, Cys4 and Cys6. The first zinc finger motif was discovered 
in the Xenopus laevis transcription factor IIIA which is a Cys2His2 type occurring as a 
tandem repeat of nine single zinc fingers.[138] Adjacent fingers are stitched together by a 
linker sequence TGXKP (X is any amino acid), highly conserved among the Cys2His2 type 
of zinc finger domains. These constructs play an essential structural role in facilitating 
DNA recognition by maintaining appropriate spacing between two consecutive domains. 
The wide occurrence of the Cys2His2 of zinc finger motifs, together with their ability to 
interact not just with DNA but also with RNA and some other proteins, makes them an 
interesting target for a detailed elucidation of structure and recognition properties.[139]  
 
4.2. Interaction of the Cys2His2 type of zinc finger domain Zif268 with 
the consensus DNA binding site 
The consensus sequence of the Cys2His2 type of zinc finger, consisting of nearly 30 amino 
acids, is of the form (F/Y)-X-Cys-X2-5-Cys-X3-(F/Y)-X5-Ψ-X2-His-X3-5-His in which Ψ is an 
amino acid residue with a hydrophobic side chain whereas X can be any amino acid 
residue.[140]  The structural stability of the zinc finger domains is dependent solely on a 
small set of conserved amino acids. Coordination of the conserved cysteine and histidine 
residues with the zinc ion drives the folding process of individual zinc fingers to form a 
3-dimensional compact globular domain consisting of an antiparallel β-sheet and an 
α-helix (Figure 4.1a). Two of the conserved cysteine residues are located in the β-sheet 
fold while the other two conserved histidine residues are present in the α-helix. The 
removal of the zinc ion leads to denaturation of the protein,[141] and replacing either of 
the conserved histidine or cysteine ligands leads to inactivity of the protein.[142, 143]  
Additionally, the core of the zinc finger domain consisting of three conserved 
hydrophobic amino acids, Tyr5/Phe5, Phe16 and Leu22, plays a crucial role in 
determining its structural stability by holding the entire construct around the zinc 




towards its role in mediating DNA binding. Furthermore, sequence specificity arises from 
base pair interaction with side chains of particular amino acid residues located at the 












                                  




Figure 4.1: (a) Structure of single Cys2His2 type of zinc finger in Zif268 wherein binding of the Zn
2+
 to two of 
the cysteine and histidine residues along with a conserved hydrophobic core stabilizes the ββα fold. 
(b) Zif268 domain wrapped around the consensus DNA binding site (5'-GCGTGGGCGT-3')* 
(5'-ACGCCCACGC-3') as a tandem repeat of three zinc fingers shown in red, purple and green, respectively 
(pdb code: 1AAY).
[9]
 Images genetrated by PyMOL. (c) The amino acid sequence derived from the Zif268 
domain utilized in this study, wherein the α-helical domains are highlighted in grey, the anti-parallel 
β-sheets in blue and the conserved hydrophobic residues are star marked.
[9] 
 
X-ray crystallographic analyses were performed in order to understand the structural 
aspects of the zinc finger domains that facilitate site-specific recognition of DNA 
(Figure 4.1b). The polypeptide consisting of a tandem repeat of three zinc finger domains 
of the murine protein Zif268 was co-crystallized with its consensus binding site, 
(a) (b) 
(c) 




(5'-GCGTGGGCGT-3')*(5'-ACGCCCACGC-3').[9] The sequence of the polypeptide consisted 
of 90 amino acid residues (Figure 4.1c). The crystal structure of the Zif268 complex 
displays the protein wrapped around the major groove of DNA, making conserved base 
pair contacts with amino acid residues placed at positions -1, 2, 3 and 6 in the α-helical 
domain. The position of the α-helix of individual zinc finger domain in the major groove is 
slightly slanted such that the axis of the α-helix is oriented at an angle of 45˚ with the axis 
of the DNA duplex. The binding of the Zif268 is accompanied with widening of the major 
groove.[145] The amino acid residues at positions -1, 3 and 6 contact the three consecutive 
base pairs on the primary DNA strand whereas the residue at position 2 contacts the 
nucleobase in the complementary strand (Figure 4.2).[146]  
                      
 
Figure 4.2: Representation of the interactions between various amino acid residues within the Zif268 
domain and its consensus DNA binding sequence.
[146] 
 
It is interesting to note that among all three zinc fingers within Zif268 domain, the 
residues at -1 and 2 are identical. An arginine at position -1 exhibits hydrogen bonding 
interactions with a guanine whereas an aspartic acid at position 2 interacts with the 
exocyclic amine of an adenine/cytosine on the complementary DNA strand (Figure 4.3a). 
Furthermore, the residues interact with the phosphate backbone of DNA via bridging 
water molecules as well as with each other via hydrogen bonding between the aspartate 




residue forms a hydrophobic contact with cytosine whereas in finger 2 a histidine residue 
forms hydrogen bonding with a guanine residue in addition to van der Waals interaction 
with a neighbouring thymine (Figure 4.3b). Additional interactions are provided by an 
arginine residue at position 6 in fingers 1 and 3 which is involved in hydrogen bonding 
with a guanine (Figure 4.3c). Taking all these interactions into consideration it is apparent 
that the recognition of DNA by zinc finger domains is predominantly driven by the helical 
domain.[148, 149] Therefore, individual zinc fingers recognize a subsite of the DNA duplex 
consisting of four base pairs, three of which belong to the primary DNA strand and the 
fourth one lies on the complementary DNA strand interacting with the residue at 
position 2 in helical domain. The latter interaction causes adjacent zinc finger domains to 
have an overlap in the recognition subsite and plays an important role in determining the 
specificity of binding a particular DNA sequence. Moreover, a tandem repeat of three 
zinc fingers in the Zif268 motif substantially enhances the sequence specificity by making 
contacts with 9 consecutive base pairs on the primary DNA strand. Adopting this modular 
design of zinc fingers and applying a combinatorial approach offer the possibility to 
enhance the span of specifically recognizing a multitude of DNA sequences of a varying 
length.   
   
 
 
Figure 4.3: (a) Interaction of the conserved arginine at position -1 with the aspartic acid at position 2 within 
the α-helical domain as well as with the guanine and cytosine on the primary and complementary DNA 
strand, respectively.  (b) Interaction of the histidine at position 3 in finger 2 with a guanine on the primary 








4.3. Engineering zinc finger domains 
The unique framework of the Cys2His2 type of zinc finger domain in combination with the 
available selection strategies offers the possibility to engineer a specific DNA binding 
protein for targeting any given nucleic acid sequence.[146] Chimeric protein domains can 
be prepared by the combination of such DNA binding modules in order to accommodate 
other domains known to perform certain biochemical transformations such as DNA 
cleavage, mutagenesis, transcription activation and repression, gene correction and 
silencing (Figure 4.4).[147] The novel chimeric domains acquire enhanced recognition 
properties from the zinc finger DNA binding module and hence are able to target the 
specific gene of interest. In this section emphasis has been laid on the design of zinc 
finger nucleases for site specific DNA cleavage with the aim of developing artificial 
restriction endonucleases. 














Figure 4.4: An overview of the diverse biochemical transformations performed by engineered zinc finger 
proteins prepared by combination of the zinc finger DNA binding module with various functional domains 
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4.3.1. Sequence selection  
In order to understand the aspects of sequence recognition by the zinc finger motifs 
several techniques have been employed including X-ray crystallography, NMR studies, 
site specific mutagenesis and phase display experiments. The cocrystal structure of the 
Zif268-DNA complex clearly indicates the importance of amino acid residues located at 
positions -1, 2, 3 and 6 in the recognition α-helix for DNA binding.[9, 150, 151] By means of 
interactions with the DNA major groove, these residues facilitate individual zinc finger 
domains to recognize a three base pair code. The specificity of binding towards a target 
DNA sequence can be altered by exchanging one or more amino acid residues at these 
key positions.  
                  
Figure 4.5: The interactions of amino acid side chains located at the key positions (-1, 2, 3, 6) in the 
recognition helix with a given 4 base pair subsite on the DNA duplex. The amino acids marked in bold are 
the most frequently observed in phage display assay for specificity towards a particular base pair 
interaction and those marked with an asterisk are frequently found in structural analysis. The interaction of 
the question marked amino acids is uncertain with the corresponding base pair whereas blank positions in 




Phage display methods provide a more rational route to identify novel zinc finger motifs 
with distinct DNA binding specificities.[152-156] The method relies on the selection of amino 
acid sequences for the zinc finger domain under consideration from a randomized 
library. Comparison of similarities in sequences that are capable of recognizing the same 
nucleotide triplet allows deduction of a recognition code, which can be visualized as a 




interaction (Figure 4.5).[149, 154] The main drawback of this method is that it assumes 
these interactions to be completely independent of each other. Furthermore, when 
considering a tandem repeat of zinc fingers the binding of adjacent fingers is a synergistic 
event due to an overlap in the DNA binding subsite consisting of 4 base pairs. However, 
this interdependence of neighbouring domains is not taken into account during the 
sequence selection procedure. The method is biased towards selection of a three base 
pair code of the form GNN (wherein N is any nucleotide), hence limiting the selection of 
the recognition code from a very confined subset of trinucleotide sequences.[157] The 
solution to overcome this limitation lies in exploiting the very synergistic binding of 
adjacent zinc fingers. Though, the proposed recognition code is not always most suited 
with respect to its binding specificity but can provide valuable information to begin with 
predicting the possible sequences. Further optimization can lead to better sequence 
choices.  Several advances have been made in strategies to design a specific binder for a 
longer preset DNA sequence. These strategies include a combination of single 
preselected fingers,[158]  sequential selection of individual fingers to build the polymeric 
protein[159] or parallel selection of domains from two premade libraries followed by 
splicing the two selected units.[160]  
 
4.3.2. Zinc finger nuclease technology 
One of the most attractive applications of the zinc finger DNA binding module is to design 
artificial endonucleases with specificity for novel restriction sites. Restriction enzymes 
are often put to use in biotechnology and molecular biology field for genome editing in 
cell lines.  Though several restriction enzymes are currently available, they are not always 
able to offer flexibility in choosing the desired recognition site. Engineering zinc finger 
proteins with novel sequence specificities has enormous potential in broadening the 
versatility of restriction enzyme recognition sites.[161-163] 
The zinc finger nuclease technology offers a method to design chimeric custom-made 
domains for site specific cleavage of DNA. In this technique, a non-specific DNA cleavage 




zinc finger modules with predetermined sequence specificity. The objective is to 
generate a double strand break (DSB) in the desired DNA binding site.[164] A DSB is 
achieved only by the dimeric form of the FokI endonuclease when two individual DNA 
cleavage domains are placed in close proximity to each other.[147, 165, 166] Two conjugate 
zinc finger domains bind along with the FokI domain to their corresponding closely 
positioned inverted binding sites (Figure 4.6). The in situ generated dimeric active 
nuclease leads to hydrolytic cleavage of the phosphodiester linkages in the DNA 
duplex.[147] It is important to note that the method is readily applicable to 
nonpaIindromic sequences by choosing different zinc finger DNA binding modules on 
either side of the cleavage site. A dimeric zinc finger nuclease with each monomer 
consisting of three fingers can specifically recognize a sequence of 12-18 base pairs which 
is practically sufficient to site specifically cleave a single gene from the genome of an 
organism. Implementation of the zinc finger nucleases allow high precision site directed 
mutagenesis by means of primary intrinsic repair processes termed as homology directed 
repair (HDR) and non-homologous end joining (NHEJ). HDR works by “copy and paste” 
mechanism facilitating site specific recombination in the presence of a donor 
sister chromatid as a template, leading to insertions and corrections in a gene.[167] NHEJ is 
simple ligation of the broken ends of the DSB that occurs in the absence of a template 
DNA facilitating targeted mutations and knockout of large genes.[168] Thus, the zinc finger 
nucleases technology offers tremendous potential in the direction of genetic engineering 
and developing clinical targets for human gene therapy.  
   
Figure 4.6: Induction of double strand break (DSB) in DNA by the heterodimeric zinc finger nuclease (ZNF) 
constructed by combination of the natural nuclease domain of FokI endonuclease with the two different 






4.4. Hydrolytic cleavage of DNA phosphodiester linkage by 
multinuclear metal complexes  
The importance of designing DNA cleaving agents with novel specificities has become 
apparent due to its wide range of applications.[161-163, 169-172] Despite being very stable 
under physiological conditions (pH  ̴7), the negatively charged DNA is an excellent target 
for metal cations as a result of electrostatic attraction forces between the two. Several 
naturally occurring nucleases consist of metal binding sites assisting in the cleavage of 
phosphodiester linkages.[173-175] The binding of the metal ion to a water molecule results 
in significant lowering of its pKa generating a more nucleophilic hydroxide group even at 
physiological pH, which plays a key role in the hydrolytic reaction (Figure 4.7).[176, 177] 
Moreover, the metal ion assists in pre-organization of the active site as well as in charge 
neutralization and stabilization of the incoming nucleophile, the DNA phosphate groups, 
the transition state intermediates and the leaving group. Understanding the mechanism 
of DNA cleavage used by natural metallonucleases can assist in the design of highly 
efficient artificial nucleases.  
 
                          
     
Figure 4.7: Enzymatic cleavage of the phosphodiester linkage at P-O3'.
[171] 
 
Typically, the active site of metalloenzymes consists of multinuclear metal binding sites 
acting cooperatively in the catalytic reaction. First row transition metals complexes, 




charge density and Lewis acid character.[171, 172, 176, 177] Metalloenzymes for the cleavage 
of phosphate linkages such as the alkaline phosphatase utilizes a binuclear Zn(II) complex 
within the catalytic core whereas phospholipase C and P1 nuclease rely on a tri-nuclear 
Zn(II) complex for their activity (Figure 4.8).[178, 179] While phospholipase C and 
P1 nuclease preferably cleave phosphodiester linkages, alkaline phosphatase has a 
different substrate selectivity and is involved in hydrolysis of monoesters.  
 
                  
 
Figure 4.8: Examples of multinuclear zinc complexes involved in cleavage of phosphate linkages.
[178, 179] 
 
Alkaline phosphatase is one of the most extensively studied among all binuclear zinc 
based enzymes facilitating phosphate transfer reaction in a series of intermediate steps 
(Figure 4.9).[173, 175] The presence of a binuclear metal coordination within the active site 
significantly enhances the rate of hydrolytic reaction.[180-183] While one of the two Zn(II) 
ions coordinates with the ester oxygen, the other coordinates with the phosphate 
oxygen of the substrate creating a phosphate bridge between the metal centres. The 
second Zn(II) centre activates the serine residue for nucleophilic attack on the 
phosphorus atom leading to the formation of a phosphoserine enzyme intermediate. 
This leads to the cleavage of the phosphate ester and sets the first Zn(II) coordination site 
free. The newly generated vacant site becomes available for a water molecule. Activation 
of the water molecule upon coordination with the Zn(II) ion at an alkaline pH results in 
formation of a hydroxide species, which subsequently leads to hydrolysis of the 
phosphoserine linkage. In addition to the two central Zn(II) ions that are placed at an 
optimum distance of 4 Å for facilitating the enzymatic reaction, a third Mg(II) ion is 




the catalytic reaction the Mg(II) ion has been found to play an auxiliary role in enhancing 
the activity of the enzyme.[173, 183, 184]  
                                       
 




4.4.1. Biomimetic systems as artificial nucleases 
Design of biomimetic systems provides a way to harness the potential of multinuclear 
metalloenzymes for the development of therapeutic agents as well as assists in 
elucidating the mechanism of the enzymatic reaction itself.[185] The side chains of amino 
acid residues including imidazole of the histidine residue, sulfide of the cysteine, and 
carboxylate of aspartic and glutamic acid are the most common metal coordinating 
ligands within protein domains. In order to mimic metalloenzymes, the same metal ions 
as utilized in the native system should be employed. Additionally, the artificial metal 
ligands should be designed such that they are functionally and structurally similar to the 
amino acid residues coordinating to the metal ion in the natural system. Furthermore, in 
the multinuclear ligand systems the metal ions should be positioned in close proximity to 
each other to facilitate optimal conditions for the catalytic reaction. This task is fulfilled 
by utilizing bridging ligands such as phenolates, carboxylates, pyrozolyl rings, macrocycles 
or aliphatic linkers, in design of functional model complexes for holding the metal centres 




aromatic azacycles offers the possibility to control the hydrolytic cleavage of 
phosphodiester linkages by manipulating the pH of the system.[189]  
 
 





4.4.2. Design of site specific model nucleases utilizing DNA recognition 
motifs   
The combination of DNA cleaving domains with DNA recognizing domains has not only 
shown to improve their recognition properties but also immensely enhances their 
nuclease activity.[190, 191] Moreover, this approach offers the possibility to design artificial 
restriction enzymes for site-specific cleavage of any given DNA sequence. As discussed in 
the previous section, binuclear metal centre play a key role in determining the activity of 
most of the natural nucleases. Hence, bimetallic ligands systems, mimicking the active 
site of the natural nuclease, with an ability to hydrolyse phosphodiester linkages can be 
utilized as DNA cleaving functionalities. Examples of DNA binding domains applied for the 
design of high affinity hybrid biomimetic systems include DNA intercalators, peptides, 
peptide nucleic acid sequences and antisense oligonucleotides.[192-195] One of the most 




complex within the DNA binding domain while retaining its DNA recognition property as 
well as meeting the requirements for effective DNA cleavage.  
   
 
Figure 4.10: (a) The structure of binuclear Zn(II) chelating heptapeptide. (b) The mode of binding of the 




The peptide based binuclear Zn(II) complex reported by Scrimin and co-workers 
demonstrated an exceptional ability to cleave plasmid DNA with a first order rate 
constant of 1.0  10-5 s-1 at pH 7.0 and 3.6 µM complex concentration.[171, 193] The 
peptide sequence consisted of seven amino acid residues forming a 310-helical domain 
from which two Tacn (triazacyclononane) ligands protrude (Figure 4.10). The two Zn(II) 
coordinating ligands facing each other are spaced apart by a distance of 6 Å. Despite not 
satisfying the criteria of optimum intermetallic distance as found in natural nuclease, the 













5. Synthesis and DNA interaction of a modified 
Zif268 domain containing an allosteric metal 
binding site 
 
The versatility to engineer zinc finger domains for any given DNA sequence offers the 
possibility to attain a high degree of specificity towards the cognate DNA. Furthermore, 
the role of the zinc coordination site within the zinc finger domains can be extended 
from merely being a structural entity into a catalytically active site for facilitating 
reactions such as DNA cleavage. However, introduction of the artificial metal binding 
pockets in protein domains is a challenging task as it can potentially disrupt the three 
dimensional geometry of the protein. Therefore, the design of the multinuclear ligand 
systems should be carefully chosen such that they resemble naturally occurring amino 
acids and fit appropriately into the catalytic domain of the protein. This section sheds 
light on the synthesis of an artificial binuclear zinc chelating amino acid mimicking 
histidine and its incorporation into the Zif268 domain.  
The Zif268 domain utilized in this study consists of a tandem repeat of three individual 
zinc fingers in order to enhance sequence specificity towards the cognate DNA. The first 
two zinc fingers (Zf12) were prepared by expression in E. coli whereas the third zinc 
finger (Zf3) was modified to contain the histidine mimicking amino acid. The two peptide 
fragments were combined by native chemical ligation to form the Zf13 domain 
containing a tandem array of three zinc fingers. The DNA interaction properties of the 
various Zf13 domains prepared by following the semi-synthetic strategy were studied 
with its consensus DNA sequence. The ultimate goal of the project is to design an 
artificial nuclease for site-specific cleavage of DNA by utilizing the recognition properties 






5.1. Synthesis of an artificial amino acid mimicking histidine 
The Zif268 is a Cys2His2 type of zinc finger domain wherein two histidine and two cysteine 
residues of single zinc finger domains complex with a Zn(II) to form the ββα protein fold. 
Modification of the Zif268 domain was carried out by replacing a histidine residue with 
an artificial histdine mimicking amino acid. A substituted triazole derivative was 
employed to resemble the imidazole ring of the histidine and functionalized with a 1,4,7-
triazacyclononane (Tacn) ring.[11] While the N2 or N3 atoms of the triazole ring readily 
available for coordination with various metal ions provide the first metal binding site,[196, 
197] the Tacn ring consisting of three nitrogen atoms provides the second metal binding 
site. The dinuclear complexes of the bis(Tacn) ligand system have shown to efficiently 
cleave DNA phosphate ester linkages by cooperative action of the two metal centres 
strategically placed in close proximity to each other.[186, 198, 199] Incorporation of such 
Zn(II) chelating units within the Zif268 domain facilitate introduction of an allosteric 
metal coordination site in addition to the native site and hence, offer the possibility to 
assist in site-specific cleavage of DNA phosphodiester linkages. 
Click chemistry approach offers a bio-orthogonal synthetic strategy for preparation of 
triazoles by coupling between an azide and an alkyne unit.[200] The synthesis of the 
artificial amino acid mimicking histidine was carried out according to the procedure 
reported earlier by A. Nadler.[11] In order to impart binuclear zinc chelation property to 
the artificial amino acid, a substituted Tacn ligand bearing an azide functionality was 
conjugated with Fmoc-propargylglycine. The synthesis of the azide substituted Tacn 
ligand started with tosylation of diethylenetriamine 24 (Scheme 5.1). The resulting 
N,N’,N’’-tri(tosyl)diethylenetriamine 25 was connected with ethylene ditosylate in the 
presence of sodium hydride to yield the tosyl protected triazacyclononane 26. Removal 
of the tosyl groups was followed by protection of the Tacn ring with (Boc)2O. The 
reaction led to the formation of mono-, di- and tri-boc protected Tacn ligand. The di-boc 
protected product 1,4-bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 27 was isolated 
from the mixture utilizing column chromatography. Ethylene glycol ditosylate 28 was 
treated with sodium azide to yield 2-azido-ethyl tosylate 29. Further substitution of 27 




                     
 





Finally, the synthesis of the triazole based histidine mimicking amino acid 32 was 
achieved by conjugation of the azide functionalized Tacn ligand with 
Fmoc-propargylglycine by utilizing copper(I) catalyzed azide-alkyne cycloaddition 
conditions (Scheme 5.2). The building block 32 was applied in the Fmoc SPPS protocol for 
the preparation of the Zf3 domain.   
                  
 




5.2. Preparation of the synthetic Zf3 domain   
The sequence of the Zf3 domain consists of 25 amino acid residues from Cys65 to Lys89. 
The synthesis of the peptide fragment was achieved by Fmoc based SPPS protocol 
starting from Fmoc-Lys(Boc)-Wang resin.  Standard coupling conditions using HBTU/HOBt 
as activators and DIPEA as base were applied. The deprotection of the Fmoc group was 
achieved in 20% piperidine. The peptide was cleaved off the resin utilizing a cleavage 
solution consisting of TFA/H2O/TIS/EDT (94/2.5/1/2.5). Three variants of the Zf3 domains 
were synthesized following the above mentioned procedure (Figure 5.1). The zinc finger 
domains consisting of adjacent cysteine residues readily undergo oxidation to form 
disulfide bridges with each other. The synthesized peptide fragments were isolated in the 
oxidized form after RP-HPLC purification.   
 
                    
                  
                
                
                 
 
 




Firstly, an unmodified Zf3 domain Zf3Wildtype 33 was synthesized for comparative 
studies. Secondly, the histidine residues, His81 and His85, in the Zf3 sequence were 
replaced with the histidine mimicking artificial amino acid residue one at a time leading 
to the formation of the modified zinc finger domains Zf3Tacn81 34 and Zf3Tacn85 35 
containing an additional zinc coordination site. The reduction of the disulfide containing 
peptides is necessary prior to usage and is accomplished by treatment with the highly 
selective disulfide reducing agent tris(2-carboxyethyl)phosphine (TCEP).  
 
5.3. Expressed protein ligation  
Expressed protein ligation (EPL) or intein mediated protein ligation (IPL) offers a semi 
synthetic approach for the preparation of large peptide sequences. Inteins are protein 
subdomains that enable the proteins to undergo a self splicing mechanism, thereby 
facilitating ligation of flanking ends of neighbouring protein sequences with a peptide 
linkage.[201] Exploiting this intein mediated splicing mechanism used by nature offers a 
wide range of applications in the field of biotechnology and molecular biology.[202-204] In 
this work, the self cleavage ability of inteins has been put to use for generation of a 
recombinantly expressed protein in E. coli in the form of a peptide thioester, which is one 
of the substrates for protein ligation. The EPL relies on chemo-selective native chemical 
ligation between the expressed peptide fragment consisting of a C-terminal thioester and 
the synthetic peptide fragment consisting of an N-terminal cysteine residue.  
 
5.3.1. Protein expression in E. coli for the preparation of the Zf12 domain 
The expression of the Zf12 domain was carried out utilizing the IMPACTTM kit supplied by 
New England Biolabs. The method provides a highly efficient and simplified protein 
purification protocol utilizing a C-terminal fusion expression vector such as pTXB1 for the 
generation of a C-terminal thioester. The gene coding for the Zf12 domain fused together 
with the gene coding for the intein tag, pTXB1-Zf12, was introduced into E. coli cells lines 




Furthermore, the intein tag consists of a chitin binding domain which can be exploited for 
purification of expressed protein by affinity chromatography on a chitin column 
(Figure 5.2 A). A detailed protocol for protein expression and purification of the fusion 
protein are given in section 7.2. Introduction of thiol containing compounds such as 
MesNa to the chitin column saturated with the fusion protein induces a self cleavage 
mechanism of the intein tag, facilitating separation of the Zf12 domain from itself. The 
expressed zinc finger domain, Zf12 obtained as a peptide thioester 36 after purification 
by affinity chromatography was further purified by RP-HPLC (Figure 5.2 B, 5.2 C).  
   
             
                               
 
                                 
Figure 5.2: (A) Schematic representation of the expression protocol of the Zf12 domain. (B) RP-HPLC 









5.3.2. Preparation of Zf13 domains by native chemical ligation 
Solid phase peptide synthesis developed by Merrifield,[205] is a highly versatile method 
offering the possibility to synthesize non-native peptide sequences as well as 
incorporation of artificial amino acids at any given position within the sequence. 
However, one of the major shortcomings of SPPS is its inability to synthesize large 
peptides restricting the length of the sequence to  approximately 50 amino acids.[206] The 
development of native chemical ligation (NCL) by the Kent research group,[207] has 
revolutionized the field of peptide chemistry by providing an efficient method to 
synthesize reasonably large peptide sequences. NCL is a chemoselective reaction 
between two unprotected peptides leading to the formation of a peptide linkage at the 













Figure 5.3: Representation of the native chemical ligation reaction scheme between a peptide fragment 
containing a C-terminal thioester and an N-terminal cysteine containing peptide. 
 
One of the two peptides consists of a C-terminal thioester while the other consists of an 
N-terminal cysteine residue. The reaction follows a capture/rearrangement pathway 




containing peptide undergoes nucleophilic attack with the thiol of the N-terminal 
cysteine. The second step involves a rapid and irreversible intermolecular S to N acyl shift 




Scheme 5.3: NCL between the expressed Zf12 thioester 36 and the synthetic peptide Zf3Tacn81 34 leading 
to the formation of the ligated Zf13Tacn81 38. The other two Zf13 domains Zf13Wildtype 37 and 
Zf13Tacn85 39 were prepared in an analogous manner. 
 
The Zf13 domains consisting of a tandem repeat of three zinc fingers were synthesized by 
native chemical ligation between the expressed Zf12 thioester 36 and the synthetic Zf3 
domains. The Zf3 peptide sequences after SPPS and RP-HPLC purification were isolated in 
the oxidized form containing disulfide bridges between adjacent cysteine residues. The 
Zf3 domains were reduced with TCEP to release the thiol of the N-terminal cysteine 




domain. The reactions were carried out under denaturing conditions in the presence of 
6 M Gnd.HCl to prevent aggregation while maintaining a high concentration of 
reactants.[206-208] The average yield of the ligation reaction was around 20%. The 
Zf13Tacn81 38 and Zf13Tacn85 39 consist of a histidine mimicking artificial amino acid 
bearing a triazacyclononane ligand in the Zf3 domain instead of His81 and His85, 
respectively. The Zf13Wildtype 37 is the native sequence prepared for comparative 
studies.  
       
 
Figure 5.4: Sequence of the Zf13 domains prepared by native chemical ligation: Zf13Wildtype (37), 
Zf13Tacn81 (38), Zf13Tacn85 (39). X is the histidine mimicking artificial amino acid bearing a 
triazacyclononane ligand.  
 
5.4. Determination of the structure and DNA recognition of the 
modified zinc finger domains   
CD spectroscopy offers an efficient method to study the secondary structure and folding 
patterns of biomolecules such as nucleic acid sequences and proteins. Introduction of an 
artificial amino acid residue within the zinc finger domain might perturb its 
conformational stability as well as influence its DNA recognition. In this section CD 




pattern of the modified zinc finger domains with respect to the naturally occurring zinc 
finger sequence.   
The Zn(II) ion plays a structural role in stabilizing the ββα fold around the tetrahedral  
metal  complex in zinc finger constructs.[9] The folding pattern of the modified zinc finger 
constructs Zf3Tacn81 34 and Zf3Tacn85 35 was measured in the absence or presence of 
the Zn(II) ion and compared with the unmodified construct Zf3Wildtype 33 (Figure 5.5). 
The zinc fingers were reduced with TCEP prior to use and the measurement was 
performed in 2.5 mM Tris buffer (pH = 7.8) containing 0.5 mM TCEP and 50 µM of Zf3 
peptides. CD spectra of the Zf3 domains were recorded in absence and presence of 
100 µM of Zn2+. The binding of the metal ion should be able to induce protein folding, 
thereby, making the zinc finger constructs more structured.  
 
                 




















Figure 5.5: (A) Comparison of the CD spectra of the Zf3Tacn81 34 with Zf3 Wildtype 33 in the absence and 






absence and presence of Zn(II) ion. The measurements were performed in 2.5 mM Tris buffer (pH = 7.8) 
containing 0.5 mM TCEP and 50 µM of Zf3 peptides in absence and presence of 100 µM of Zn
2+
. 
The observed CD spectra is a net result of the combination of α-helix, β-sheet and 
random coil structures. Their characteristic CD spectra are as following: 1) An α-helix 
features a negative maxima at 222 nm and 208 nm, and a positive molar ellipticity at 
193 nm.[209] 2) A β-sheet features a negative maxima at 218 nm and a positive molar 
ellipticity at 195 nm.[210] 3) A random coil features very low positive molar ellipticity at 
210 nm and negative molar ellipticity at around 195 nm.[211] With the addition of Zn(ll) ion 
all three zinc finger constructs Zf3Wildtype 33, Zf3Tacn81 34 and Zf3Tacn85 36  indicate 
an increase in the negative molar ellipticity at 222 nm, a decrease in the negative molar 
ellipticity at 208 nm and a positive molar ellipticity at 190 nm. Additionally, the negative 
molar ellipticity maximum at around 200 nm is slightly red shifted in the presence of 
Zn (II). All these spectral changes together indicate the Zf3 domains become more 
structured upon Zn(II) binding. The CD profile of the modified zinc finger domains 
Zf3Tacn81 34 and Zf3Tacn85 35 is quite similar to that of the unmodified domain 
Zf3Wildtype 33, indicating that the modification does not cause any major structural 
perturbation or changes in the folding pattern of the modified domains. Furthermore, 
the binuclear zinc chelation ability of the modified zinc finger constructs Zf3Tacn81 34 
and Zf3Tacn85 35 was confirmed by mass spectrometry utilizing the ZipTip protocol 
(Figure5.6 A and Figure 5.6 B). However, both mono-nuclear and bi-nuclear species were 
observed in the mass spectrum (see details in section 7.8.1). 
 






Figure 5.6: ESI-HRMS of the calculated charged state [M+H+2Zn]5+ of the binuclear zinc complex of 
(A) Zf3Tacn81 34 and (B) Zf3Tacn85 35.   
CD spectroscopy can also be utilized in order to study the DNA interaction of the zinc 
finger domains with their consensus DNA sequence. The CD spectrum of the 30 bp 
dsDNA 5'-GTGTGTGTGTGATCTTAGCGTGGGCGTAAG-3', consisting of the Zif268 binding 
site, was measured in the presence of the zinc finger constructs Zf3Wildtype 33, 
Zf3Tacn81 34, Zf3Tacn85 35 and Zf13Tacn85 39 and compared with that of the DNA 
alone (see appendix Figure. A1). Changes in the CD profile of the dsDNA in the presence 
of the various zinc finger domains hint towards their interaction with DNA. However, the 
observed spectral changes do not provide substantial evidence to support the DNA 
binding ability of the zinc finger constructs. Therefore, further studies utilizing a gel 
mobility shift assay were performed in order to examine their DNA binding ability.  
 
5.5. Consensus DNA binding studies  
Polyacrylamide gel electrophoresis was performed under native conditions in order to 
study the binding interactions of the zinc finger constructs with the Zif268 consensus 
sequence contained within a 30-mer DNA duplex. The duplex DNA was formed by 
annealing the oligomer 5'-GTGTGTGTGTGATCTTAGCGTGGGCGTAAG-3'consisting of a 
FAM label at the 5'-end and its complimentary sequence 5'-CTTACGCCCACGCT- 
AAGATCACACACACAC-3'. The zinc finger (1 mM) constructs were reduced with an 
aqueous solution of TCEP (5 mM) for 30 min and dialyzed against a Zn2+ rich buffer 
system (40 mM Tris, 200 mM NaCl, 1 mM TCEP, 10 µM ZnCl2, pH = 7.8) for 6 h in order to 
induce peptide folding. Subsequently, excess of Zn2+ was removed by overnight dialysis 
against a buffer system (40 mM Tris, 200 mM NaCl, 1 mM TCEP, 1 µM ZnCl2, pH = 7.8) 
with lower ZnCl2 concentration. Prior to electrophoresis the DNA was incubated with the 
peptides such that the rf (Cpeptide/CDNA) value was varied between 0 and 40. The 
incubation was carried out for 45 min at 0 ˚C in Tris buffer (40 mM Tris, 200 mM NaCl, 
1 mM TCEP, 1 µM ZnCl2, pH = 7.8). The binding of the peptide to the DNA can be 




migrating band in comparison to that of the unbound DNA corresponds to the peptide 












Figure 5.5: Gel electrophoresis assay to study the interaction of the Zf13 constructs with the 30mer DNA 
duplex consisting of the ZIF268 consensus sequence. The duplex DNA (0.5 µM) was incubated with 
increasing concentration of peptides such that the rf (Cpeptide/ CDNA) values were varied from 0 to 40. The 
incubation was done for 45 min at 0 ˚C in 40 mM Tris, 200 mM NaCl, 1 mM TCEP, 1 µM ZnCl2, pH = 7.8.  
 
The zinc finger peptides reconstituted with Zn2+ retain their intrinsic folding pattern and 
recognize their consensus DNA binding site whereas the apopeptides are unable to bind 
to the DNA (see appendix Figure A.2). The Zf13Wildtype 37 leads to the formation of a 
slower migrating band at a lower peptide concentration (rf = 1) in comparison to the 
modified zinc finger constructs, Zf13Tacn81 38 and Zf13Tacn85 39, containing an 
allosteric metal binding site (rf = 5). Therefore, introduction of the histidine mimicking 
artificial amino acid bearing the TACN ligand decreases the binding affinity of the 
modified zinc finger constructs 38 and 39.  Beyond a certain peptide concentration 
(rf > 10) the DNA begins to precipitate in the wells. The DNA is completely bound to the 
Zf13Wildtype 37 at an rf value 5, however, in case the modified Zf13 domains Zf13Tacn81 
38 and Zf13Tacn85 39 it was not possible to clearly visualize the completely bound DNA 
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5.6. Plasmid DNA cleavage experiments  
Agarose gel electrophoresis was performed in order to examine in the DNA cleavage 
ability of the modified Zf13 constructs. The pJET cloning vector was engineered to 
contain the Zif268 consensus DNA sequence at two different positions within the plasmid 
DNA as binding sites for the Zf13 domain. The zinc finger constructs were reduced 
followed by reconstitution with Zn2+ ion according to the procedure mentioned in section 
5.5. Excess of unbound Zn2+ ion was removed by overnight dialysis against a buffer 
system (40 mM Tris, 200 mM NaCl, pH = 7.8) completely excluding Zn2+ and TCEP as they 
were found to interfere with the DNA cleavage assay. Prior to electrophoresis the DNA 
was incubated with the peptides such that the rf (Cpeptide/CDNA) value was varied between 
0 and 600. The incubation was carried out for 72 h at 37 ˚C in Tris buffer (40 mM Tris, 
200 mM NaCl, pH = 7.8). The supercoiled form of plasmid DNA due to its compact 
structure migrates faster on gel in comparison to the open circular form. The cleavage of 
a phosphodiester linkage in the supercoiled form results in the formation of the open 
circular form of the plasmid DNA. Thus, the DNA cleavage ability of the zinc finger 
constructs can be monitored by the formation of increasing amount of the slower 
migrating open circular plasmid DNA.   
The Zf13Wildtype 37 influences the migration pattern of both the supercoiled and 
relaxed form of DNA (Figure 5.6 A). However, there is no evidence of DNA cleavage as 
the amount of open circular form of DNA remained constant even after a prolonged 
incubation time of 72 h with the peptide. The changes in the migration properties of the 
supercoiled and relaxed form of DNA could be associated with induction of DNA 
conformation changes upon binding to the Zf13Wildtype 37. On the contrary, the 
modified zinc finger constructs Zf13Tacn81 38 and Zf13Tacn85 39 led to a mild increase 
in the intensity of the open circular form of plasmid DNA, starting at an rf value 100. 
However, increasing the rf value did not seem to improve the DNA cleavage reaction and 
led to precipitation of the sample in the wells (Figure 5.6 B and Figure 5.6 C).  Further 
experiments need to be performed in order to optimize the cleavage reaction as well as 

















Figure 5.6: Agarose gel electrophoresis to study the DNA cleavage ability of the Zf13 constructs 
Zf13Wildtype 37, Zf13Tacn81 38 and Zf13Tacn85 39 with pJET cloning vector modified to containing two 
Zif268 binding site. The DNA was incubated with the peptides at 37 ˚C for 72 h, with rf (Cpeptide/CDNA) varying 
from 0 to 600, 40 mM Tris, 200 mM NaCl, pH = 7.8 and electrophoresis was performed on 1% agarose gel. 
(A) 
Zf13Wildtype (37) 
 rf       0         100      200       300      400      500    600 


























6. Summary and Conclusion 
Peptide-DNA recognition plays an important role in performing several essential 
biochemical functions in the cell. Development of strategies to modulate these 
interactions has the potential to control cellular events such as transcription, regulation 
of gene expression, recognition and repair of damaged genes, etc.  The design of small 
model peptides presented in this work is based on appended domains of proteins which 
are found to be crucial in terms of generating a particular response or function. The 
model peptides include metal binding sites due to their well defined geometry and ability 
to stabilize the entire protein structure around the coordination sphere of the metal ion. 
Moreover, peptidomimetic scaffolds based on chimeric metal-peptide conjugates offer a 
possibility to harness the recognition properties of natural metalloenzymes and hence, 
assist in performing biochemical reactions in a sequence specific manner.   
The first part of this thesis (chapter 2 and 3) sheds light on the potential of hybrid 
platinum complex-peptide conjugates and their applicability in developing novel 
potential chemotherapeutic agents. One of the main reasons behind the 
chemotherapeutic ability of cisplatin and related platinum drugs is their ability to bind to 
adjacent guanine residues within a DNA sequence and produce a kink in the duplex.[43-47] 
However, the currently available platinum based chemotherapeutics lack specificity 
towards DNA and their use is often associated with undesired toxic side effects.[20] The 
main idea behind the design of chimeric platinum complexes was to improve DNA 
targeting in chemotherapy. Furthermore, design of such chimeric drugs with enhanced 
recognition and improved pharmacological properties has the potential to overcome the 
drawbacks of the currently marketed chemotherapeutics. IHF is a DNA architectural 
protein binding to its consensus sequence with a high degree of specificity.[109] The 
binding of IHF to the DNA minor grove is accompanied by induction of a sharp U-turn in 
the duplex by intercalation of a proline residue in between adjacent base pairs.[5] The 




have a synergistic effect on the DNA bending and binding properties of the hybrid 
platinum complex (Figure 6.1). 
 
               
 
Figure 6.1: DNA targeting utilizing a chimera of a Pt complex and an IHF mimicking peptide by means of 
minor grove binding and electrostatic interactions with negatively charged DNA. 
 
The design of the platinum complex/peptide chimera proposed in this study is based on a 
model peptide reported earlier in Diederichsen group.[6] Various peptides were 
synthesized that mimicked subdomains of IHF in order to establish enhanced DNA 
recognition. The DNA interaction properties of the unplatinated IHF mimic IHF-1, 
platinated IHF mimics IHF-2/3/4, platinated lysine dendrimer P1 and the cyclic unit P2 
were compared. Agarose gel electrophoresis indicates the ability of platinated IHF 
mimics IHF-2/3/4 to unwind the negatively supercoiled pUC18 plasmid DNA within 2 h 
reaction time already at a low peptide/nucleotide concentration. The effect is observed 
at a higher peptide/nucleotide concentration for the unplatinated mimic IHF-1 and the 
platinated lysine dendrimer P1 whereas the unplatinated cyclic P2 does not seem to have 
an unwinding effect at all. Polyacrylamide gel electrophoresis indicated enhanced 
targeting of DNA duplexes consisting of adjacent guanine residues by the platinated IHF 
mimics IHF-2/3/4. While denaturing gels provide evidence supporting the formation of 
covalent linkages between the DNA and the platinated IHF mimics even in the presence 
of excess cisplatin. Thus, the IHF mimicking platinum/complex peptide chimeras are able 




the other hand indicate their ability to bind to DNA sequences already modified with 
cisplatin. Such interactions might have a synergistic effect on cisplatin induced DNA 
bending and hence, on the chemotherapeutic efficacy of the drug. These results validate 
the design of the IHF mimicking Pt complex/peptide chimera consisting of the cyclic 
minor grove recognizing unit, the positively charged lysine dendrimer and the platinum 
chelating unit contained within the glycine linker tethering the two peptidic units. 
Though it was not possible to attain sequence specific recognition with the platinated IHF 
mimics, these provide good lead structures to begin with. Further optimization of the 
design offers the possibility to generate a library of Pt complex/peptide chimera as 
potential chemotherapeutics. 
The second part of the thesis (chapter 4 and 5) involves synthesis of a modified Zif268 
domain, a Cys2His2 type of zinc finger. The wide occurrence and extra-ordinary properties 
of the Cys2His2 type of zinc fingers to sequence specifically bind to DNA make them a 
lucrative target to mimic.[138, 139] Every individual zinc finger domain has the ability to 
recognize a subsite of 3-4 base pairs on the duplex.[148, 149] Following a combinatorial 
approach for preparing novel zinc finger motifs, with single DNA recognizing zinc finger 
domains connected together in tandem, offers a possibility to design a highly specific 
binder for any given DNA sequence. The aim of this work was to design artificial zinc 
finger nucleases for site specific DNA cleavage. The zinc finger domain proteins due to 
their modular design and high affinity towards cognate DNA can be applied for 
engineering artificial nucleases by incorporation of additional metal binding sites within 
its structure. The artificial amino acid residues can be functionalized to introduce 
multiple metal binding sites within the protein domains. In this study, the Zif268 
sequence was modified to contain a histidine mimicking amino acid bearing a 
triazacyclononane (TACN) ligand.  The TACN ligand provides an allosteric Zn(II) 
coordination site and is expected to assist in cleavage of the DNA phosphodiester 
backbone (Figure 6.2). The Zif268 domain consisting of a tandem repeat of three zinc 
fingers was prepared by following a semi-synthetic strategy that utilizes intein mediated 





Figure 6.2: The Zif268 domain containing a tandem repeat of three zinc fingers wherein the third zinc 
finger consisting of a histidine mimicking artificial amino acid providing an allosteric Zn
2+
 binding site and 
can further offer the possibility of DNA cleavage. (pdb code: 1AAY).
[9]
 Image genetrated by PyMOL.  
 
The histidine mimicking amino acid was incorporated into Zf3 domain by SPPS whereas 
the Zf12 domain was expressed in E. coli. The two peptide fragments were connected to 
form the Zf13 domains by native chemical ligation. The Zf13Tacn81 38 and Zf13Tacn85 
39 consisted of the artificial amino acid in the Zf3 domain at His81 and His85 whereas 
Zf13Wiltype 37 consisted of the native peptide sequence. The binuclear zinc chelation 
ability of the modified Zf3 constructs Zf3Tacn81 34 and Zf3Tacn85 35 was confirmed by 
mass spectrometry. Furthermore, CD spectroscopy confirms that introduction of the 
artificial amino acid into the Zf3 domains cause only minimal structural perturbation and 
changes in the folding pattern of the peptides. However, native polyacrylamide gel 
electrophoresis performed utilizing the Zif268 consensus sequence reveals that the 
modification of the zinc finger constructs decreases their DNA recognition ability. 
Agarose gel electrophoresis was performed to study the nuclease activity of the Zf13 




Zif268 domain. The experimental results indicate poor DNA cleavage ability of the 
modified zinc finger constructs Zf13His81 38 and Zf13His85 39 even after prolonged 
incubation time of 72 h at 37 ˚C and very high peptide/DNA concentration. In order to 
design Zif268 model systems with better nuclease activity novel amino acid mimics 
providing an additional metal coordination sites should be incorporated. The goal is to 
keep the multinuclear metal coordination sites within the model peptide in close 
proximity to the DNA backbone as well as to maintain appropriate intermetallic distances 
between them in order to facilitate phosphodiester hydrolysis.  
Model peptides mimicking high affinity DNA binding modules can be exploited for 
achieving enhanced recognition properties. In this work, peptide mimics have been 
proposed for the two naturally occurring proteins, the IHF and the Zif268 domain, that 
bind to DNA with a high degree of sequence selectivity. Combination of these model 
peptides to other effector domains is expected to provide enhanced DNA recognition 
properties to the novel chimeric proteins and furthermore, alter their activity. Design of 
such molecules can prove to be a valuable tool in biomedical applications including 
















7. Experimental Section    
 
7.1. Materials and General Methods Applied for Synthesis 
 
Solvents 
All the technical grade solvents were distilled prior to use. Anhydrous (stored over 
molecular sieves), analytic and HPLC grade solvents were supplied from Acros Organics 
(Geel, Belgium), Fluka (Taufkirchen, Germany),  Sigma-Aldrich (Taufkirchen, Germany), 
Fisher Scientific (Nidderau, Germany) and VWR (Darmstadt, Germany). Solvent systems 
for HPLC purification as well as all the buffers systems utilized in various experiments 
were prepared using ultrapure water obtained from a water purification system 
Simplicity from Merck Millipore (Billerica, USA).  
 
Reagents 
All the reagents were of analytical grade and were utilized without any further 
purification. All the amino acid derivatives, coupling reagents and resins utilized in solid 
peptide synthesis were purchased from NovaBiochem (Darmstadt, Germany), GL 
Biochem (Shanghai, China), ABCR (Karlsruhe, Germany), Bachem (Bubendorf, 
Switzerland), and IRIS Biotech (Marktredwitz, Germany). All other reagents were 
purchased from Merck (Darmstadt, Germany), Carl Roth GmbH (Karlsruhe, Germany), 
Fisher Scientific GmbH (Nidderau, Germany), Alfa Aesar (Karlsruhe, Germany), Bachem 
(Bubendorf, Switzerland), TCI (Eschborn, Germany), VWR (Darmstadt, Germany), 
NovaBiochem (Darmstadt, Germany), Sigma Aldrich (Taufkirchen, Germany) and Acros 
Organic (Geel, Belgium). ZipTip pipette tips for mass analysis of Zn2+ bound samples were 




PURIMEX (Grebenstein, Germany), IBA (Goettingen, Germany) and Biomers (Ulm, 
Germany). Other Biochemical reagents were supplied by Fermentas (St. Leon-Rot, 
Germany), Biorad (Munich, Germany) and GERBU (Heidelberg, Germany). 
 
Reactions 
All the air and moisture sensitive reactions were carried out under inert (argon/nitrogen) 
atmosphere. The utilized glassware was first flame dried under vacuum followed by 
purging argon. Reactions done in small scales were carried out in Eppendorf caps by 
utilizing a purge and refill technique. The reaction buffers were degassed by applying 
vacuum while purging argon into the solution at the same time with the help of a 
cannula.   
 
Lyophilization 
The HPLC fractions were evaporated under low vacuum to get rid of most of the 
acetonitrile.  The resulting aqueous solutions were lyophilized using a freeze drying 
device Christ Alpha-2-4 attached to a high vacuum pump. For lyophilization of samples 
with relatively smaller volume an evacuable Christ RCV-2-18 ultracentrifuge connected to 
the lyophilizer was utilized. All the samples were frozen over liquid nitrogen before being 
attached to the lyophilizer. 
 
Thin Layer Chromatography (TLC) 
The progress of the reaction was monitored by TLC using aluminium backed plates 
coated with silica gel 60 F254 (layer thickness: 0.20 mm) from Merck. Fluorescence 
quenching at wavelength 254 nm was exploited to detect the spots corresponding to 
respective compounds on the TLC plate. Non-Fluorescence quenching substances were 
visualized by staining the plate with ninhydrin staining solution (1.5 g ninhydrin, 3 mL 




Flash Chromatography   
The crude reaction mixture was purified by means a fritted glass column using Merck 
Silica Gel 60 (particle size: 40-62 µm). The crude product was either absorbed on silica (3-
5 fold weight excess) or prepared as a concentrated solution in the eluent and added to 
the column packed with wet silica gel (50-100 fold weight excess). The elution was 
performed under a positive pressure of 0.1-1 bar. Solvent systems used for elution are 
mentioned along with each individual reaction protocol. 
 
High Performance Liquid Chromatography (HPLC) 
Reverse phase HPLC was conducted using Amersham Pharmacia Biotech systems 
(Äkta basic, Pump-type P-900, variable wavelength UV detector 900). UV absorption of 
the peptides was detected at wavelengths 215 nm, 254 nm and 280 nm while performing 
HPLC under a linear gradient of one the following solvent systems:  
A [0.1% TFA, H2O] to B [0.1% TFA, MeCN/H2O (8/2)]; 
A [0.1% TFA, H2O] to C [0.1% TFA, MeCN/H2O (9/1)]; 
A [0.1% TFA, H2O] to D [0.1% TFA, MeCN] 
The samples were prepared in ultrapure water containing minimum amount of MeCN 
needed to dissolve the substance completely and then were also filtered prior to 
injection into the system. The column used for HPLC is mentioned along with the 
analytical data of the corresponding compound. The flow rates for analytical, semi 
preparative and preparative columns were 1 mL/min, 3 mL/min and 10 mL/min 








Nuclear Magnetic Resonance Spectroscopy (NMR) 
All the NMR spectra were recorded with Varian instruments (Mercury 300, Unity 300, 
INOVA 500, INOVA 600). Chemical shifts are quoted in parts per million (ppm) downfield 
of TMS (δTMS = 0 ppm). As internal standards the resonances from the rest protons of 
deuterated solvents CDCl3: 7.24 ppm (
1H-NMR) and 77.0 ppm (13C-NMR), [D6]DMSO: 
2.49 ppm (1H-NMR) and 39.5 ppm (13C-NMR), CD3OD 4.87 ppm (
1H-NMR) and 49.1 ppm 
(13C-NMR)  were used. Signal multiplicities were abbreviated as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad. Coupling constants nJXX  are 
stated in hertz (Hz), where n is the order of coupling and X stands for the nuclei. 
 
Mass Spectroscopy 
The electron spray ionization mass spectrums (ESI-MS) were measured using Finnigan 
instruments (type LCQ or TSQ 7000) or Bruker spectrometers (types Apex-Q IV 7T and 
micrOTOF API). High resolution mass spectrums were collected on Bruker Apex-Q IV 7T or 
Bruker micrOTOF, respectively. 
 
Preparation Zn2+ bound zinc fingers for mass analysis using ZipTip 
 The zinc fingers (0.1 mM in H2O) were first reduced by TCEP (0.5 mM in H2O) for 2 h at 
room temperature to make the thiol of the cysteine residues available for complex 
formation.  Thereafter, 500 µL of ZnCl2 (2.5 mM Tris buffer, 100 µM of Zn
2+, pH = 7.8) was 
added and incubated at room temperature for 1 h. Prior to mass spectrometric 
measurement the ZipTip pipette tip was used for desalting and concentrating the sample 
as following: 
  The tip was placed on the pipettor followed by aspirating and dispensing several times 
through the media for binding the sample to the chromatography media fixed at the end 




  Then the tip was several times aspirated and dispensed through water which used as 
washing solvent to remove contaminants such as excess salts from the buffer and the 
unbound Zn2+ ion. 
 The purified sample was eluted in H2O/ACN (1/1, v/v). 
 The process was repeated 5-6 times and all the purified samples were pooled together, 
lyophilized and subjected to mass analysis.  
 
UV spectroscopy 
The UV spectrums were recorded using Nanodrop ND-2000c (d = 0.1 cm) or a JASCO 
V-550 UV/VIS spectrophotometer (d = 1 cm). The molar extinction coefficients for DNA 
samples were obtained by summing up individual coefficients of each base pair at 260 
nm. The absorbance of the samples was measured at the same wavelength and their 
concentrations were determined by applying the LAMBERT-BEER law. 
 
CD Spectroscopy 
The CD spectra were recorded either using a Jasco-810 or a Jasco-1500 
spectropolarimeter equipped with a Jasco-PTC432S or a Julabo-F250 temperature 
controller respectively. Quartz precision cell with a thickness of 1 mm was used for the 
measurements. The sample cell was flushed with nitrogen prior to as well as during the 
measurement. The following parameters were applied for the measurement:  The 
spectrums were recorded at a constant temperature of 20 ˚C within a wavelength range 
of 260-190 nm for peptides and 360-200 nm for DNA. The following parameters were 
applied for the measurement:  1 nm band width, 0.1 s response time, standard 
sensitivity, 0.1 nm data pitch and 50 nm/min scanning speed. The measured spectrums 
obtained as an average of eight curves were background corrected and smoothed 
applying the means movement method. Experimental conditions are mentioned in detail 






Wherein  is the degree of ellipticity, d is the cell path length, CD is the circular dichroism 
value and C is the concentration of the measured sample.   
 
Thermal Melting Analysis 
Thermal melting analysis of dsDNA was performed in 1 cm quartz cuvettes utilizing a Cary 
100 UV/Vis spectrophotometer (Varian) equipped with a multiple cell holder and a 
peltier controlled temperature setup. Complementary DNA strands were mixed in 1:1 
ratio in 10 mM phosphate buffer (Na2HPO4/NaH2PO4, pH = 5.8) and annealed to form the 
duplex. The peptides were added to the duplex and pre-incubated with it for 17 h at 
37 ˚C prior to the measurement such that the duplex concentration was 1 µM and the 
peptide concentration was 5 µM in 10 mM phosphate buffer (Na2HPO4/NaH2PO4, 
pH = 5.8).   The absorbance versus temperature profiles were measured at 250 nm and 
the data points were taken after every 0.5 ˚C for the following three cycles: heating from 
20-95 ˚C, cooling from 95-10 ˚C and then heating from 10-95 ˚C. The heating/cooling rate 
during the cycle was 0.7 ˚C/min. The Tm values were obtained from the maximum of the 
first derivative of the cooling curve from 95-10 ˚C. All experiments were performed in at 
least triplicates on independent occasions. 
 
Annealing DNA Oligonucleotides 
DNA oligomers obtained as lyophilised solid from the supplier were dissolved in a known 
quantity of ultrapure MilliQ water and the concentration of DNA in each sample was 
determined. Thereafter, complementary DNA strands were resuspended in the annealing 
buffer contained in a microfuge tube such that in the resulting mixture the two strands 
were present in equimolar ratio. The tube was placed on a heat block at 95 ˚C for 5 min 
and then slowly cooled to room temperature on a workbench. The annealing DNA 




7.2. Materials and General methods Applied in Biochemistry 
  
Basic Handling 
All equipment that comes into contact with the bacterial cultures was sterilized prior to 
usage and wherever applicable disposable pre-sterilized items were used. Inoculations 
and cultivations of bacterial cultures were performed under a laminar flow biological 
safety cabinet Prettl-Telsta Bioll-A from Telstar. Autoclaved MilliQ water was used for the 
preparation of bacterial media and in other biochemistry procedures such as plasmid 
amplification, protein expression etc. 
  
Materials 
Luria-Bertani (LB)-media:[212] Tryptone (1%, w/v), yeast (0.5%, w/v) and NaCl (1%, w/v) 
were dissolved in double distilled water and autoclaved at 120 ˚C for 20 min.    
 
LB plates: Tryptone (1%, w/v), yeast (0.5%, w/v), NaCl (1%, w/v) and agar (7.5%, w/v) 
were dissolved in double distilled water and autoclaved at 120 ˚C for 20 min. After 
cooling to 55˚C a desired antibiotic was added to the media and in poured in sterile Petri 
dishes. 
 
Antibiotics: Depending on the antibiotic marker present within the sequence of the 
plasmid DNA, in order to select the transformed E. coli cells, a suitable antibiotic is 
introduced into the media. The concentration of antibiotics carbinicillin and 
chloramphenicol used in the experiments is 100 µg/mL.    
 
Cell Strain: Competent E. coli strain ER2566 used for protein expression was obtained 




Vectors: Plasmid vector pTXB1 (carbinicillin resistant) was used for recombinant protein 
expression of the Zf12 domain and the pJET (carbinicillin and chloramphenicol resistant) 
vector was used for cloning the Zif268 consensus sequence. 
 
Preparation of Competent E. coli Cells 
Competent E. coli cells were prepared in order to facilitate easy uptake of foreign 
plasmid DNA into the cells prior to cellular transformation. A single colony from the LB 
plate was inoculated into 5 mL of LB media and cultivated overnight by shaking at 37 ˚C. 
Overnight culture of 2 mL was inoculated into 50 mL of LB medium followed by shaking 
vigorously at 37 ˚C for about 2 h (until this time the OD600  ~ 0.3). The cell culture was 
centrifuged at 3000 rpm at 4 ˚C after cooling on ice for 10-15 min. The supernatant was 
discarded and the cell pellet was resuspended in 10 mL of pre-cooled solution of 0.1 M 
CaCl2. The suspension was incubated on ice for additional 20 min and the centrifugation 
was repeated. Thereafter, cell pellet was again resuspended in 5 mL of pre-cooled 
solution of 0.1 M CaCl2 containing 15% glycerol, aliquoted in batches of 500 µL, quickly 
frozen on nitrogen and stored at -80 ˚C.  
 
Cultivation of E. coli Cells 
Bacterial cells from a glycerol stock were streaked on an agar plate with a help of a sterile 
metal loop (sterilized by flaming) and incubated at 37 ˚C while placed upside down until 
some microbial colonies appear on it. A typical 5 mL liquid culture was inoculated with a 
single colony picked from the agar plate and an appropriate amount of a desired 
antibiotic was added to it. Thereafter, the cells were cultivated at 37 ˚C while shaking at 







Transformation of competent E. coli cells 
Competent E. coli cells were taken out of -80 ˚C and thawed on ice. To 100 µL of the 
cellular suspension 2-3 µL of plasmid DNA was added and incubated on ice for 30 min. 
Thereafter, the cells were subjected to a heat shock at 42 ˚C for 45 sec and immediately 
placed on ice for about 30 sec. After addition of 900 µL of LB medium to this mixture it 
was incubated at 37 ˚C for 1 h.  From this mixture 100 µL was streaked on a LB agar plate 
containing a suitable antibiotic. The remaining cells were centrifuged at 6000 rpm for 1 
min and 800 µL the supernatant was discarded. The pellet was resuspended and also 
streaked on the agar plate. The plates were incubated overnight at 37 ˚C while placed 
inverted until some transformed single colonies appeared on them.  
 
Extraction of Plasmid DNA 
E. coli cells were transformed with the pJET containing the Zif268 consensus sequence. 
50 mL of LB medium containing appropriate antibiotic (50 µL of each, carbinicillin and 
chloramphenicol) was inoculated with single colonies from the agar plate and incubated 
overnight at 37 ˚C on a shaker.   Thereafter, the plasmid was purified using Qiagen 
Plasmid Midi Kit by carefully following the manufacturer’s protocol which was based on 
modified alkaline lysis of the cells, followed by subsequent binding of DNA under low salt 
and pH conditions compatible with the anion exchange chromatography. The DNA pellet 
obtained was ethanol precipitated twice using 70% EtOH in water; the residue was 
dissolved in a known quantity of autoclaved MilliQ water and quantified using the 
Nanodrop ND-2000c spectrometer. 
   
Protein Expression in E. coli 
The Zf12 domain was obtained by recombinant protein expression in E. coli. The E. coli 
cells were transformed with the expression clones, pTXB1, containing the gene coding for 
intein tag fused to the gene coding for Zf12 domain. Single colonies were picked and 




carbinicillin in this case) were inoculated with them. These cultures were incubated at 
37 ˚C while shaking for 24 h and were further used to inoculate expression cultures 
containing 400 mL of LB medium and the respective antibiotic. The cultures were 
cultivated for additional 4-5 h at 37 ˚C on a shaker followed by addition of 40 µL IPTG 
(1 mM) and further incubation at 16 ˚C for about 24 h.  Later on the cells were 
centrifuged at 4000 rpm for 20 min while the temperature was maintained at 4 ˚C. The 
cell pellet was frozen on nitrogen and then transferred to -80 ˚C. This process makes the 
cell wall more fragile and easy to rupture. 
Thereafter, the cell pellet was thawed on ice and was resuspended in BPer (cell lysis 
reagent, Thermoscientific) in a concentration of 1 g/mL.  Complete lysis of the cell wall 
was achieved by pulsed sonification (5 × 45 sec, 50% power, 50% impulse) on ice utilizing 
a Sonoplus GM 7 from Bandelin. Most of the cellular debris was discarded by 
centrifugation at 14000 rpm for 20 min while the temperature was 4 ˚C. The supernatant 
contained the all proteins expressed in the cell including the Zf12 domain, obtained in 
fusion with the intein tag containing the chitin binding domain, which was purified by 
affinity chromatography. 
 
Purification of the Expressed Protein by Affinity Chromatography[213] 
 IMPACT (Intein Mediated Purification with an Affinity Chitin-binding Tag) is a method for 
purification of proteins that utilizes the self-cleavage ability of intein, a protein splicing 
component, to separate the desired protein from the affinity tag. The crude cell lysate 
containing the CBD-Zf12 fused protein was purified using Chitin beads obtained from 
New England Biolabs. Entire purification step was performed at 4 ˚C with only cold 
solutions. Firstly, the chitin column was prepared by loading 100 mL of chitin beads on a 
vertical column and then equilibrated with 2 bed volumes of water and 10 bed volumes 
of column buffer (20 mM HEPES, 500 mM NaCl, 0.1% Tween20, 20 mM TCEP, pH = 8). 
The lysate was loaded onto the column overnight at a flow rate of 0.5-1 mL/min until all 
the CBD-Zf12 fused protein was immobilized on the chitin beads. Thereafter, the column 




to remove the unspecifically bound cellular proteins. On-column cleavage of the intein 
tag was induced with the help of the thiol MeSNa (Sodium 2-mercaptoethanesulfonate). 
After 3 bed volumes of cleavage buffer (20 mM HEPES, 500 mM NaCl, 0.1% Tween20, 20 
mM TCEP, 250 mM MeSNa, pH = 8) were quickly flushed onto the column, the flow was 
stopped and the column was allowed to stand at 4 ˚C for 16-40 h. This led to complete 
cleavage of the target protein which was then eluted using the column buffer. While the 
intein-CBD tag remained on the column Zf12 domain was obtained as a thioester.        
 
Gel Electrophoresis  
 Gel electrophoresis, including polyacrylamide and agarose gels, is an efficient method to 
separate, analyse and purify DNA and protein fragments under an externally applied electric 
field based on size as well as charge. The gel matrix is chosen depending of the size of the 
molecules that need to be analyzed. Agarose gels can be used to separate DNA fragments 
that are in the range of 200 bp-50 kb depending on the percentage of agarose in the gels. 
Shorter oligonucleotide fragments in range of 5-500 bp can be separated on polyacrylamide 
gels. Our interest in this study was to analyze interaction between the synthesized peptide 
sequences, mimicking a naturally occurring protein domain, and their consensus DNA 
sequence.   
 
Agarose Gel Electrophoresis 
Agarose is a polysaccharide made up of alternating units of D-galactose and 3,6-anhydro-
L-galactose. Melting the agarose in a desired buffer system followed by cooling it leads to 
the formation of a cross-linked porous gel matrix that is often utilized to separate of 
large biomolecules. In this study, agarose gel electrophoresis were performed under non-
denaturing conditions in order to visualize the DNA unwinding ability of IHF mimicking/Pt 
complex peptides chimeras and for testing the DNA cleavable ability of the modified Zf13 
domains. Plasmid vectors pUC18 and pJET were used for this study respectively. Agarose 
gels were prepared by dissolving 1% (w/v) of agarose in 1× TAE-buffer, keeping into 




avoid zinc chelation with EDTA. To every 5 volumes of the sample, 1 volume of 6× DNA 
loading dye from Fermentas was added prior to loading the sample in the well. The 
length of the DNA fragments was estimated by loading the following mixture into one of 
the wells as control: 1 volume of 6× GeneRuler 1 kb DNA Ladder Mix and 1 volume 6× 
DNA loading dye from Fermentas mixed with 4 volumes of water. Depending on the 
length of the gel it was run at a constant voltage (6 V/cm) for about 2 h.  Thereafter, the 
gel was incubated in an ethidium-bromide staining solution (0.5 μg/mL) for 30 min as it 
has ability to intercalate between the DNA base pairs by means π- π stacking. It was then 
possible to visualize the DNA bands utilizing a UV-transilluminator ECX-F26-MX from 
Vilber Lourmat.  
 
50xTAE Buffer (1 L):  242 g Tris Base  
     57.1 mL glacial acetic acid 
100 mL 0.5 M EDTA 
pH adjusted to 8 
 
6xDNA Loading Dye:  10 mM Tris HCl (pH = 7.6) 
60 mM EDTA 
0.03% bromophenol blue 
0.03% xylene cyanol FF 
60% Glycerol   
 
Polyacrylamide Gel Electrophoresis 
Like agarose gels, polyacrylamide gels are also cross-linked porous materials. However, 
the pore size in polyacrylamide gels is much smaller and is suitable for the separation of 
polynucleotides with 5-500 base pairs. The gel matrix is formed by co-polymerization of 




of TEMED and APS used for radical initiation reaction.  OWLTM S4S Aluminium backed 
sequencing system from Thermo Scientific was used for electrophoresis. In order to 
visualize the DNA sequences fluorescent DNA sequences labelled with 6-FAM at the 5’ 
end were used in the experiments. After the electrophoresis was complete the gel was 
visualized utilizing the Typhoon 9400 Variable Mode Gel Imager from Amersham 
Biosciences (GE Healthcare) by scanning under the blue laser module and quantified by 
the ImageQuant software.  
 
Native PAGE 
Native or non-denaturing polyacrylamide gel electrophoresis allows separation of double 
stranded DNA fragments based on their size. In addition, it is possible to retain the 
DNA-protein interactions assisted by ionic, electrostatic or Vander Waal forces.   
The gel plates 20 × 45 cm were carefully washed with double distilled water followed by 
wiping with a solution of 70% EtOH in water and air drying. The plates were assembled 
by inserting the spacers (0.4 mm thick) in between them and were secured by clamping. 
50 mL of gel solution of desired concentration was prepared and poured in between the 
glass plates. After the polymerization was the complete the glass plates were secured in 
the electrophoresis apparatus and the gel was pre-run at a constant current of 15 mA 
and later after loading the samples at 20 mA in 1× TBE buffer. Prior to loading the 
samples 3 µL of 30% glycerol was added to them. While performing electrophoresis with 
the zinc fingers EDTA was excluded from the buffer system as it binds to divalent metals.     
 
 10x TBE Buffer (1 L):  108 g Tris Base 
  55 g Boric acid 
40 mL 0.5 M EDTA  





Gel Solution (50 mL):  15 mL & 25 mL of Rotiphorese Gel 40 for 12% & 20% gel   
    5 mL of 10× TBE 
    270 µL of 10% APS 
27 µL of TEMED 
Add MilliQ water to adjust the total volume to 50 mL 
 
Urea-Denaturing PAGE 
Denaturing polyacrylamide gels were performed to separate single stranded DNA 
fragments. Unlike native gels, non-covalent interactions cannot be visualized by 
performing urea-denaturing PAGE. However, for this study the method is suitable to test 
the ability of IHF mimicking peptides to covalently modify DNA as well as to investigate 
the DNA cleavage ability of zinc finger domains. The procedure for preparing the gel was 
similar to that of native gel except that the gel solution contained an additional 8 M urea 
for denaturation. 1 volume of TriTrack DNA loading dye from Fermentas was added to 5 
volumes of the sample prior to electrophoresis. 
 
6x TriTrack Loading Dye: 10 mM Tris HCl (pH = 7.6) 
60 mM EDTA 
0.03% bromophenol blue 
0.03% xylene cyanol FF 
0.15% orange G 







7.3. Solid Phase Peptide synthesis 
 
All peptides were synthesized by standard Fmoc solid phase peptide synthesis 
(Fmoc-SPPS) protocol using preloaded resins.  Fmoc-Lys(Boc)-Wang (0.34 mmol/g) was 
used for the synthesis of the zinc finger domains. H-Ileu-2-Chlorotrityl resin 
(0.57 mmol/g) was used for the synthesis of the cyclic peptide of IHF whereas 
Fmoc-Gly Novasyn TGT resin (0.21 mmol/g) was used for the synthesis of the dendrimeric 
peptide of IHF. 
 
Automated Solid Phase Peptide Synthesis 
Automated solid phase peptide synthesis was carried out on a microwave assisted 
peptide synthesizer Liberty TM (CEM, Kamp-Lintford, Germany) equipped with a Discover 
microwave reaction cavity (CEM). The resin was swollen in DCM for at least 30 min and in 
NMP for at least 1 h. All the Fmoc-amino acids were prepared as 0.2 M solutions in NMP. 
Standard reagents were used for deprotection of the Fmoc group (20% piperidine in 
NMP), activation of the free amino acid (0.5 M HBTU/HOBt, 0.2 M DIPEA in DMF) and for 
washing (NMP, DCM) in between the steps. The standard cycle involved two subsequent 
deprotection steps of 30 s and 180 s each. All amino acids were double coupled at 50 ˚C 
for 10 min except cysteine, histidine and arginine.  Coupling of arginine was performed at 
room temperature for 25 min followed by microwave assisted coupling for 10 min at 50 
˚C. Amino acids histidine and cysteine were coupled without microwave assistance at 
room temperature for an hour.   
 
Manual Solid Phase Peptide Synthesis 
Manual SPPS was carried out at a 0.05-0.1 mM scale using preloaded resins in a BD 
syringe (acid/base resistant) equipped with a polyethylene frit. Prior to the synthesis, the 




Fmoc group from the amino acid attached to the resin was deprotected using 20% 
piperdine in NMP (2 mL in 100 mg resin), thereafter the reaction was carried out for 10 
min at room temperature and the procedure was repeated twice. All amino acids were 
double coupled in minimum amount of NMP at room temperature for 45 min. For 
coupling the synthetically modified amino acid building blocks (3 eq) activators 
HATU/HOAt (2.9/3 eq) were used whereas natural amino acids (5 eq) were coupled using 
HBTU/HOBt (4.9/5 eq). The activators were used in combination with an equimolar ratio 
of activator base 35% DIPEA (3/5 eq) in NMP. Washing in between the steps was done 
with NMP (5 × 5 mL), DCM (5 × 5 mL) and again with NMP (5 × 5 mL). 
 
 Manual SPPS of lysine dendrimer 
The synthesis of the lysine dendrimer was performed using Fmoc-Gly-Novasyn TGT resin 
(0.21 mmol/g) at a scale of 0.1 mmol. All amino acids were sequentially double coupled 
manually onto the resin. After coupling the amino acids contained within the glycine 
linker (6 glycine residues and the platinum chelating building block) Fmoc-Lys(Fmoc)-OH 
was coupled according to the above mentioned procedure to give the first generation 
dendrimer. For the synthesis of the second generation and the third generation lysine 
dendrimer 10 eq and 20 eq of Fmoc-Lys(Fmoc)-OH were coupled again, respectively. The 
proportion of the activators (HATU/HOAt) and the activator base (DIPEA) utilized in the 
coupling reaction were increased accordingly.  
 
Resin Loading Density measurement[214] 
Loading density of the resin after coupling amino acids on it was determined by 
measuring UV absorption of dibenzofulvene (Ɛ304 = 7624 L mol
-1 cm-1), the product of 
Fmoc cleavage. A known quantity (≤ 5 mg) of dried resin was weighed in a 10 mL 
graduated flask and to it was added 2 mL of 2% DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) 
in DMF. The mixture was diluted to 10 mL by adding MeCN after gently stirring it for 1.5 




diluting it to 25 mL by adding MeCN. A reference was prepared in a similar way without 
the addition of the resin. The UV absorbance was recorded at 304 nm and the resin 




where Abssample and Absref are the absorbances of the sample and the reference, 




Qualitative analysis was performed for detecting free primary amino groups after a 
coupling step by using Kaiser test. The following three reagents were used:  
Reagent A = Prepared by dissolving 1 g of ninhydrin in 20 mL of ethanol. 
Reagent B = Prepared by dissolving 80 g of liquefied phenol in 20 mL of ethanol. 
Reagent C = Prepared by mixing 1 mL of 0.001 M aqueous solution of KCN in 49 mL 
pyridine. 
A few beads of the resin were taken in a glass vial and washed thoroughly with ethanol. 
2-3 drops of reagent A, B and C were added to the vial and the suspension was heated at 
110 ˚C for 5 min. The presence of free amines upon reaction with ninhydrin leads the 
formation of a deep blue colored resin beads. Kaiser test is not reliable for peptides 








The resin contained in syringe equipped with a PE-frit was washed thoroughly with 5 × 5 
mL DCM, 5 × 5  mL MeOH, 5 × 5 mL DCM and again with 5 × 5 mL MeOH. After drying the 
resin overnight under reduced pressure the following cleavage conditions were applied:- 
 
(a) Cleavage from Wang resin: 
Cleavage of the peptide from resin as well as global deprotection of all the amino acid 
side chain protecting groups from the resin was performed in a solution containing 
TFA/H2O/TIS/EDT (94/2.5/1/2.5). The reaction was done for 2 h at room temperature and 
the cleavage solution was subsequently filtered. 
 
(b) Cleavage from NovaSyn TGT and 2- Chlorotrityl resin: 
Cleavage of the peptide from the resin while keeping all the amino side chain protecting 
groups intact was done in a solution containing 30% hexafluoroisopropanol (HFIP) in 
DCM. The reaction was performed at room temperature for 45 min and the cleavage 
solution was subsequently filtered. 
 
Post Cleavage workup 
The cleavage solution was concentrated by blow drying with nitrogen. Addition of ice 
cold diethylether or t-butylmethylether (MTBE) led to the precipitation of the crude 
product, which was further isolated by centrifugation (9000 rpm, 10 min, -5 ˚C). After 
decanting the supernatant the precipitation was repeated once again. The pellet was 







7.4. Native Chemical Ligation (NCL) 
After the protein expression, intein mediated cleavage of the Zf12 domain using a thiol 
containing reagent MESNA rendered the Zf12 as a C-terminal peptide thioester. 
Therefore, the product obtained was directly applicable as a substrate for native 
chemical ligation with any peptide containing an N-terminal cystine residue. However, 
the synthetic domain, Zf3 after SPPS was obtained in the oxidized form containing 
disulfide brides between the cysteine residues of the peptide. In order to release the 
thiol of the N-terminal cysteine residue and make it available for NCL, the disulfide 
bridges were first reduced with TCEP. The Zf3 peptides (3 mM) were dissolved in a 
thoroughly degassed solution of 10 mM Na2HPO4/NaH2PO4, 6 M Gnd.HCl and 20 mM 
TCEP and the pH was adjusted to 4 for optimal reduction. After performing the reaction 
for 2 h at room temperature, an equal volume of a solution containing Zf12 peptide 
thioester (1 mM) in 500 mM Na2HPO4/NaH2PO4 and 6 M Gnd.HCl was added it and the 
pH was maintained in the range 7.8 to 8. The ligation reaction was performed for 24 h at 
room temperature. Thereafter, the reaction mixture was subjected to RP-HPLC, the 
peaks from different substrates were analyzed utilizing mass spectroscopic 












7.5. Synthesis of the artificial amino acid building blocks contained in 
IHF mimicking peptides 
 
7.5.1. Synthesis of the platinum chelating unit 
N-Allyloxycarbonyl-N,N’-dimethylethylenediamine 
                                  
To a solution of N,N’-dimethylethylenediamine 1 (3.27 mL, 30 mmol, 1 eq)  in EtOH p.a. 
(100 mL) allyl phenyl carbonate (4.82 mL, 30 mmol, 1eq) was added dropwise. The 
reaction mixture was continued to stir overnight at room temperature followed by 
removing the solvent under reduced pressure. The residue was dissolved in water (100 
mL) and the pH was adjusted to around 3 by adding 1 M HCl. After extracting the 
aqueous phase by DCM (4 × 100 mL) it was made strongly alkaline by adjusting the pH to 
around 13 with the addition of NaOH. The organic phase was discarded and the basic 
aqueous layer was again extracted with DCM (4 × 100 mL).  The combined organic phase 
was washed with 2 M NaOH (3 × 100 mL) and dried over sodium sulphate. Removal of 
solvent under reduced pressure yielded the product N-allyloxycarbonyl-N,N’-
dimethylethylenediamine 2 (3.2 g, 18.6 mmol, 62%) as a colourless oil.       
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 5.94-5.81 (m, 1-H, CH=CH2), 5.28-5.12 (m, 2-H, 
CH=CH2),  4.55-4.50 (m, 2-H, -OCH2), 3.35 (t,
 3JH-H =  6.6 Hz, 2-H, N-CH2), 2.90 (s, 3-H, N-
CH3), 2.70 (t,
 3JH-H =  6.6 Hz, 2-H, NH-CH2), 2.39 (s, 3-H, NH-CH3), 1.36 (sbr, 1-H, NH). 
 
13C-NMR (500 MHz, CDCl3): δ (ppm) = 156.1 (C=O), 133.0 (-CH=CH2), 117.1 (-CH=CH2), 




ESI-MS m/z: 173.1 [M+H]+, 195.1 [M+Na]+, 345.2 [2M+H]+, 367.2 [2M+Na]+.   
 
ESI-HRMS: calculated for [C8H17N2O2]
+ ([M+H]+) = 173.1285, found = 173.1286; calculated 
for [C8H16N2O2Na]
+ ([M+Na]+) = 195.1104, found = 195.1108.  
 
(S)-N-tert-butoxycarbonyl-δ-hydroxy-norvaline benzyl ester[124] 
 
                  
 
To a solution of N-Boc-Glutamic acid benzyl ester 3 (5 g, 14.82 mmol, 1 eq) in anhydrous 
THF (70 mL) N-Ethylmorpholine (2.05 mL, 16.3 mmol, 1.1 eq) and isobutyl chloroformate 
(2.13 mL, 16.3 mmol, 1.1 eq) were added at -10 ˚C under argon. The mixture was 
continued to stir for an additional 10 min at -10 ˚C followed by addition of a solution of 
sodium borohydride (1.68 g, 44.4 mmol, 3 eq) in MeOH (280 mL). Thereafter, the 
reaction was stirred for 30 min at -10 ˚C and another 30 min at room temperature. The 
reaction mixture was neutralized by addition of 1 N HCl (30 mL approx) such that the 
final pH was in the range of 3-4.  The solvents were removed under reduced pressure and 
the residue was dissolved in EtOAc (120 mL). The organic layer was successively washed 
with 1 N HCl, 6% aq KHCO3 and brine, dried over sodium sulphate and removed under 
vacuum. Purification by column chromatography [eluent: Pentane/EtOAc, 3/2 (v/v)] 
yielded (S)-N-tert-butoxycarbonyl-δ-hydroxy-norvaline benzyl ester 4 (4.3 g, 13.3 mmol, 




Rf = 0.21 (Pentane/EtOAc = 2/1, v/v). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.42-7.29 (m, 5-H, Ar-H), 5.29-5.11 (m, 3-H, NHBoc, 
CH2Ph),  4.42-4.31 (m, 1-H, H-α), 3.61 (t, 
3JH-H =  6.2 Hz, 2-H, H-δ), 2.00-1.56 (m, 4-H, H-β, 
H-γ), 1.42 (s, 9-H, tBoc-CH3). 
 
13C-NMR (500 MHz, CDCl3): δ (ppm) = 172.7 (COBn), 155.4 (CONH), 135.4 (Ar-C), 128.6 
(Ar-C), 127.7 (Ar-C), 127.1 (Ar-C), 80.3 [C(CH3)3], 67.5 (CH2-Ph), 62.1 (C-δ), 53.3 (C-α), 
29.4, 28.4, 28.3 [C(CH3)3].   
 
ESI-MS m/z: 346.2 [M+Na]+ , 669.4 [2M+Na]+.   
 
ESI-HRMS: calculated for [C17H25NO5Na]
+ ([M+Na]+) = 346.1625, found = 346.1622; 
calculated for [C17H24NO5]
 - ([M-H]-) = 322.1660, found = 322.1665. 
 
(S)-N-tert-butoxycarbonyl-δ-bromo-norvaline benzyl ester[124] 
 
                    
 
N-Boc-δ-hydroxy-norvaline benzyl ester 4 (4 g, 12.37 mmol, 1 eq) was dissolved under 




followed by addition of CBr4 (6.14 g, 18.5 mmol, 1.5 eq) and PPh3 (4.65 g, 18.5 mmol, 1.5 
eq) to it. The reaction was continued to stir at -5 ˚C for 30 min and 2 h at room 
temperature. Purification by column chromatography [eluent: Pentane/EtOAc, 9/1 (v/v)] 
yielded (S)-N-tert-butoxycarbonyl-δ-bromo-norvaline benzyl ester 5 (3.28 g, 8.5 mmol, 
69%) as a pale yellow oil. 
 
Rf = 0.4 (Pentane/EtOAc = 9/1, v/v). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.41-7.30 (m, 5-H, Ar-H), 5.23-5.06 (m, 3-H, NHBoc, 
CH2Ph),  4.42-4.32 (m, 1-H, H-α), 3.41-3.34 (m, 2-H, H-δ), 2.00-1.75 (m, 4-H, H-β, H-γ), 
1.44 (s, 9-H, tBoc-CH3). 
 
13C-NMR (500 MHz, CDCl3): δ (ppm) = 172.2 (COBn), 155.3 (CONH), 135.3 (Ar-C), 128.7 
(Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 80.2 [C(CH3)3], 67.3 (CH2-Ph), 53.0 (C-α), 32.9, 31.6, 
28.7, 28.5 [C(CH3)3].   
 
ESI-MS m/z: 386.1 [M+H]+ , 408.1 [M+Na]+, 773.2 [2M+H]+, 795.2 [2M+Na]+.   
 
ESI-HRMS: calculated for [C17H25NO4Br]
+ ([M+H]+) = 386.0961, found = 386.0959; 
calculated for [C17H24NO4BrNa]










diamino)norvaline benzyl ester 
 
                   
 
N-allyloxycarbonyl-N,N’-dimethylethylenediamine 2 (4.01 g, 23.31 mmol, 3 eq) was 
dissolved in dry DMF (40 mL) under argon atmosphere at room temperature. To this 
solution DIPEA (4 mL, 23.31 mmol, 3 eq) was added followed by dropwise addition of a 
solution of (S)-N-tert-butoxycarbonyl-δ-bromo-norvaline benzyl ester 5 (3 g, 7.77 mmol, 
1 eq) in dry DMF (35 mL).  After letting the reaction mixture to stir for 48 h at room 
temperature the solvent was removed under vacuum. The residue was dissolved in 
EtOAc and the organic phase was washed with water, dried over sodium sulphate and 
concentrated under vacuum. Purification by column chromatography [eluent: 
Pentane/EtOAc, 1/1 (v/v) → EtOAc (100%)] yielded (S)-N-(tert-butoxycarbonylamino)-δ-
(N-(allyloxycarbonyl)-N,N’-dimethylethylenediamino)norvaline benzyl ester 6 as a 
colourless oil (3 g, 6.29 mmol, 81%). 
 
Rf = 0.53 (Ethylacetate/Methanol = 9/1, v/v). 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.40-7.30 (m, 5-H, Ar-H), 7.28 (d, 
3JH-H = 7.5 Hz, 
1-H, NH), 5.97-5.84 (m, 1-H, CH=CH2 ), 5.30-5.05 (m, 4-H, CH=CH2, CH2-Ph), 4.49 (dt, 2-H, 
4JH-H = 1.5 Hz,
 3JH-H = 5.4 Hz, CH2-Alloc), 4.10-3.97 (m, 1-H, α-CH), 3.27 (t,
 3JH-H = 6.9 Hz, 2-
H, CO-NCH2), 2.83 (s, 3-H, CO-NCH3), 2.39 (t, 





6.9 Hz, 2-H, δ-CH2),  2.12 (s, 3-H, NCH3), 1.72-1.55 (m, 2-H, β-CH2), 1.46-1.40 (m, 2-H, γ-
CH2), 1.38 (s, 8-H, 
tBoc-CH3) , 1.29 (s, 1-H, 
tBoc-CH3, rotamer). 
 
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 172.4 (CO-OBn), 155.5 (CO-Boc), 155.1 (CO-
Alloc), 136.0 (Phipso), 133.5 (-CH2-CH=CH2), 128.3, 127.9, 127.7 (Ph), 116.6 (-CH2-CH=CH2), 
78.1 [C(CH3)3], 65.6 (CH2-Ph), 64.9 (-CH2-CH=CH2), 56.5 (δ-CH2), 54.4 (NCH2), 53.5 (α-CH), 
46.1 (CO-NH2), 41.6 (NCH3), 33.9 (CO-NCH3), 28.4 (β-CH2), 28.1 [C(CH3)3], 23.0 (γ-CH2). 
 
ESI-MS m/z: 478.3 [M+H]+ , 476.3 [M-H]-. 
   
ESI-HRMS: calculated for [C25H40N3O6]
+ ([M+H]+) = 478.2912, found = 478.2917; 
calculated for [C25H39N3O6Na]
+ ([M+Na]+) = 500.2731, found = 500.2725. 
 
 
Figure 7.1: 1H-NMR spectra of (S)-N-(tert-butoxycarbonylamino)-δ-(N-(allyloxycarbonyl)-N,N’-






Figure 7.2: 13C-NMR spectra of (S)-N-(tert-butoxycarbonylamino)-δ-(N-(allyloxycarbonyl)-N,N’-














dimethylethylenediamino)norvaline benzyl ester 
 
       
 
(S)-N-(tert-butoxycarbonylamino)-δ-(N-(allyloxycarbonyl)-N,N’-dimethylethylenediamino) 
norvaline benzyl ester 6 (1.8 g, 3.77 mmol, 1 eq) was dissolved in dioxane (16.5 mL). To it 
was added water (11 mL) and 1 M aq. NaOH (5.5 mL) and the resulting solution was 
stirred for 6 h at room temperature. Thereafter, the reaction mixture was neutralized by 
addition of 1 M HCl (5.5 mL) and concentrated under reduced pressure followed by 
lyophilization. The residue was dissolved in TFA/H2O (95/5, v/v, 30 mL) while cooling at 0 
˚C and the mixture was allowed to stir for 15 min at 0 ˚C followed by stirring at room 
temperature for 6 h. After removing the TFA under reduced pressure the water phase 
was co-evaporated with 1 N HCl (3 × 15 mL) followed by lyophilization. The residue 
obtained was then dissolved in 10% Na2CO3 (25 mL) and to it Fmoc-OSu (1.53 g, 4.53 
mmol, 1.2 eq) solubilised in dioxane (16 mL) was added dropwise at 0 ˚C. The reaction 
mixture was stirred at 0 ˚C for 15 min and then at room temperature for another 4 h. The 
organic phase was removed under reduced pressure and the aqueous phase was diluted 
by addition of water (35 mL) followed by washing with Et2O (3 × 70 mL). Thereafter, the 
aqueous phase was acidified to pH 3 with the addition of 1 N HCl and extracted with 
EtOAc (4 × 70 mL). The combined organic phase was dried over sodium sulphate and 
evaporated under vacuum. After purification by column chromatography [eluent: 
DCM/MeOH, 9/1 (v/v) → DCM/MeOH, 4/1 (v/v)] the product (S)-N-(((9H-fluoren-9-
yl)methoxy)carbonyl)-δ-(N-(allyloxycarbonyl)-N,N’-dimethylethylenediamino)norvaline 




Rf = 0.15 (DCM/MeOH = 5/1, v/v). 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.88 (d, 
3JH-H = 6.72 Hz, 2-H, C4-Fmoc ), 7.70 (m, 
2-H, C1-Fmoc), 7.40 (t, 3JH-H = 7.5  Hz, 2-H, C3-Fmoc), 7.33-7.30 (m, 2-H, C2-Fmoc), 5.95-
5.87 (m , 1-H, CH-Alloc), 5.25 (d, 3JH-H = 18.6 Hz, 1-H, =CH2), 5.17-5.13 (m, 1-H, =CH2), 
4.50-4.48 (m, 2-H, CH2-Alloc), 4.31-4.24 (m, 2-H, CH2-Fmoc), 4.23-4.19 (m, 1-H, CH-Fmoc), 
3.92-3.88 (m , 1-H, α-CH), 3.29 (t, 3JH-H = 6.6 Hz, 2-H, CONCH2), 2.83 (sbr, 3-H, CONCH3), 
2.44 (t, 3JH-H = 6.6 Hz, 2-H, NCH2), 2.33 (sbr, 2-H, δ-CH2), 2.16 (s, 3-H, NCH3), 1.74-1.68 (m, 
1-H, β-CH2), 1.62-1.56 (m, 1-H, β-CH2), 1.49-1.41 (m, 2-H, γ-CH2). 
 
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 174.2 (COOH), 155.8 (CO-Fmoc), 155.1 (CO-
Alloc), 143.7 (C6-Fmoc),   140.7 (C5-Fmoc), 133.52 (CH=Alloc), 127.5 (C3-Fmoc), 127.0 
(C2-Fmoc), 125.2 (C1-Fmoc), 120.0 (C4-Fmoc), 116.7 (=CH2Alloc), 65.5 (CH2Alloc), 65.0 
(CH2Fmoc), 56.7 (δ-CH2), 54.7 (NCH2), 54.1 (α-CH), 46.7 (CH-Fmoc), 45.8 (CONCH2), 41.5 
(NCH3), 33.9 (CONCH3), 29.1 (β-CH2), 23.0 (γ-CH2).      
 
ESI-MS m/z: 510.3 [M+H]+, 532.3 [M+Na]+, 548.2 [M+K]+, 1019.5 [2M+H]+. 
 
ESI-HRMS: calculated for [C28H36N3O6]






Figure 7.3: 1H-NMR spectra of (S)-N-(((9H-fluoren-9-yl)methoxy)carbonyl)-δ-(2-(allyloxycarbonyl)-




Figure 7.4: 13C-NMR spectra of (S)-N-(((9H-fluoren-9-yl)methoxy)carbonyl)-δ-(N-(allyloxycarbonyl)-








                     
 
Boc-Lysine 8 (5 g, 20.3 mmol, 1 eq) was dissolved in MeOH (200 mL) and it this solution 
37% of formaldehyde (9.3 mL, 295 mmol, 14.53 eq) was added dropwise over a period of 
5 min while stirring continuously. The solution was degassed thoroughly by purging with 
argon followed by addition of 18 g of Pd/C (5 wt%). Thereafter, the flask was flushed with 
H2 gas and then a balloon filled with H2 was attached to it. After stirring the reaction 
mixture at room temperature for 24 h the solid components were filtered by passing 
through a celite bed. Purification by column chromatography [eluent: Acetone/water, 
3/1 (v/v)] yielded Nα-boc-NƐ-dimethyl-L-Lysine 9 (4.56 g, 16.62 mmol, 82%) as a white 
solid.  
 
Rf = 0.6 (Acetone/Water = 3/1, v/v). 
 
1H-NMR (300 MHz, CD3OD-d4): δ (ppm) = 3.95-3.91 (m, 1-H, α-H), 3.04 (t, 
3JH-H = 8.1 Hz, 2-





13C-NMR (125 MHz, CD3OD-d4): δ (ppm) = 179.5 (COOH), 157.6 [CO-C(CH3)3], 80.0 
[CO-C(CH3)3], 58.6 (Ɛ-C), 56.6 (α-C), 43.3 [N(CH3)2] , 33.6 (β-C), 28.8 [CO-C(CH3)3], 25.2 (δ-
C), 23.6 (γ-C).  
 
ESI-MS m/z: 275.2 [M+H]+, 297.2 [M+Na]+, 549.4 [2M+H]+, 571.4 [2M+Na]+, 273.2 [M-H]-, 
547.4 [2M-H]-. 
 
ESI-HRMS: calculated for [C13H27N2O4]
+ ([M+H]+) = 275.1965, found = 275.1969; 
calculated for [C13H25N2O4]
 - ([M-H]-) = 273.1820, found = 273.1824. 
 






          
 
To a suspension of Nα-(Fmoc)-L-Asparginine 10 (2.0 g, 5.64 mmol, 1 eq) in ethylacetate 
(20 mL), n-propanol (20 mL) and water (20 mL) was added PIDA (2.36 g, 7.33 mmol, 1.3 




reaction mixture was filtered and the filter cake was washed with propanol (2 × 10 mL), 
methanol (2 × 10 mL) and ethyl acetate (2 × 10 mL). After drying the residue under 
vacuum the product Nα-Fmoc-L-Diaminopropionic acid 11 (1.1 g, 3.37 mmol, 60%) was 
obtained as a white solid.          
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 12.48 (sbr, 1-H, COOH), 7.88 (d, 
3JH-H = 7.4 Hz, 2-
H, C4-Fmoc), 7.70  (d, 3JH-H = 7.4 Hz, 2-H, C1-Fmoc), 7.40 (t, 
3JH-H = 7.4 Hz, 2-H, C3-Fmoc), 
7.31 (t, 2-H,  3JH-H = 7.4 Hz, C2-Fmoc), 6.76 (sbr, 1-H, NH-Boc), 6.30 (sbr, 2-H, NH2), 4.31 (d,
 
3JH-H = 6.9 Hz, 2-H, Fmoc-CH2), 4.20 (t,  
3JH-H = 5.9 Hz, 1-H, Fmoc-CH, 4.09 (dd, 
3JH-H = 7.1 
Hz, 1-H, Dap-Hα), 3.31-3.24 (m, 2-H, Dap-Hβ). 
 
ESI-MS m/z: 327.1 [M+H]+, 349.1 [M+Na]+, 675.2 [2M+Na]+, 325.1 [M-H]-, 651.3 [2M-H]-. 
 
ESI-HRMS: calculated for [C18H19N2O4]
+ ([M+H]+) = 327.1339, found = 327.1335; 
calculated for [C18H18N2O4Na]
+ ([M+Na]+) = 349.1159, found = 349.1147; calculated for 
[C18H17N2O4]









 Allyl chloroformate (0.54 mL,5.06 mmol 1.5 eq) was added dropwise at 0 ˚C to a solution 
of Nα-Fmoc-L-Diaminopropionic acid 11 (1.1 g, 3.37 mmol, 1 eq) and Na2CO3 (1.79 g, 
16.85 mmol, 5 eq) in Dioxane/water (1/1, 30 mL). After the reaction mixture was allowed 
to stir at 0 ˚C for 40 min it was acidified to pH~1-2 by addition of 10% HCl and extracted 
with DCM (3 × 30 mL). Purification by column chromatography [eluent: MeOH/DCM, 1/9 
(v/v)] yielded Nα-Fmoc-Nβ-Alloc-L-2,3-Diaminopropionic acid 12 (1.08 g, 2.63 mmol, 78%) 
as white solid. 
    
Rf = 0.38 (MeOH/DCM = 1/4, v/v). 
 
1H-NMR (300 MHz, CD3OD-d4): δ (ppm) = 7.74 (d, 
3JH-H = 4.5 Hz, 2-H, C4-Fmoc), 7.62 (dd, 
4JH-H = 1.5 Hz, 
3JH-H = 4.35, 2-H, C1-Fmoc), 7.34 (t, 
3JH-H = 4.5 Hz, C3-Fmoc), 7.28-7.24 (m, 2-
H, C2-Fmoc), 5.91-5.83 (m, 1-H, CH2=CH), 5.26-5.10 ( m, 2-H, CH2=CH), 4.49 (d,
 3JH-H = 3.3 
Hz, 2-H, Fmoc-CH2), 4.34-4.27 (m, 3-H, Dap-Hα, 2-H, CH2=CH-CH2-), 4.17 (t, 
3JH-H = 4.2 Hz, 
1-H, Fmoc-CH), 3.61-3.41 (m, 2-H, Dap-Hβ).
 
 
13C-NMR (125 MHz, CD3OD-d4): δ (ppm) = 173.6 (COOH), 158.9 (CO-Fmoc), 158.5 (CO-
Alloc), 145.2 (C6-Fmoc),   142.5 (C5-Fmoc),  134.3 (CH=Alloc),  128.7 (C3-Fmoc), 128.1 
(C2-Fmoc), 126.3 (C1-Fmoc), 120.9 (C4-Fmoc), 117.5 (=CH2Alloc), 68.2 (CH2Alloc), 66.6 
(CH2Fmoc), 55.7 (α-CH), 48.3 (CH-Fmoc), 43.0 (β-CH2).       
 
ESI-MS m/z: 433.2 [M+Na]+, 843.3 [2M+Na]+, 409.1 [M-H]-,819.3 [2M-H]-. 
 
ESI-HRMS: calculated for [C22H22N2O6Na]






7.6. Synthesis of IHF Mimicking Peptides  
 




                
 
The linear peptide 13 was synthesized using 2-chlorotrityl resin preloaded with 
isoleucine. The synthesis was carried out at a scale of 0.1 mmol in accordance with the 
Fmoc automated SPPS protocol (mentioned in section 7.3). Cleavage of the peptide from 
the resin using 30% HFIP in DCM followed by HPLC purification yielded the peptide 13 
(165.1 mg, 0.078 mmol, 78%) as a white solid.  
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
36.8 min. 
 
ESI-MS m/z: 1070.1 [M+H+Na]2+ , 2117.1 [M+H]1+.    
 
ESI-HRMS: calculated for [C105H156N18O26S]
2+ ([M+2H]2+) = 1059.0589, found = 1059.0597; 
calculated for [C105H155N18O26S]
+ ([M+H]+) = 2117.1106, found = 2117.1113; calculated for 
[C105H154N18O26SNa]







                                          
 
The linear peptide 13 (165.1 mg, 0.078 mmol, 1 eq) was dissolved in a mixture of 
anhydrous DCM/DMF (80 mL, 9:1) under argon atmosphere. To it DIC (10 eq), NMM (3 
eq) and HOAt (1 eq) were added while stirring vigorously and solution was continued to 
stir for 48 h at room temperature. After the solvent was removed under reduced 
pressure purification of the crude product using RP-HPLC yielded the alloc protected 
cyclo peptide 14 (134.22 mg, 0.064 mmol, 82%) as a white solid.  
  
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250x10 mm, 5 µm),   80-100% gradient of B in 30 min, flow rate 3 mL/min, tR  = 15.04 min. 
 
ESI-MS m/z: 2121.0 [M+Na]+, 2099.1 [M+H]+ , 1050.0 [M+2H]2+.    
 
ESI-HRMS: calculated for [C105H153N18O25S] ([M+H]
+) = 2099.1000, found = 2099.1007; 
calculated for [C105H152N18O25SNa]
+ ([M+Na]+) = 2120.0819, found = 2120.0819; 
calculated for [C105H154N18O25S]








                                          
 
The alloc protected cyclic peptide 14 (75 mg, 36 µmol, 1 eq) was dissolved in 7 mL of dry 
DMF under argon atmosphere. To it was added dimethylborane complex Me2NH.BH3 
(85 mg, 1.44 mmol, 40 eq) and tetrakis(triphenylphosphine)palladium(0) Pd(PPh3)4  
(4.2 mg, 3.6 µmol, 0.1 eq) and the mixture was allowed to stir at room temperature for 
6 h. Thereafter, the solvent was removed under reduced pressure and the residue was 
purified by RPLC. The alloc deprotected cyclo peptide 15 (53 mg, 26.3 µmol, 73%) was 
obtained as a white solid.    
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250x21.0 mm, 5 µm),   70-100% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
20.4 min. 
 
ESI-MS m/z: 1008.1 [M+2H]2+ , 2015.1 [M+H]+, 1019.1 [M+H+Na]2+.      
 
ESI-HRMS: calculated for [C101H149N18O23S]
+ ([M+H]+) = 2015.0788, found = 2015.0757; 
calculated for [C101H150N18O23S]
2+ ([M+2H]2+) = 1008.0431, found = 1008.0414; calculated 
for [C101H149N18O23SNa]








                                            
  
The cyclic peptide 15 (5 mg, 2.48 µmol, 1 eq) was dissolved in 95% of TFA in H2O (1.5 mL) 
and the mixture was stirred at room temperature for 45 min. Thereafter, the solvent was 
evaporated by blow drying with air. The crude product was precipitated out by pouring 
pre-cooled diethylether. Cold centrifugation followed by decanting the supernatant, 
lyophilization from water and purification by RP-HLPC yielded the peptide P2 (2.12 mg, 
1.69 µmol, 68%) as a white solid.    
 
HPLC Purification: Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   60-100% gradient of B in 30 min, flow rate 10 mL/min, 
tR = 13.2 min. 
 
ESI-MS m/z: 1251.7 [M+H]+, 626.3 [M+2H]2+.    
 
ESI-HRMS: calculated for [C52H87N18O18]
+ ([M+H]+) = 1251.6440, found = 1251.6442; 
calculated for [C52H88N18O18]












                          
The synthesis of the lysine dendrimer was performed manually according the procedure 
(mentioned in section 7.3). Cleavage of the peptide from the resin using 30% (HFIP) in 
DCM followed by purification with RP-HPLC yielded the peptide 16 (113 mg, 62 µmol, 
62%) as a white solid. 
 
HPLC Purification: Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   20-40% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
8.9 min. 
 
ESI-MS m/z: 1828.2 [M+H]+, 914.6 [M+2H]2+, 610.1 [M+3H]3+, 457.0 [M+4H]4+.    
 
ESI-HRMS: calculated for [C84H156N21O23]
+ ([M+H]+) = 1828.1710, found = 1828.1671; 
calculated for [C84H155N21O23Na]
+ ([M+Na]+) = 1850.1529, found = 1850.1501; calculated 
for [C84H157N21O23]
2+ ([M+2H]2+) = 914.5891, found = 914.5898; calculated for 
[C84H158N21O23]
3+ ([M+3H]3+) = 610.0618, found = 610.0627; calculated for 
[C84H159N21O23]







                       
The dendrimer 16 (60 mg, 32.83 µmol, 2 eq) was dissolved in dry DMF (3.5 mL) under 
argon atmosphere and to it were added DIC (13.8 µL, 0.131 mmol, 8 eq), NMM (18.1 µL, 
0.164 mmol, 10 eq) and HOAt (17.69 mg, 0.13 mmol, 7.9 eq). After stirring the mixture at 
room temperature for 10 min the cyclic peptide 15 (33.1 mg, 16.42 µmol, 1 eq) was 
added to it and allowed to stir for additional 48 h.  Thereafter, removal of the solvent 
under vacuum followed by purification of the residue by RP-HPLC yielded the product 20 
(25.73 mg, 6.73 µmol, 41%) as a white solid.  
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   30-100% gradient of C in 30 min, flow rate 3 mL/min, tR  = 21.4 min. 
 
ESI-MS m/z: 1912.6 [M+2H]2+ , 1275.4 [M+3H]3+ , 956.8 [M+4H]4+.   
 
ESI-HRMS: calculated for [C185H303N39O45S]
2+ ([M+2H]2+) = 1912.6197, found = 1912.6200; 
calculated for [C185H304N39O45S]
3+ ([M+3H]3+) = 1275.4156, found = 1275.4166; calculated 
for [C185H305N39O45S]
4+ ([M+4H]4+) = 956.8135, found = 956.8151; calculated for 
[C185H306N39O45S]




[Lys(Me)2]4Lys2LysGly7-cyclo [-DapD-ProGlyArgAsnProLysThrGlyGluAspIle-]  
 
                        
 
The peptide 20 (25.73 mg, 6.73 µmol) was dissolved in 95% TFA in H2O (2 mL) and stirred 
for 45 min at room temperature. Thereafter, the solvent was blow dried with argon and 
the residue was purified by RP-HPLC yielding the product 21 (7.34 mg, 2.76 µmol, 41%) as 
a pale yellow crystalline solid. 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   3-40% gradient of C in 30 min, flow rate 3 mL/min, tR  = 17.1 min. 
 
ESI-MS m/z: 1330.8 [M+2H]2+ , 887.5 [M+3H]3+, 665.9 [M+4H]4+, 532.9 [M+5H]5+, 
444.3 [M+6H]6+.    
 
ESI-HRMS: calculated for [C116H209N39O32]








7.6.3. Synthesis of IHF-2 
 
[Boc-Lys(Me)2]4Lys2LysGly-5-(2-(allyloxycarbonyl)-N,N’-dimethylethylene 
diamino) pentanoic acid-Gly5-OH 
 
                   
The synthesis of the lysine dendrimer was performed manually according the procedure 
(mentioned in section 7.3). Cleavage of the peptide from the resin using 30% (HFIP) in 
DCM followed by purification with RP-HPLC yielded the peptide 17a (98 mg, 48 µmol, 
48%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 10 mL/min, 
tR = 24.48 min. 
 
ESI-MS m/z: 2040.3, [M+H]+, 1020.7 [M+2H]2+ , 680.8 [M+3H]3+ , 510.8 [M+4H]4+.    
 
ESI-HRMS: calculated for [C95H176N23O25]
+ ([M+H]+) = 2040.3232, found = 2040.3204; 
calculated for [C95H175N23O25Na]
+ ([M+Na]+) = 2061.3022, found = 2061.3015; calculated 
for [C95H177N23O25]
2+ ([M+2H]2+) = 1020.6652, found = 1020.6649; calculated for 
[C95H178N23O25]







              
The dendrimer 17a (80 mg, 39.22 µmol, 2 eq) was dissolved in dry DMF (4 mL) under 
argon atmosphere and to it were added DIC (16.5 µL, 0.157 mmol, 8 eq), NMM (21.6 µL, 
0.196 mmol, 10 eq) and HOAt (21.78 mg, 0.16 mmol, 7.9 eq). After stirring the mixture at 
room temperature for 10 min the cyclic peptide 15 (39.5 mg, 19.61 µmol, 1 eq) was 
added to it and allowed to stir for additional 48 h.  Thereafter, removal of the solvent 
under vacuum followed by purification of the residue by RP-HPLC yielded the product 
21a (37.2 mg, 9.22 µmol, 47%) as a white solid. 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   55-75% gradient of C in 30 min, flow rate 3 mL/min, tR  = 20.31 min. 
 
ESI-MS m/z: 1345.8 [M+3H]3+ , 1009.6 [M+4H]4+, 807.9 [M+5H]5+.    
 
ESI-HRMS: calculated for [C196H325N41O47S]
4+ ([M+4H]4+) = 1009.6008, found = 1009.6005; 
calculated for [C196H326N41O47S]







                
To a solution of peptide 21a (30 mg, 7.43 µmol, 1 eq) in dry DMF (3 mL) were added 
Me2NH.BH3 (17.68 mg, 0.3 mmol, 40 eq) and Pd(PPh3)4 (0.86 mg, 0.743 µmol, 0.1 eq) 
under argon atmosphere. The reaction mixture was allowed to stir for 6 h at room 
temperature. The solvent was removed under vacuum and the residue was purified by 
RP-HPLC yielding the peptide 22a (19.38 mg, 4.90 µmol, 66%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   60-100% gradient of B in 30 min, flow rate 10 mL/min, 
tR = 14.4 min. 
 
ESI-MS m/z: 1976.7 [M+2H]2+ , 1318.1 [M+3H]3+, 988.8 [M+4H]4+, 791.3 [M+5H]5+.   
 
ESI-HRMS: calculated for [C192H319N41O45S]
2+ ([M+2H]2+) = 1976.6850, found = 1976.6772; 
calculated for [C192H320N41O45S]
3+ ([M+3H]3+) = 1318.1258, found = 1318.1269; calculated 
for [C192H321N41O45S]
4+ ([M+4H]4+) = 988.8462, found = 988.8457; calculated for 
[C192H322N41O45S]








                    
 
A solution of K2PtCl4 (61 mg, 0.147 mmol, 30 eq) and peptide 22a (19.38 mg, 4.90 µmol, 
1 eq) in DMF/H2O (3.5 mL, 9/1) was stirred at room temperature for 48 h in dark. 
Thereafter, the solvent was removed under reduced pressure and the residue was 
purified by RP-HPLC yielding the product 23a (14.26 mg, 3.38 µmol, 69%) as a white solid.  
 
HPLC Purification:  Column All 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   15-70% gradient of B in 30 min, flow rate 3 mL/min, tR  = 35.1 min. 
 
ESI-MS m/z: 2109.6 [M+2H]2+ , 1406.8 [M+3H]3+, 1055.6 [M+4H]4+.    
 
ESI-HRMS: calculated for [C192H319Cl2N41O45PtS]
2+ ([M+2H]2+) = 2109.6356, found = 
2109.6349; calculated for [C192H320Cl2N41O45PtS]
3+ ([M+3H]3+) = 1406.7595, found = 
1406.7646; calculated for [C192H321Cl2N41O45SPt]








               
 
The peptide 23a (14.26 mg, 3.38 µmol) was dissolved in 95% TFA in H2O (2 mL) and 
stirred for 45 min at room temperature. Thereafter, the solvent was blow dried with 
argon and the residue was purified by RP-HPLC yielding the product IHF-2 (4.43 mg, 1.45 
µmol, 43%) as a pale yellow crystalline solid. 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   10-40% gradient of B in 30 min, flow rate 3 mL/min, tR  = 14.4 min. 
 
ESI-MS m/z: 1527.3 [M+2H]2+, 1018.5 [M+3H]3+, 764.2 [M+4H]4+, 611.5 [M+5H]5+, 
509.8 [M+6H]6+. 
 
ESI-HRMS: calculated for [C123H226Cl2N41O32Pt]
3+ ([M+3H]3+) = 1018.5446, found = 
1018.5440; calculated for [C123H227Cl2N41O32Pt]





7.6.4. Synthesis of IHF-3 
 
[Boc-Lys(Me)2]4Lys2LysGly3-5-(2-(allyloxycarbonyl)-N,N’-dimethylethylene 
diamino) pentanoic acid-Gly3-OH 
 
                
The synthesis of the lysine dendrimer was performed manually according the procedure 
(mentioned in section 7.3). Cleavage of the peptide from the resin using 30% (HFIP) in 
DCM followed by purification with RP-HPLC yielded the peptide 17b (108 mg, 53 µmol, 
53%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
23.6 min. 
 
ESI-MS m/z: 2040.4 [M+H] +, 1020.7 [M+2H]2+ , 680.8 [M+3H]3+, 510.9 [M+4H]4+.    
 
ESI-HRMS: calculated for [C95H176N23O25]
+ ([M+H]+) = 2040.3232, found = 2040.3206; 
calculated for [C95H177N23O25]
2+ ([M+2H]2+) = 1020.6652, found = 1020.6668; calculated 
for [C95H178N23O25]





diamino) pentanoic acid-Gly3- cyclo[-DapD-ProGlyArg(Pbf)Asn(Trt)ProLys(Boc) 
Thr(tBoc)Gly Glu(tBu)Asp(tBu)Ile-] 
 
                       
 
To a solution of dendrimer 17b (83 mg, 40.7 µmol, 2 eq) in dry DMF (4 mL) under argon 
DIC (17.1 µL, 0.163 mmol, 8 eq), NMM (22.4 µL, 0.204 mmol, 10 eq) and HOAt (21.88 mg, 
0.161 mmol, 7.9 eq) were added. After stirring the mixture at room temperature for 10 
min the cyclic peptide 15 (41 mg, 20.35 µmol, 1 eq) was added and reaction allowed to 
stir for additional 48 h.  Thereafter, removal of the solvent under vacuum and 
purification of the residue by RP-HPLC yielded the product 21b (43.55 mg, 10.79 µmol, 
53%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   30-100% gradient of C in 30 min, flow rate 10 mL/min, 
tR = 22.4 min. 
 






2+ ([M+2H]2+) = 2018.6956, found= 2018.6982, calculated for 
[C196H324N41O47S]
3+ ([M+3H]3+) = 1346.1328, found = 1346.1352; calculated for 
[C196H325N41O47S]
4+ ([M+4H]4+) = 1009.8514, found = 1009.8536; calculated for 
[C196H326N41O47S]






                
 
To a solution of peptide 21b (40 mg, 9.91 µmol, 1 eq) in 4 mL of dry DMF under argon 
atmosphere were added Me2NH.BH3 (23.33 mg, 0.396 mmol, 40 eq) and Pd(PPh3)4 
(1.15 mg, 0.991 µmol, 0.1 eq). The reaction mixture was allowed to stir for 6 h at room 
temperature. The solvent was removed under vacuum and the residue was purified by 
RP-HPLC yielding the peptide 22b (30.15 mg, 7.63 µmol, 77%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 





ESI-MS m/z: 1976.7 [M+2H]2+ , 1318.1 [M+3H]3+, 988.8 [M+4H]4+, 791.3 [M+5H]5+.   
 
ESI-HRMS: calculated for [C192H319N41O45S]
2+ ([M+2H]2+) = 1976.6850, found = 1976.6837; 
calculated for [C192H320N41O45S]
3+ ([M+3H]3+) = 1318.1258, found = 1318.1268; calculated 
for [C192H321N41O45S]






                  
 
A solution of K2PtCl4 (95.1 mg, 0.229 mmol, 30 eq) and peptide 22b (30.15 mg, 7.63 
µmol, 1 eq) in DMF/H2O (5 mL, 9/1) was stirred at room temperature for 48 h in dark. 
Thereafter, the solvent was removed under reduced pressure and the residue was 
purified by RP-HPLC yielding the product 23b (19.95 mg, 4.73 µmol, 62%) as a white solid.  
 
HPLC Purification:  Column All2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 




ESI-MS m/z: 2109.6 [M+2H]2+ , 1406.8 [M+3H]3+, 1055.3 [M+4H]4+, 845.5 [M+5H]5+.    
 
ESI-HRMS: calculated for [C192H319Cl2N41O45PtS]
2+ ([M+2H]2+) = 2109.6397, found = 
2109.6356; calculated for [C192H320Cl2N41O45PtS]
3+ ([M+3H]3+) = 1406.7595, found = 
1406.7627; calculated for [C192H321Cl2N41O45PtS]






                 
 
The peptide 23b (19.95 mg, 4.73 µmol) was dissolved in 95% TFA in H2O (2 mL) and 
stirred for 45 min at room temperature. Thereafter, the solvent was blow dried with 
argon and the residue was purified by RP-HPLC yielding the product IHF-3 (8.09 mg, 2.65 
µmol, 56%) as a pale yellow crystalline solid. 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   10-40% gradient of B in 30 min, flow rate 3 mL/min, tR  = 14.85, 




ESI-MS m/z: 1528.3 [M+2H]2+ , 1018.9 [M+3H]3+, 764.4 [M+4H]4+, 611.7 [M+5H]5+.    
 
ESI-HRMS: calculated for [C123H225Cl2N41O32Pt]
2+ ([M+2H]2+) = 1528.3140, found = 
1528.3128; calculated for [C123H226Cl2N41O32Pt]
3+ ([M+3H]3+) = 1018.8782, found = 
1018.8782; calculated for [C123H227Cl2N41O32Pt]
4+ ([M+4H]4+) = 764.4105, found = 
764.4100; calculated for [C123H228Cl2N41O32Pt]
5+ ([M+5H]5+) = 611.7299, found = 
611.7290; calculated for [C123H229Cl2N41O32Pt]
6+ ([M+6H]6+) = 509.9428, found = 
509.9423. 
 





                
   
The synthesis of the lysine dendrimer was performed manually according the procedure 
(mentioned in section 7.3). Cleavage of the peptide from the resin using 30% (HFIP) in 
DCM followed by purification with RP-HPLC yielded the peptide 17c (118 mg, 58 µmol, 




HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 10 mL/min, 
tR  = 24.65 min. 
 
ESI-MS m/z: 2040.4 [M+H]+, 1020.7 [M+2H]2+ , 680.8 [M+3H]3+, 510.8 [M+4H]4+.   
 
ESI-HRMS: calculated for [C95H176N23O25]
+ ([M+H]+) = 2040.3232, found = 2040.3183; 
calculated for [C95H177N23O25]
2+ ([M+2H]2+) = 1020.6652, found = 1020.6639; calculated 
for [C95H178N23O25]






                
 
The dendrimer 17c (85 mg, 41.6 µmol, 2 eq) was dissolved in dry DMF (4 mL) under argon 
atmosphere and to it were added DIC (17.5 µL, 166.4 µmol, 8 eq), NMM (22.9 µL, 




room temperature for 10 min the cyclic peptide 15 (41.9 mg, 20.8 µmol, 1 eq) was added 
to it and allowed to stir for additional 48 h.  Thereafter, removal of the solvent under 
vacuum followed by purification of the residue by RP-HPLC yielded the product 21c 
(36.93 mg, 9.15 µmol, 44%) as a white solid. 
 
HPLC Purification: Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 250 × 21.0 
mm, 5 µm),   30-100% gradient of B in 30 min, flow rate 3 mL/min, tR  = 25.1 min. 
 
ESI-MS m/z: 2018.7 [M+2H]2+, 1346.1 [M+3H]3+, 1009.9 [M+4H]4+, 808.1 [M+5H]5+. 
 
ESI-HRMS: calculated for [C196H324N41O47S]
3+ ([M+3H]3+) = 1346.1328, found = 1346.1347; 
calculated for [C196H325N41O47S]
4+ ([M+4H]4+) = 1009.8514, found = 1009.8531; calculated 
for [C196H326N41O47S]














                 
To a solution of peptide 21c (35 mg, 8.67 µmol, 1 eq) in 3.5 mL of dry DMF under argon 
atmosphere were added Me2NH.BH3 (20.2 mg, 0.347 mmol, 40 eq) and Pd(PPh3)4 
(1.0 mg, 0.0867 µmol, 0.1 eq). The reaction mixture was allowed to stir for 6 h at room 
temperature. The solvent was removed under vacuum and the residue was purified by 
RP-HPLC yielding the peptide 22c (24.65 mg, 6.24 µmol, 72%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, spreparative, 
250 × 21.0 mm, 5 µm),   60-80% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
16.2 min. 
 
ESI-MS m/z: 1318.1 [M+3H]3+ , 988.8 [M+4H]4+, 791.3 [M+5H]5+, 659.6 [M+6H]6+.   
 
ESI-HRMS: calculated for [C192H320N41O45S]
3+ ([M+3H]3+) = 1318.1258, found = 1318.1275; 
calculated for [C192H321N41O45S]
4+ ([M+4H]4+) = 988.8462, found = 988.8482; calculated 
for [C192H322N41O45S]
5+ ([M+5H]5+) = 791.2784, found = 791.2795; calculated for 
[C192H323N41O45S]








                 
 
A solution of K2PtCl4 (77.63 mg, 0.187 mmol, 30 eq) and peptide 22c (24.65 mg, 6.24 
µmol, 1 eq) in DMF/H2O (4 mL, 9/1) was stirred at room temperature for 48 h in dark. 
Thereafter, the solvent was removed under reduced pressure and the residue was 
purified by RP-HPLC yielding the product 23c (18.7 mg, 4.43 µmol, 71%) as a white solid.  
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   15-70% gradient of B in 30 min, flow rate 3 mL/min, tR  = 35.2 min. 
 
ESI-MS m/z: 1406.8 [M+3H]3+ , 1055.3 [M+4H]4+.    
 
ESI-HRMS: calculated for [C192H320Cl2N41O45SPt]
3+ ([M+3H]3+) = 1406.7595, found = 
1406.7617; calculated for [C192H321Cl2N41O45SPt]
4+ ([M+4H]4+) = 1055.3215, found = 
1055.3226; calculated for [C192H322Cl2N41O45SPt]








                
The peptide 23c (18.7 mg, 4.43 µmol) was dissolved in 95% TFA in H2O (2 mL) and stirred 
for 45 min at room temperature. Thereafter, was solvent blow dried with argon and the 
residue was purified by RP-HPLC yielding the product IHF-4 (6.9 mg, 2.26 µmol, 51%) as a 
pale yellow crystalline solid.    
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   10-40% gradient of B in 30 min, flow rate 3 mL/min, tR  = 15.0, 15.7, 
16.16  min. 
 
ESI-MS m/z: 1019.2 [M+3H]3+ , 764.4 [M+4H]4+, 611.7 [M+5H]5+, 509.9 [M+6H]6+, 
437.2 [M+7H]7+. 
 
ESI-HRMS: calculated for [C123H226Cl2N41O32Pt]
3+ ([M+3H]3+) = 1019.2118, found = 
1019.2139; calculated for [C123H227Cl2N41O32 Pt]
4+ ([M+4H]4+) = 764.4105, found = 
764.4124; calculated for [C123H228Cl2N41O32 Pt]









                    
To a solution of peptide 17c (45 mg, 22 µmol, 1 eq) in 4.5 mL of dry DMF under argon 
atmosphere were added Me2NH.BH3 (52 mg, 0.88 mmol, 40 eq) and Pd(PPh3)4 (2.55 mg, 
2.2 µmol, 0.1 eq). The reaction mixture was allowed to stir for 6 h at room temperature. 
The solvent was removed under vacuum and the residue was purified by RP-HPLC 
yielding the peptide 18 (17 mg, 8.7 µmol, 40%) as a white solid. 
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 10 mL/min, 
tR = 21.81 min. 
 
ESI-MS m/z: 978.7 [M+2H]2+ , 652.8 [M+3H]3+, 489.8 [M+4H]4+, 392.1 [M+5H]5+.    
 
ESI-HRMS: calculated for [C91H173N23O23]
2+ ([M+2H]2+) = 978.6548, found = 978.6550; 
calculated for [C91H174N23O23]
3+ ([M+3H]3+) = 652.7723, found = 652.7728; calculated for 
[C95H175N23O23]
4+ ([M+4H]4+) = 489.8310, found = 489.8316; calculated for 
[C95H176N23O23]







                      
 
A solution of K2PtCl4 (108.34 mg, 0.261 mmol, 30 eq) and peptide 18 (17 mg, 8.7 µmol, 
1 eq) in DMF/H2O (4 mL, 9/1) was stirred at room temperature for 48 h in dark. 
Thereafter, the solvent was removed under reduced pressure and the residue was 
purified by RP-HPLC yielding the product 19 (12.18 mg, 5.48 µmol, 63%) as a white solid.  
 
HPLC Purification:  Column Pep 1 (MN_Nucleodur100_5_C18, RP-C18, preparative, 
250 × 21.0 mm, 5 µm),   5-60% gradient of B in 30 min, flow rate 10 mL/min, tR  = 
25.33 min. 
 
ESI-MS m/z: 1111.6 [M+2H]2+ , 741.1 [M+3H]3+, 556.1 [M+4H]4+, 446.1 [M+5H] 5+.    
 
ESI-HRMS: calculated for [C91H173Cl2N23O23Pt]
2+ ([M+2H]2+) = 1111.6052, found = 
1111.6068; calculated for [C91H174 Cl2N23O23Pt]
3+ ([M+3H]3+) = 741.0723, found = 
741.0737; calculated for [C91H175 Cl2N23O23Pt]








                   
 
The peptide 19 (12.18 mg, 5.48 µmol) was dissolved in 95% TFA in H2O (1.5 mL) and 
stirred for 45 min at room temperature. Thereafter, the solvent was blow dried with 
argon and the residue was purified by RP-HPLC yielding the product P1 (4.78 mg, 
2.63 µmol, 48%) as a pale yellow crystalline solid.    
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   5-30% gradient of B in 30 min, flow rate 3 mL/min, tR  = 17.91, 
19.38, 20.74  min. 
 
ESI-MS m/z: 911.0 [M+2H]2+ , 607.7 [M+3H]3+, 456.0 [M+4H]4+, 366.0 [M+5H]5+.   
 
ESI-HRMS: calculated for [C71H141Cl2N23O15Pt]
2+ ([M+2H]2+) = 910.9997, found = 910.9999; 
calculated for [C71H142Cl2N23O15Pt]
3+ ([M+3H]3+) = 607.6689, found = 607.6694; calculated 
for [C71H143Cl2N23O15Pt]










                          
 
To a solution of diethylenetriamine 24 (9.4 mL, 0.087 mol, 1 eq) and triethylamine 
(40 mL, 0.287 mol, 3.3 eq) in dichloromethane (400 mL) was added tosylchloride 
(51.48 g, 0.27 mol, 3.1 eq) at 0 ˚C. After stirring the reaction for 12 h at room 
temperature the solvent was removed under reduced pressure. Recrystallization in 
methanol yielded N,N’,N’’-tri(tosyl)diethylenetriamine 25 (44.8 g, 0.079  mol, 91%).   
 
Rf = 0.8 (Methanol/Dichloromethane = 1/9, v/v). 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.67-7.62 (m, 6-H, Ar-H), 7.56-7.53 (m, 2-H, N-
H), 7.40-7.35 (m, 6-H, Ar-H), 3.04 (t, 3JH-H = 7.5 Hz, 4-H, CH2), 2.83 (t,
 3JH-H = 7.5 Hz, 4-H, 
CH2),  2.39 (s, 9-H, CH3). 
 
ESI-MS m/z: 566.0 [M+H]+ , 587.9 [M+Na]+, 564.1 [M-H]-, 1129.3 [2M-H]-.   
 
ESI-HRMS: calculated for [C25H32N3O6S3]
+ ([M+H]+) = 566.1453, found = 566.1447; 
calculated for [C25H30N3O6S3]







                    
 
To a solution of sodium hydride (5.7 g, 0.237 mol, 3 eq) in dry DMF (100 mL) 
N,N’,N’’-tri(tosyl)diethylenetriamine 25 (44.8 g, 0.079 mol, 1 eq)  dissolved in dry DMF 
(300 mL) was added under argon at 0 ˚C. The reaction mixture was stirred for 1 h at 0 ˚C 
and 2 h at room temperature. Thereafter, a solution of ethylene ditosylate (29.23 g, 
0.079 mol, 1 eq) in DMF (200 mL) was added to it dropwise 120 ˚C over a period of 
45 min and subsequently stirred at 120 ˚C for 48 h.  After destroying the excess sodium 
hydride by dropwise addition of MeOH (25 mL), the solvents were removed under 
reduced pressure and ice cold water (500 mL) was added to the mixture. Filtration 
followed by recrystallization in ethanol yielded 1,4,7-Tritosyl-1,4,7-triazacyclononane 
(40.24 g, 0.068 mol, 86%). 
 
Rf = 0.56 (Methanol/Dichloromethane = 1/9, v/v). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.69 (d, 
3JH-H = 9 Hz, 6-H, Ar-H), 7.32 (d, 
4JH-H = 6 Hz, 
6-H, Ar-H), 3.42 (s, 12-H, CH2), 2.41 (s, 9-H, CH3).      
 
ESI-MS m/z: 592.2 [M+H]+, 614.2 [M+Na]+, 590.1 [M-H]-.   
 
ESI-HRMS: calculated for [C27H32N3O6S3]
- ([M-H]-) = 590.1459, found = 590.1454; 
calculated for [C27H33N3O6S3Na]






                            
 
Tritosyl-1,4,7-triazacyclononane 26 (10 g, 16.9 mmol) was refluxed at 120-130 ˚C for 6 h 
in concentrated H2SO4. After cooling the reaction mixture to 0 ˚C it was poured into ice 
cold ethanol (600 mL). Addition of ice cold diethyl ether (600 mL) led to precipitation of a 
pale yellow solid. The solid was filtered and dissolved in conc. NaOH (aq). The water 
phase was extracted with CHCl3 (3x300 mL), dried over Na2SO4 and concentrated under 
reduced pressure (>300 mbar, product is volatile). Triazacyclononane obtained as a pale 
yellow oil was dissolved in dry DCM (40 mL) and Et3N (4.2 mL, 30.42 mmol, 1.8 eq) was 
added to it under argon atmosphere. Thereafter, a solution of (Boc)2O (6.64 g, 30.42 
mmol, 1.8 eq) in dry DCM (20 mL) was slowly added at 0 ˚C over a period of 30 min and 
the reaction was continued to stir for  another 6 h at room temperature. The solvent was 
removed under reduced pressure. Purification by column chromatography [eluent: 
EtoAc/MeOH, 95/5 (v/v)] yielded 1,4-Bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 27 
(3.2 g, 9.71 mmol, 58%) as a viscous colourless oil  . 
 
Rf = 0.37 (Methanol/Dichloromethane = 1/4, v/v). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 3.48-3.41 (m, 4-H, 5-CH2, 6-CH2), 3.28-3.21 (m, 4-H, 
3-CH2, 8-CH2), 2.94-2.90 (m, 4-H, 2-CH2, 9-CH2), 1.47 (s, 18-H, 
tBoc-CH3).      
 




ESI-HRMS: calculated for [C16H32N3O4]
+ ([M+H]+) = 330.2387, found =330.2387; calculated 
for [C16H31N3O4Na]




                              
 
Sodium azide (4.2 g, 64.8 mmol, 1.2 eq) was added to a solution of 1,2-
bis(tosyloxy)ethane 28 (20 g, 54 mmol, 1 eq)  in dry DMF (140 mL) and stirred at 100 ˚C 
for 24 h. The solvent was removed under reduced pressure. The residue was suspended 
in water (100 mL), extracted with ether (3 x 300 mL), dried over Na2SO4 and 
concentrated in vacuum. Purification by column chromatography (eluent: 
dichloromethane) yielded (2-azidoethyl)tosylate 29 as a colourless oil (6.25 g, 
25.6 mmol, 48%). 
 
Rf = 0.77 (dichloromethane). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.81 (dd, 
3JH-H = 8.4 Hz, 2-H, Ar-H), 7.36 (dd, 
3JH-H = 
8.1 Hz, 2-H, Ar-H), 4.16 (t, 3JH-H = 5.1 Hz, 2-H, CH2), 3.5-3.45 (m, 2-H, CH2), 2.45 (s, 3-H, 
CH3).      
 
ESI-MS m/z: 264.1 [M+Na]+ ,  505.1 [2M+Na]+.   
 
ESI-HRMS: calculated for [C9H11N3O3SNa]






                  
   
1,4-bis(tert-butoxycarbonyl)-1,4,7-triazacylonane 27 (1.12 g, 3.4 mmol, 1 eq), K2CO3 (0.56 
g, 4.08 mmol, 1.2 eq) and (2-azidoethyl)tosylate (0.9 g, 3.74 mmol, 1.1 eq) were 
suspended in dry MeCN (25 mL) under inert atmosphere. The reaction mixture was 
refluxed for 48 h followed by cooling to room temperature and filtration. After removing 
the solvent under reduced pressure and the residue was purified by column 
chromatography [eluent: DCM (100%) → DCM/MeOH, 95/5 (v/v)]. The product 7-(2-
Azidoethyl)-1,4-bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 30 (1.1 g, 2.76 mmol, 
81%) was obtained as a colourless oil. 
 
Rf = 0.79 (Methanol/Dichloromethane = 5/95, v/v). 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 3.47-3.43 (m, 4-H, CH2), 3.33-3.23 (m, 6-H, CH2), 
2.78-2.69 (m, 6-H, CH2), 1.47 (s, 18-H, 
tBoc-CH3).  
     
ESI-MS m/z: 399.3 [M+H]+ , 421.2 [M+Na]+, 819.5 [2M+Na]+. 
   
ESI-HRMS: calculated for [C18H35N6O4]
+ ([M+H]+) = 399.2714, found = 399.2714; 
calculated for [C18H34N6O4Na]






             
 
After thoroughly degassing a solution of 7-(2-Azidoethyl)-1,4-bis(tert-butoxycarbonyl)-
1,4,7-triazacyclononane 30 (1 g, 2.52 mmol, 1 eq) and Fmoc-L-propargyl-glycine 31 (0.7 g, 
2.52 mmol, 1eq) in dry DMF (13.5 mL), CuI (96 mg, 0.5 mmol, 0.2 eq) and sodium 
ascorbate (0.5 g, 2.52 mmol, 1 eq) were added to it under argon. The reaction mixture 
was stirred at room temperature for 12 h followed by removing the solvent under 
reduced pressure. Purification of the residue by column chromatography [eluent: 
MeOH/DCM 10/90, v/v] afforded the product Nα-Fmoc-β-[1-(2-bbt-ethyl)-1,2,3-triazol-4-
yl]-L-alanine 32 as a bright yellow solid (1.54 g, 2.1 mmol, 83%).  
 
Rf = 0.75 (Methanol/Dichloromethane = 20/80, v/v). 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.88-7.86 (m, 2-H, Ar-CH), 7.75 (s, 1-H, triazol-
H), 7.67-7.64 (m, 2-H, Ar-CH), 7.42-7.28 (m, 4-H, Ar-CH), 7.02 (sbr, 1-H, NH), 4.36-4.27 (m, 
2-H, NArCH2), 4.21-4.13 (m, 3-H, Fmoc-CH, Fmoc-CH2), 4.10-4.05 (m, 1-H, Hα), 3.27-3.16 
(m, 4-H, tacn-CH2), 3.12-3.01 (m, 5-H, tacn-CH2, β-CH2), 2.94-2.81 (m, 3-H, NCH2, β-CH2), 







13C-NMR (100 MHz, CDCl3): δ (ppm) =     155.51 (COOH), 154.60 (C=O), 154.56 (C=O), 
143.93 (Ar-C), 143.78 (Ar-C), 143.75 (Ar-C), 140.58 (Ar-C), 127.49 (Ar-C), 126.96 (Ar-C), 
125.14 (Ar-C), 122.64 (Ar-C), 119.96 (Ar-C), 78.49 [O-C(CH3)3], 78.40 [O-C(CH3)3], 78.36 
[O-C(CH3)3], 65.52 (Fmoc-CH2), 55.68, 55.01, 53.80, 53.49, 53.37, 52.99, 50.44, 49.75, 
49.30, 49.04, 48.51, 48.28, 48.00, 47.86, 46.59 (Fmoc-CH), 28.04 [C(CH3)3].  
 
ESI-MS m/z: 734.4 [M+H]+ , 756.4 [M+Na]+.   
 
ESI-HRMS: calculated for [C38H52N7O8]
+ ([M+H]+) = 734.3872, found = 734.3861; 
calculated for [C38H51N7O8Na]
+ ([M+Na]+) = 756.3680, found = 756.3691. 
   
 
 



















7.8. Preparation of the Zinc Finger Domains 
  
7.8.1. Solid phase synthesis of Zf3 domains 
Zf3Wildtype 
 
                             
 
Zf3Wildtype was synthesised using Fmoc-Lys(Boc)-Wang (0.34 mmol/g). The synthesis 
was carried out at a scale of 0.1 mmol in accordance with Fmoc automated SPPS protocol 
(section 7.3). Cleavage of the peptide from the resin using TFA/H2O/TIS/EDT 
(94/2.5/1/2.5) followed by HPLC purification yielded the Zf3wildtype (99 mg, 32.1 mmol, 
32.1%) as a white solid in the oxidised disulfide form of the peptide 33 (Zf3Wildtype). 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 3 mL/min, tR  = 
16.81 min. 
 
ESI-MS m/z: 514.1 [M+6H]+6 , 616.7 [M+5H]+5, 770.9 [M+4H]+4.    
 
ESI-HRMS: calculated for [C129H225N49O35S2]
6+ ([M+6H]6+) = 514.1124, found = 514.1126; 
calculated for [C129H224N49O35S2]






Reduction of Zf3Wildtype and Zn2+ Complexation:  
A general procedure for reduction of the zinc finger domain followed by Zn2+ 
complexation and visualization of the Zn2+ bound form of the peptide in the mass spectra 
are explained in section 7.1.     
 
ESI-MS m/z:  corresponding to the mononuclear zinc complex = 524.8 [M+4H+Zn]6+, 
629.5 [M+3H+Zn]5+, 786.6 [M+2H+Zn]4+, 1048.5 [M+H+Zn]3+. 
  
ESI-HRMS: calculated for the mononuclear complex [C129H224N49O35S2Zn]
5+ ([M+3H+Zn]5+) 
= 629.5192, found = 629.5196; calculated for [C129H223N49O35S2Zn]
4+ ([M+2H+Zn]4+) = 
786.6472, found = 786.6475; calculated for [C129H222N49O35S2Zn]
3+ ([M+H+Zn]3+ = 
1048.5272, found = 1048.5275. 
 
Zf3Tacn81 
               
 
Zf3Tacn81 was synthesised using Fmoc-Lys(Boc)-Wang (0.34 mmol/g) resin at a scale of 
0.1 mmol. The first eight amino acids in the sequence were coupled according to the 
manual SPPS protocol and the rest of the sixteen amino acids were coupled according to 
the Fmoc automated SPPS (section 7.3). Cleavage of the peptide from the resin using 




(56 mg, 17.3 mmol, 17.3%) as a white solid in the oxidised disulfide form of the peptide 
34 (Zf3Tacn81). 
 
HPLC Purification:  Column Pep 2 (MN_Nucleodur100_5_C18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm), 10-60% gradient of B in 30 min, flow rate 3 mL/min, tR  = 16.77 min. 
 
ESI-MS m/z:  540.5 [M+6H]6+, 648.2 [M+5H]5+, 809.9 [M+4H]4+, 1079.9 [M+3H]3+   
 
ESI-HRMS: calculated for [C136H241N53O35S2]
6+ ([M+6H]6+) = 540.4694, found = 540.4700; 
calculated [C136H240N53O35S2]
5+ ([M+5H]5+) = 648.1614, found = 648.1622, 
[C136H239N53O35S2]
4+ ([M+4H]4+) = 809.9499, found = 809.9506. 
 
Reduction of Zf3Tacn81 and Zn+2 Complexation:  
A general procedure for reduction of the zinc finger domain followed by Zn2+ 
complexation and visualization of the Zn2+ bound form of the peptide in the mass spectra 
are explained in section 7.1.  
 
ESI-MS m/z: corresponding to mononuclear zinc complex = 660.9 [M+3H+Zn]5+; 
corresponding to the binuclear zinc complex = 673.5 [M+H+2Zn]5+. 
 
ESI-HRMS: calculated for the oxidized mononuclear complex [C136H240N53O35S2Zn]
5+ 
([M+3H+Zn]5+) = 660.9472, found = 660.9478, calculated for the binuclear complex 
[C136H238N53O35S2Zn2]






                                                      
Figure 7.7: ESI-HRMS of measured and calculated charged state [M+3H+Zn]5+ of the mononuclear zinc 
complex of Zf3Tacn81 34.  
 
 
                        
                                        
Figure 7.8: ESI-HRMS of measured and calculated charged state [M+H+2Zn]5+ of the binuclear zinc 









              
 
Zf3Tacn85 was synthesised using Fmoc-Lys(Boc)-Wang (0.34 mmol/g) at a scale of 
0.1 mol. The first four amino acids in the sequence were coupled according to the 
manual SPPS protocol and the rest of the twenty amino acids were coupled according to 
the Fmoc automated SPPS (section 7.3). Cleavage of the peptide from the resin using 
TFA/H2O/TIS/EDT (94/2.5/1/2.5) followed by HPLC purification yielded the Zf3Tacn85 
(68 mg, 21 mmol, 21%) as a white solid in the oxidised disulfide form of the peptide 35 
(Zf3Tacn85). 
 
HPLC Purification: Column Pep 2 (MN_Nucleodur100_5_18, RP-C18, semi-preparative, 
250 × 10 mm, 5 µm),   10-60% gradient of B in 30 min, flow rate 3 mL/min, tR  = 
16.61 min.  
 
ESI-MS m/z:  540.5 [M+6H]6+, 648.4 [M+5H]5+, 810.2 [M+4H]4+, 1079.9 [M+3H]3+.  
 
ESI-HRMS: calculated for [C136H241N53O35S2]
6+ ([M+6H]6+) = 540.4694, found = 540.4699; 
calculated for [C136H240N53O35S2]
5+ ([M+5H]5+) = 648.3618, found = 648.3624, 
[C136H239N53O35S2]





Reduction of Zf3Tacn85 and Zn2+ Complexation:  
A general procedure for reduction of the zinc finger domain followed by Zn2+ 
complexation and visualization of the Zn2+ bound form of the peptide in the mass spectra 
are explained in section 7.1.  
 
ESI-MS m/z: corresponding to the mononuclear complex = 550.96 [M+4H+Zn]5+  , 660.75 
[M+3H+Zn]5+, 825.93 [M+2H+Zn]4+; corresponding to the binuclear complex = 561.28 
[M+2H+2Zn]6+, 673.33 [M+H+2Zn]5+, 841.66 [M+2Zn]4+. 
 
ESI-HRMS: calculated for the oxidized mononuclear complex [C136H240N53O35S2Zn]
5+ 
([M+3H+Zn]5+) = 660.7467, found = 660.7486, calculated for the binuclear complex 
[C136H239N53O35S2Zn2]
6+ ([M+2H+2Zn]6+) = 561.2762, found = 561.2765; calculated for the 
binuclear complex [C136H238N53O35S2Zn2]
5+ ([M+H+2Zn]5+) = 673.3299, found = 673.3297.   
 
                                                             
Figure 7.9: ESI-HRMS of measured and calculated charged state [M+3H+Zn]5+ of the mononuclear zinc 






        
 
Figure 7.10: ESI-HRMS of measured and calculated charged state [M+H+2Zn]5+ of the binuclear zinc 


















7.8.2. Expression of Zf12 domain 
 
Zf12 Expressed Domain 
 
                          
 
The expressed Zf12 domain 36 was prepared by protein expression in accordance with 
the protocol mentioned in section 7.2. 
 
 HPLC Purification: Column 18 (Phenomenex_Jupiter_5u_C18_300A, RP-C18, semi-
preparative, 250 × 10 mm, 5 µm),   20-50% gradient of B in 30 min, flow rate 3 mL/min, 
tR  = 23.26 min. 
 
ESI-MS m/z:  600.4 [M+13H]13+, 650.2 [M+12H]12+, 709.2 [M+11H]11+, 780.1 [M+10H]10+, 
866.5 [M+9H]9+, 974.8 [M+8H]8+, 1114.1 [M+7H]7+, 1299.8 [M+6H]6+.   
 
ESI-HRMS: calculated for the oxidized form of 36 [C328H528N110O98S7]
12+ ([M+12H]12+) = 
650.2314, found = 650.2326; calculated for [C328H527N110O98S7]
11+ ([M+11H]11+) = 
709.1606, found = 709.1619, calculated for [C328H526N110O98S7]
10+ ([M+10H]10+) = 
780.0762, found = 780.0769, calculated for [C328H525N110O98S7]
9+ ([M+9H]9+) = 866.5281, 
found = 866.5286, calculated for [C328H524N110O98S7]





7.8.3. Preparation of Zf13 domain by native chemical ligation between Zf3 




                     
 
The peptide Zf13Wildtype 37 was prepared by native chemical ligation between the 
peptide Zf3Wildtype 33 and the expressed peptide Zf12 36 according to the procedure 
mentioned in section 7.4. 
 
 HPLC Purification: Column All 3 (MN_Nucleodur100_5_C18, RP-C18, analytical, 
250 × 4.6 mm, 5 µm),   20-50% gradient of B in 30 min, flow rate 1 mL/min, tR  = 21.1 min. 
 
Yield: 1.2 mg [0.11 µmol, 22%]. 
 
ESI-MS m/z:  716.13 [M+15H]15+, 767.25 [M+14H]14+, 826.19 [M+13H]13+, 894.95 
[M+12H]12+, 976.31 [M+11H]11+, 1073.74 [M+10H]10+, 1192.93 [M+9H]9+.  
 
ESI-HRMS: calculated for the oxidized form of 37 [C455H747N159O130S7]
16+ ([M+16H]16+) = 
671.4043, found = 671.4041; calculated [C455H746N159O130S7]
15+ ([M+15H]15+) = 716.1643, 
found = 716.1639, [C455H745N159O130S7]






          
 
The peptide Zf13Tacn81 38 was prepared by native chemical ligation between the 
peptide Zf3Tacn81 34 and the expressed peptide Zf12 36 according to the procedure 
mentioned in section 7.4. 
 
HPLC Purification: Column All 3 (MN_Nucleodur100_5_C18, RP-C18, analytical, 
250 × 4.6 mm, 5 µm),   10-50% gradient of B in 30 min, flow rate 1 mL/min, tR  = 
25.62 min. 
 
Yield: 0.95 mg [0.087 µmol, 17.46%]. 
 
 ESI-MS m/z:  681.3 [M+16H]16+, 726.6 [M+15H]15+, 778.4 [M+14H]14+, 838.3 [M+13H]13+, 
908.0 [M+12H]12+, 990.6 [M+11H]11+.  
 
ESI-HRMS: calculated for the oxidized form of 38 [C462H762N163O130S7]
17+ ([M+17H]17+) = 
641.1531, found = 641.1530; calculated [C462H761N163O130S7]
16+ ([M+16H]16+) = 681.3502, 
found = 681.3513, [C462H760N163O130S7]
15+ ([M+15H]15+)  = 726.6395, found = 726.6395, 
[C462H759N163O130S7]
14+ ([M+14H]14+) = 778.3988, found = 778.3999, [C462H758N163O130S7]
13+ 
([M+13H]13+) = 838.2753, found = 838.2756, [C462H757N163O130S7]
12+ ([M+12H]12+)  = 





          
 
The peptide Zf13Tacn85 was prepared by native chemical ligation between the peptide 
Zf3Tacn81 35 and the expressed peptide Zf12 36 according to the procedure mentioned 
in section 7.4. 
 
HPLC Purification: Column All 3 (MN_Nucleodur100_5_C18, RP-C18, analytical, 
250 × 4.6 mm, 5 µm),   10-50% gradient of B in 30 min, flow rate 1 mL/min, tR  = 
25.58 min. 
 
Yield: 1.32 mg [1.21 µmol, 24.25%]. 
 
ESI-MS m/z:  606.1 [M+18H]18+, 641.7 [M+17H]17+, 681.7 [M+16H]16+, 727.1 [M+15H]15+, 
778.9 [M+14H]14+, 838.8 [M+13H]13+, 908.5 [M+12H]12+, 991.0 [M+11H]11+.  
 
ESI-HRMS: calculated for the oxidized form of 39 [C462H758N163O130S7]
13+ ([M+13H]13+)  = 
838.7377, found = 838.7364, [C462H757N163O130S7]








CD spectra of various zinc finger constructs with their consensus DNA 
binding site            
 






     
         
Figure A.1: Comparison of the CD spectra of the 30mer dsDNA consisting of the Zif268 DNA binding site in 
the absence and presence of (A) Zf3Wildtype 33; (B) Zf3Tacn81 34; (C) Zf3Tacn85 35 and (D) Zf13Tacn85 
39. The measurements were performed in 2.5 mM Tris buffer (pH = 7.8) containing 5 µM of DNA, 25 µM of 







DNA binding of the modified zinc finger domain Zf13Tacn81 38 in the 






Figure A.3: (A) The Zf13Tacn81 38 reconstituted with Zn
2+
 ion was incubated with dsDNA in a buffer system 
containing Zn
2+
 (40 mM Tris, 200 mM NaCl, 1 mM TCEP, 1 µM ZnCl2, pH = 7.8) and (B) The apopeptide 
Zf13Tacn81 38 was incubated with dsDNA in a buffer system excluding Zn
2+ 
(40 mM Tris, 200 mM NaCl, 
1 mM TCEP, pH = 7.8). Rf values were varied from 0 to 40; wherein rf = Cpeptide/ CDNA. 
 
Plasmid DNA map 
 
Figure A.2: pJET cloning vector modified to contain two Zif268 DNA binding sites used for analyzing the 
DNA cleavage ability of the modified Zif268 constructs.  
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List of abbreviations 
 
A   Adenine 
Å   Angstrom (10-8 cm) 
AA  amino acid 
Alloc  allyloxycarbonylchloride 
Approx Approximately 
APS  Ammonium persulfate 
aq  aqueous    
BBT   BisBocTacn 
Bn   Benzyl  
Boc   Butyloxycarbonyl  
bp   base pairs 
br  broad 
Bu  butyl 
CBD   Chitin Binding Domain 
C   Cytosine 
˚C   degree Celsius 
CD   Circular Dichroism 
cm   centimeter 




d   doublet 
dd   doublet of doublet 
DCM   Dichloromethane 
DIC   diisopropylcarbodiimide 
DIPEA   diisopropylethylamine 
DMF   dimethylformamide 
DNA   deoxyribonucleic acid 
ds   double strand 
Ɛ   extinction co-efficient 
EDT   1,2-ethanedithiol 
EPL   Expressed Protein Ligation 
ESI-MS  Electron Spray Ionization Mass Spectroscopy 
et al.   et alii 
Et3N   Triethylamine 
EtOAc   Ethylacetate 
EtOH   Ethanol 
Et2O   Diethylether 
eq   equivalents  
FAM  carboxyfluorescein 
Fig.  Figure number 





g   gram 
G   Guanine 
Gnd.HCl Guanidine hydrochloride  
h   hours 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium        
3-oxid hexafluorophosphate 
HBTU  N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium 
hexafluorophosphate 
HFIP   hexafluoroisopropanol 
HOAt   1-Hydroxy-7-azabenzotriazole  
HOBt   1-Hydroxybenzotriazole 
HPLC   High Performance Liquid Chromatography 
HRMS   High Resolution Mass Spectroscopy 
HMG  High mobility group 
IHF  Integration host factor 
IMPACT Intein Mediated Purification with an Affinity Chitin-Binding Domain 
IPL  Intein mediated protein ligation 
IPTG  isopropyl-beta-D-thiogalactopyranoside 
IRTG   International Research Training Group 
J   coupling constant 




LB  luria broth 
m   multiplet 
MeCN/ACN  Acetonitrile 
MeOH   Methanol 
MESNA  sodium 2-mercaptoethanesulfonate 
mg   milligram 
MHz   megahertz 
min   minute 
mL   millilitre 
mM   millimolar 
µM   micromolar 
MMR  mismatch repair pathway 
NaAsc  sodium ascorbate 
NCL   Native Chemical Ligation 
NER  Nucleotide excision repair 
nm   nanometer 
nM   nanomolar 
NMM  N-Methylmorpholine 
NMP   N-Methyl-2-pyrrolidone 
NMR   Nuclear Magnetic Resonance 




PAGE   Polyacrylamide Gel Electrophoresis 
Pbf   2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl protecting group 
Pd/C   Activated Palladium Carbon  
PE   polyethylene 
PG  protecting group 
PIDA  (diacetoxyiodo)benzene 
ppm   parts per million 
q   Quartet 
rf   ratio of the peptide to DNA 
Rf   retention Factor 
RNA   Ribonucleic acid 
RP   reverse phase 
rpm   rotations per minute   
r.t.   room temperature 
s   singlet 
sec  seconds 
SPPS   Solid Phase Peptide Synthesis 
ss   singlestrand 
t   triplet 
T   Thymine 




tBoc   tert-butoxycarbonyl 
TCEP   tris(carboxyethyl)phosphine 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
TFA   Trifluoroacetic acid 
THF   tetrahydrofuran 
TIS   Triisopropylsilane 
TLC   Thin Layer Chromatography 
Tm   Melting Temperature 
TMS   trimethylsilyl 
TosCl   Tosylchloride 
tR   retention time 
Trt   trityl protecting group 
UV   Ultra-Violet 
V   Volt 
v/v  volume by volume 
W   Watt 
wt%   weight percentage 
Zf    zinc finger domain 
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